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1.1 Introduction  
 
1.1.1  History and classification 
The association between oligoamenorrhea, obesity, bilateral polycystic ovaries and 
hirsutism has been reported for the first time in 1935 by Stein and Leventhal (Stein 
and Leventhal, 1935). A primary ovarian defect was inferred since bilateral wedge 
resection of the ovaries restored cycle abnormality and 2 of 7 patients conceived 
(Stein, 1967). The wide variability of clinical and histological findings associated 
with polycystic ovaries resulted in the inability to clearly identify any consistent 
characteristic feature of the syndrome (Goldzieher and Axelrod, 1963). The term 
Stein Leventhal syndrome was replaced by polycystic ovary syndrome (PCOS). 
Excessive androgen production has initially been attributed to abnormal adrenal 
function. Hyperandrogenism due to diminished granulosa cell aromatase activity 
(responsible for the conversion of androgens to estrogens) of the polycystic ovaries 
(PCO) has subsequently been demonstrated (Axelrod and Goldzieher, 1962). In 
1970, Yen and co-workers (Yen et al., 1970) described abnormalities in the 
hypothalamic-pituitary-axis evidenced by inappropriate follicle-stimulating hormone 
(FSH) secretion along with luteinizing hormone (LH) hypersecretion. Further insight 
in the abnormal physiology of this disorder occurred when hyperandrogenism was 
demonstrated to be LH dependent (Givens et al., 1974). A subsequent milestone in 
1976 was the discovery of the association of ovarian hyperandrogenism and 
various causes of insulin resistance (Kahn et al., 1976). Thereafter, an association 
between polycystic ovaries, hyperandrogenism, and hyperinsulinemia was 
established (Burghen et al., 1980). The ultrasound manifestation of polycystic 
ovaries was first illustrated by Swanson and co-workers who demonstrated 
symmetrically enlarged ovaries containing numerous tiny cysts in various 
diameters which may be arranged in the periphery of the ovary (Swanson et al., 
1981).  
For clinical purposes, a simple classification for anovulatory infertility was 
initially proposed (Insler et al., 1968), which was subsequently modified and 
recommended by the World Health Organization (WHO) (Rowe et al., 2000) and 
the European Society for Human Reproduction and Embryology (The ESHRE 
Capri Workshop Group, 1995). According to this classification, which is based on 
the assessment of gonadotropin and estrogen levels in blood, patients are 
classified into three main categories. Patients presenting with low levels of 
gonadotropins and negligible endogenous estrogen activity constitute group I 
(WHO I), suggesting a central origin of the disease (i.e. at the hypothalamic-
pituitary level) . WHO III individuals also present with low estrogen concentrations 
but gonadotropin levels are elevated, indicating that the primary abnormality is at 
the ovarian level (i.e. premature ovarian failure (POF)). The great majority of 
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patients (80%) suffering from chronic anovulation present with serum FSH and 
estradiol levels within the normal range and are classified as WHO II. Women with 
PCOS constitute a significant proportion of WHO II women (van Santbrink et al., 
1997; Laven et al., 2002). Recently, consensus has been reached regarding the 
diagnostic criteria of PCOS. According to the revised 2003 Rotterdam criteria 
women may be diagnosed as PCOS when at least 2 out of the following 3 criteria 
are present: oligo and/or anovulation, clinical and/or biochemical signs of 
hyperandrogenism and polycystic appearance of ovaries (The Rotterdam 
ESHRE/ASRM sponsored PCOS consensus workshop group, 2004a; The 
Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group, 2004b).  
 
1.1.2  Phenotypical heterogeneity 
PCOS is the most common anovulatory disorder in women. Its cardinal features 
are hyperandrogenism and polycystic ovary morphology (Laven et al., 2002). Its 
clinical manifestations include: oligo- or amenorrhea, hirsutism and obesity. It has 
been recognized that some women with the syndrome will present with polycystic 
ovaries without clinical evidence of androgen excess. Most cross-sectional studies 
may find associations between various features such as insulin resistance with 
hyperandrogenism (Kahn et al., 1976), but a causal relationship usually remains 
speculative. Moreover, even within affected families individuals may present with a 
variety of clinical characteristics (Legro et al., 1998). To date, it has become 
evident that genetic factors are involved in PCOS and molecular studies have 
identified an array of underlying abnormalities. Despite genetic predisposition, 
additional environmental factors will lead to differences in phenotypical 
presentation and infertility. In other words, PCOS clearly is a complex genetic 
disaese. Hence, the full clinical picture only emerges in women with a genetic 
predisposition exposed to eliciting supplementary influences (predominantly 
overweight). Because various genetic as well as environmental factors play a role, 
each of them with variable influence, these patients constitute a notoriously 
heterogeneous group.  
 
1.1.3  Short and long-term sequelae 
Correct diagnosis of PCOS and division in the subgroups may be relevant because 
of its possible future short term implications and increased long-term health risks. 
Patients with PCOS might need medical treatment for hirsutism or complaints 
related to obesity. However, most patients seek medical help for irregular bleeding 
and infertility. Infertility treatment strategies are associated with an increased risk of 
developing ovarian hyperstimulation syndrome (OHSS) and multiple gestations, as 
will be discussed later.   
Additionally, there is clear evidence that PCOS is associated with an 
increased risk of developing type 2 diabetes (Dahlgren et al., 1992; Ehrmann et al., 
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1999; Dunaif, 1999; Wild et al., 2000). Moreover, there are several indications that 
women with PCOS might be at an increased risk of developing cardiovascular 
disease as well. So far, epidemiological studies have shown no direct evidence of 
an increased incidence of coronary heart disease events in middle-aged women 
with a history of PCOS (Wild, 2002). Women with PCOS are also thought to be at 
an increased risk for endometrial cancer through chronic anovulation with 
unopposed estrogen exposure of the endometrium. Indeed, in a large 
epidemiological study the presence of subfertility due to hormonal disorders was 
associated with an increased risk of endometrial cancer (Klip et al., 2000).  
 
1.2  Phenotype and clinical picture 
 
1.2.1 Folliculogenesis and ovarian dysfunction  
In the female gonad a pool of primordial follicles will be formed during embryo 
development (Baker, 1963). Primordial follicles continuously leave the nongrowing 
pool through conversion into primary follicles. This process is referred to as initial 
recruitment (McGee and Hsueh, 2000). The first sign of growth is the transition of 
the granulosa cells, surrounding the primary oocyte, from a flat to a more cuboidal 
shape (Hirshfield, 1991). Follicles progress through the secondary stage and early 
antral stages until they reach the pool of selectable follicles. These follicles have a 
diameter of 2-5 mm and a clearly formed antrum. Follicles reaching the antral 
follicle stage inevitably will undergo atresia, unless rescued by the intercycle FSH 
rise present from pubertal onset, which permits further development (Fauser and 
van Heusden, 1997). Every month one follicle will be selected and ovulate after the 
midcycle LH peak, whereas the other follicles will go into atresia. This process is 
referred to as cyclic recruitment for which FSH is essential (McGee and Hsueh, 
2000). It should be noted, however, that this classical concept has been challenged 
recently by showing stem cells exhibiting meiotic activity in the mouse ovary 
(Johnson et al., 2004). 
In WHO II patients, especially in those presenting with polycystic ovaries, the 
number of small antral follicles is generally increased due to disturbed dominant 
follicle selection (Fauser, 1994). Characteristically, in these patients follicle 
development is initiated from the primordial stage until the antral stage at which 
follicle development ceases and selection of a dominant follicle and subsequent 
ovulation is absent (Fauser, 1994). This abnormal condition may be caused by 
disturbed intra-ovarian regulation of FSH action (Fauser, 1994). There are several 
factors, produced within or outside the ovary, modifying intra-ovarian FSH activity 
(Fauser, 1996; Schipper et al., 1997). The combined activity of these regulatory 
factors together determines the eventual biological response to stimulation. Hence, 
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the presence or absence of ovarian abnormalities in patients may influence 
treatment outcome after exogenously adminstered gonadotropins.   
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting substance 
(MIS), is a dimeric glycoprotein belonging to the transforming growth factor β 
(TGFβ) superfamily of growth and differentiation factors. Only recently, insight has 
been obtained in the potential functions of AMH in the postnatal ovary (Figure 1). 
AMH is exclusively produced by granulosa cells of primary, secondary and early 
antral follicles (Durlinger, 2000). Because of the specific expression pattern in 
preantral (primary and secondary) and antral follicles, it has been suggested that 
AMH may be involved in follicle development and/or dominant follicle selection. 
AMH deficient female mice are fertile and show macroscopically normal ovaries 
(Behringer et al., 1990), but their ovaries are depleted more rapidly of primordial 
follicles compared to wild-type AMH mice (Durlinger et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 In this figure the dual role of AMH (i.e. the inhibitory effect on the recruitment of primordial 
follicles and on FSH-induced growth of preantral follicles) during growth and development of ovarian 
follicles is depicted.  
 
As more preantral and antral follicles could be detected in ovaries of AMH 
deficient mice it is thought that the more rapid depletion is caused by increased 
recruitment of primordial follicles. This was confirmed by the observation that 
addition of AMH to cultures of neonatal mice ovaries, resulted in a 40-50% 
decrease in the number of growing follicles (Durlinger et al., 2002a). The faster 
depletion of primordial follicles during early adulthood seemed to induce early 
cessation of ovulatory cycles in AMH-deficient females (Durlinger et al., 2002b).  
Besides influencing initial recruitment, AMH may affect the sensitivity of 
follicles for FSH, since AMH (-/-) mice of 4 months old had more preantral and 
antral follicles despite a lower FSH level (Durlinger et al., 1999). Preantral follicle 
development is not dependent on FSH, but FSH facilitates this early growth 
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process, indicating that these follicles indeed are sensitive to FSH. From in vitro 
and in vivo experiments it was concluded that in the absence of AMH these follicles 
are more responsive to FSH (Durlinger, 2000). This phenomenon might be of 
importance during cyclic (FSH dependent) recruitment (Durlinger et al., 2001).  
Since AMH is predominantly expressed by small follicles in mice (Durlinger 
et al., 2002b), as well as in the human (Weenen et al., 2004), AMH serum 
concentrations may be increased in patients with polycystic ovaries. Indeed, in 
PCOS patients exhibiting the classical features of the syndrome, AMH levels were 
found to be elevated compared to normal controls (Cook et al., 2002; Pigny et al., 
2003). Therefore, it might be hypothesized that AMH, as it reflects the total number 
of growing follicles, can be used as marker for the extent of disturbed 
folliculogenesis in WHO II anovulatory women, with or without polycystic ovaries. 
 
1.2.2 Phenotype and clinical presentation  
As mentioned previously, PCOS is the most common endocrine disorder in 
reproductive age women and a major cause of subfertility. Women with PCOS 
constitute an extremely heterogeneous patient group since various mechanisms 
might be responsible for the development of the same clinical picture. In order to 
clearly understand and elucidate the background and pathophysiology of all 
symptoms displayed in PCOS it might be helpful to focus on these specific 
characteristics and features. Based upon this approach the various genetic factors 
involved might be identified. And above all it might be feasible to recognize patients 
with favourable or unfavourable chances following infertility therapy prior to 
treatment. In the following section, several characteristic PCOS features used for 
classification will be briefly described.    
 
It has become clear that oligomenorrheic patients constitute a different subset of 
WHO II patients compared to amenorrheic subjects in whom anovulation is the 
rule. Amenorrheic women show significantly higher androgen levels (Laven et al., 
2002) and more frequently present with PCO (Hull, 1987; Devoto et al., 1998). 
Additionally, it was found that amenorrheic patients stand higher chances of 
remaining anovulatory upon clomiphene citrate ovulation induction treatment, 
suggesting that ovarian abnormalities indeed are more severe in amenorrheic 
patients (Imani et al., 1998). Interestingly, if ovulation was achieved, amenorrheic 
patients had a twofold higher probability of conceiving compared with 
oligomenorrheic patients (Imani et al., 1999). This disparity suggests that the FSH 
responsiveness and oocyte quality may be differentially regulated (Imani et al., 
1999). Moreover, amenorrheic women had minimal chances of pregnancy before. 
Therefore, it is less likely in these women that - once normal ovarian function is 
restored - other subfertility factors will interfere with pregnancy chances.   
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Obesity frequently coincides with PCOS and obese women classified as 
WHO II (including PCOS) represent a subgroup with more pronounced endocrine 
disturbances and likely more profound ovarian dysfunction (Laven et al., 2002). 
Moreover, applying ovulation induction, obese PCOS women require higher doses 
of clomiphene citrate (Lobo et al., 1982; Shoham et al., 1990) or gonadotropins 
(McClure et al., 1992; Imani et al., 2002a) compared to their lean counterparts. 
Hence, obese WHO II anovulatory patients constitute a subgroup with a less 
favourable treatment outcome.  
Hyperandrogenism is considered to be a key feature in PCOS (Dunaif et al., 
1992; The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop 
group, 2004a; The Rotterdam ESHRE/ASRM sponsored PCOS consensus 
workshop group, 2004b). Approximately 95% of hyperandrogenic women will suffer 
from PCOS (Barnes, 1997) and 75% of hyperandrogenic women with regular 
cycles will present with polycystic ovaries (Carmina and Lobo, 1999). Elevated 
androgens seem to be correlated with an increased risk for hirsutism, infertility and 
cycle disturbances (Balen et al., 1995). In a recently performed analysis, 
hyperandrogenic WHO II subjects tend to be more obese, have longer bleeding 
intervals and exhibit polycystic ovaries on ultrasound. Moreover, insulin resistance 
is more frequently encountered in this group compared with WHO II subjects with 
normal androgen levels (Laven et al., 2002). Additionally, hyperandrogenism 
constitutes a powerful predictor for the response to ovulation induction highlighting 
its significance for ovarian dysfunction in these women.  
Severe forms of insulin resistance are associated with polycystic ovaries and 
hyperandrogenism (Kahn et al., 1976). In addition, PCOS seems to be associated 
with abnormalities in insulin action (both insulin resistance as well as beta cell 
dysfunction (Dunaif, 1999)). These abnormalities together with obesity itself, give 
explanation to the considerably augmented prevalence of glucose intolerance 
(Dunaif, 1999). Even though hyperinsulinemic patients apparently constitute a 
different subset of anovulatory infertile subjects, insulin sensitivity is associated 
with ovarian dysfunction through hyperandrogenism (Laven et al., 2002). 
Therefore, it is worthwhile to evaluate the role of insulin resistance as a predictor of 
fertility treatment outcome and as a separate pathway involved in the 
pathophysiology of the disease.   
Upon transvaginal sonography (TVS), the ovarian volume might be 
increased (Pache et al., 1992a), the ovaries may exhibit an increased stromal 
echogenicity (Dewailly, 1997), and the follicle number might be augmented in 
PCOS patients (Obhrai et al., 1990). Recently, it was proposed to modify the 
ultrasound definition of PCO according to the presence of follicles measuring 2-9 
mm in diameter (Jonard et al., 2003). This definition should help to recognize 
different forms of PCOS and should improve phenotypic analysis amongst others in 
the frame of family studies (Jonard et al., 2003). In about 63% of all WHO II 
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anovulatory infertile patients PCO are encountered on TVS (van Santbrink et al., 
1997). According to the available literature PCO are now defined by the presence 
of an increased number of follicles and/or an increased ovarian volume (Jonard et 
al., 2003; Balen et al., 2003). The ovarian volume seems to be the only 
characteristic associated with the outcome in clomiphene citrate ovulation induction 
(Imani et al., 1998). Likewise, the identification of factors predicting ovarian 
reponsiveness might add to our understanding of the mechanism involved in 
ovarian dysfunction.  
Rather than being of constant value the described parameters are varying 
(i.e. dynamic) characteristics for each patient. Namely, it has been proven that 
weight loss results in a significant improvement of menstrual abnormalities, 
ovulation and fertility rates (Norman et al., 2002). Additionally, the oral 
contraceptive pill (OCP), commonly used in the treatment of menstrual disorders 
(Morin-Papunen et al., 2003), has been shown to decrease serum androgens 
(Falsetti and Galbignani, 1990; Coenen et al., 1996; Dahlgren et al., 1998). Apart 
from this effect OCP increases insulin sensitivity (Skouby et al., 1987; Godsland et 
al., 1992). As a consequence, phenotype expression might change for women with 
PCOS dependent on OCP use. In order to identify all PCOS patients it is amongst 
others important to quantify the effects of OCP on phenotype expression. 
 
1.3  Phenotype and genetics 
 
1.3.1 Genetic disease and influence 
Clinical genetic studies have been hampered by the lack of consensus regarding 
the definition of polycystic ovary and PCOS. The fact that the disorder is only 
clinically expressed in women during their reproductive years leads to further 
difficulties. Hence, assigning a phenotype to premenarchal girls and 
postmenopausal women is complicated. Moreover, the syndrome is associated 
with subfertility and therefore large pedigrees with multiple affected women are 
hard to find (Legro and Strauss, 2002). Besides the controversy about the exact 
nature of a possible male phenotype (Legro and Strauss, 2002), it has been 
suggested that premature balding is more prevalent among male relatives of 
women with PCOS (Franks et al., 1997). Nevertheless, the genetic basis of WHO 
II/PCOS is demonstrated by many studies showing an increased prevalence in 
individuals who have a first degree relative with the disease (Ferriman and Purdie, 
1979; Lunde et al., 1989; Govind et al., 1999). However, these studies are flawed 
by aberrant diagnostic criteria and inaccurate diagnostic methods. Despite all 
shortcomings the existing literature suggests clustering of PCOS in families with a 
mode of inheritance that is not inconsistent with an autosomal dominant pattern 
(Legro and Strauss, 2002). 
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Knowledge of the mode of inheritance (Mendelian or non-Mendelian) is 
crucial in order to determine the most powerful strategy for a study of the molecular 
basis of disease (Dekker and van Duijn, 2003). Mendelian disorders are caused by 
either a dominant or recessive mutation. In non-Mendelian or complex disorders 
the relationship between genotype and phenoype (the actual disease) is not 
straightforward, which can be attributed to the interaction of a small number of 
genes with each other, and with environmental factors (Dekker and van Duijn, 
2003). In addition, it seems that the high prevalence of affected individuals and the 
wide range of related phenotypes involved in PCOS can be explained by the 
interaction of a small number of key genes with environmental factors (i.e. a 
complex genetic disorder) (Kashar-Miller and Azziz, 1999; Crosignani and Nicolosi, 
2001; Franks et al., 2001; Legro and Strauss, 2003).  
The extent to which familial clustering of PCOS is due to inheritance or 
shared environmental factors can be assessed by comparing the extent to which 
monozygotic twins are concordant for the disease with the concordance of 
dizygotic twins. Since monozygotic twins are genetically identical while dizygotic 
twins share on average half of their genes, the difference between the 
concordance rates signifies the contribution of genetic factors to the etiology of 
PCOS. In the largest available study both mono- and dizygotic twins were included. 
Jahanfar et al. (1995) found a high degree of discordance among the available 
twins for polycystic ovaries. However, there was considerable concordance among 
affected twins with respect to biochemical parameters, including fasting insulin 
levels and androgens. These results indicate that both genetic and environmental 
factors might be involved in the etiology of PCOS. Hence, PCOS indeed might 
have a complex pattern of inheritance. 
 
1.3.2 Genetic approach 
In recent years, remarkable progress has been made in unravelling the etiology of 
several genetic disorders. Progress has been most notable for monogenetic 
disorders, in which there is a clear-cut relation between the genetic factor and the 
occurrence of disease. At present, genetic research focuses on chronic disorders 
with a complex etiology, such as PCOS. In complex disorders the risk associated 
with a mutation may depend for a large part on interaction with other genetic or 
environmental risk factors. First, the opportunities for research in the identification 
of genetic risk factors involved in complex genetic disorders, such as anovulatory 
infertility, will be discussed. 
 
Family studies 
Traditionally, family-based study design has been the backbone of genetic 
research.  Family studies have been of great importance to the identification of new 
genes. This particularly applies to monogenetic disorders, in which there is a clear-
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cut relation between genetic factor and occurrence of disease. Up until now, most 
of the progress in genetic research has been based on research of monogenetic 
diseases in large pedigrees, in which the disease is transmitted from one 
generation to the next.  
  
In family studies the method of linkage analysis is applied. Linkage analysis uses 
the principle that marker alleles are transmitted in a family together with the 
disease mutation. Relatives who develop a disease due to the same mutation are 
expected to share alleles (i.e. variants of a piece of DNA) flanking the disease 
mutation (Dekker and van Duijn, 2003). Linkage studies have been extremely 
successful in disclosing the etiology of monogenetic disorders. In complex 
disorders, several genetic and environmental factors may be implicated. Hence the 
mutation-associated risk is heavily depending on the presence of other genetic or 
environmental risk factors. As it is often impossible to clinically distinguish between 
patients who developed the disease due to a specific mutation and those who have 
a different etiology, recombination between the disease and marker may be falsely 
inferred. Therefore, the power to unravel the genetics of complex disorders has 
proven to be low (Lander and Schork, 1994).  
  
An alternative approach to analysis of complex disorders is the use of affected 
sibling-pairs (Dekker and van Duijn, 2003). Siblings share a high proportion (50%) 
of their genetic material including large parts of DNA. The à priori probability of a 
patient sharing for a certain locus no alleles with a sib is 25%; one allele is 50%; 
two alleles are again 25%. For markers located close to the disease mutation, 
affected sibs are expected to share more alleles than the average of one allele. 
The test statistic for the analysis is based on counting alleles shared by a pair of 
affected siblings. Counts exceeding the expected value under the null hypothesis 
(one allele shared) are compatible with a disease locus nearby the marker 
examined. An advantage of the sib-pair design is that two siblings with the same 
common disease are more likely to have developed the disease due to the same 
mutation than two distinctly related subjects. Furthermore, siblings do share a large 
chromosomal region around the disease gene. In principle, the disease gene may 
thus be detected with a limited number of markers. However, the statistical power 
of sib-pair studies is limited, particularly if multiple genes are involved (Lander and 
Schork, 1994). Detecting significant linkage in such disorders requires several 
hundreds to thousands of sibling pairs. Unfortunately, regarding PCOS no 
investigative team has yet assembled a sufficient number of families with affected 
sib-pairs to perform this type of analysis.  
 
Hence, to date, family studies have not proven enormously successful in the 
identification of genetic factors involved in PCOS. Consequently, the existing 
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literature is based exclusively on candidate gene studies (Legro and Strauss, 
2002).   
 
Population-based studies 
There is increasing interest in population-based studies of individuals in an isolated 
population in order to overcome the aforementioned limitations of family-based 
research. As in family studies, the basic principle of molecular studies in isolated 
populations is that besides a disease gene, DNA flanking this gene, is also passed 
on to the next generation and is thus dispersed throughout the population. Hence, 
a mutation related to the disease can be ascertained in a genomic screen by 
identifying chromosomal regions shared by patients. This alignment of marker 
alleles along a chromosome is called a haplotype.  
  
The first and most successful approach to identify new genes is genome screening, 
which involves a complete genome search for genes involved in a disorder. Such 
an approach of a genome wide screening in an isolated population does not need 
to make an assumption regarding the genes involved, the mode of inheritance, or 
disease penetrance or prevalence (Legro and Strauss, 2002). This approach starts 
by genotyping a set of simple tandem repeats (STR) (i.e. a clustered repeat of 
base pairs) or single-nucleotide polymorphisms (SNP) (i.e. a base pair substitution) 
polymorphic markers, of which the genomic location is known (Vaessen and van 
Duijn, 2001). Usually, these markers are more or less equally distributed across the 
genome, covering all chromosomes. These markers are not necessarily located in 
a gene, but often are located in non-coding areas not known to be involved in any 
biological process.  
 The rationale of genome screening in an isolated population is that marker 
alleles in the vicinity of a causally related mutation should be found more often in 
patients with a particular disorder than in controls. However, given the size of the 
genome of about 2.9 billion base pairs (Lander et al., 2001), the probability that an 
allele of a random marker is found more often in patients compared to controls by 
chance is next to zero. Therefore, patients who inherit a disease gene from a 
common ancestor not only receive the disease mutations, but also adjacent 
markers on a chromosome. A marker located physically nearby a causal mutation 
should at least be present more often in cases than in unaffected relatives or 
unrelated controls, merely flagging the mutation.  
 Thus, searching the full genome is feasible in an isolated population when 
using the basic principle that patients who inherit a disease gene from a common 
ancestor not only receive the disease mutation, but also adjacent marker alleles 
(Figure 2). This is based on the principle of linkage-disequilibrium (Khoury et al., 
1993). Using this principle, disease genes may be localized by screening the 
genome of patients by using only a comparatively few markers.  
Chapter 1 
 
 
22
 
 
 
  
In the general population, it is not yet statistically feasible to perform this type of a 
genomic screen. First, there is only a small probability that any two patients from 
the general population with a complex disorder have inherited a common gene 
defect from a common ancestor. Secondly, people derived from the general 
population will only share a small amount of DNA. This requires marker and 
disease locus to be very close in order to localise the gene in a genome screen. 
  
 Successful genome screens have been conducted in genetically isolated 
populations (Kuokkanen et al., 1997; Leppavuori et al., 1999; Aouizerat et al., 
1999; Stefansson et al., 2002). Isolated populations are typically populations that 
have arisen from a small number of ancestors. As a consequence, these 
populations show only a limited amount of genetic variation. As a result of the 
reduced genetic variability in genetically isolated populations, there is a higher 
probability that patients carry a common mutation inherited from a common 
ancestor (Vaessen and van Duijn, 2001). The drawback of studies in isolated 
populations might be the limited value when study results from genetic isolates are 
extrapolated to other populations. An advantage of studies in populations of more 
recent isolation is expected to more closely resemble that of the general 
population. However, it remains to be determined whether disease-related 
Chromosomal region shared in offspring 
 
Mutation 
 
Founder chromosome with  
disease-associated mutation 
 
Figure 2 Allele sharing in a geneticially 
isolated population. Above: founder 
chromsome with disease-associated 
mutation. Below: region surrounding the 
disease locus, shared by patients with the 
same phenotype. Although they are 
possibly unaware of this, these affected 
individuals all descend from a common 
ancestor. 
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mutations, even when detected in a recent isolate are also present in the general 
population (Vaessen and van Duijn, 2001). At present, a genome wide screen in 
Dutch PCOS patients derived from a population of recent isolation is performed 
(Mulders et al., In preparation).  
 
Still, another strategy can be followed to identify genes implicated in this complex 
disease (Vaessen and van Duijn, 2001). The most intuitive approach is to target 
candidate genes, genes that are expected to be involved in the pathophysiology of 
the disease (Dekker and van Duijn, 2003). A role of these genes in the 
pathogenesis may be suspected based on the function of the gene product, i.e. the 
protein (to determine whether mutations in a gene are involved, the gene can be 
screened for mutations or polymorphisms). These candidate gene studies test for 
overrepresentation of a specific allele of a candidate gene in a population of 
unrelated affected individuals, compared with a cohort of unrelated unaffected 
individuals (Legro and Strauss, 2003). Nevertheless, regarding PCOS there are 
some disadvantages involved in this specific approach. 
A major drawback of the candidate gene approach is that à priori knowledge 
of the pathogenesis of the disease is required: proteins or genes involved in the 
disease should be known. For anovulatory infertility, there is limited knowledge of 
proteins involved in its etiology. Another problem in this type of study is that the 
candidacy of a gene for a disorder is mostly ill-defined and the number of possible 
candidate genes is large. As a consequence, the number of incorrect estimates of 
PCOS candidate genes is likely to be high until the pathophysiology is fully 
elucidated and genes become obvious candidates. However, wrong guesses are 
not necessarily without value, since the exclusion of genes does narrow down the 
field of possible candidates. Additionally, candidate gene studies have been widely 
criticized because of repeated failure to replicate results. False positive findings 
may to a great extent be accounted for by multiple testing. Another problem, 
leading to bias is the phenomenon of population admixture (Dekker and van Duijn, 
2003). Whenever a distinct population comprises different subgroups with respect 
to genetic make-up, bias due to population admixture may occur. Bias will occur if 
the population consists of subpopulations, which differ in risk of the disease as well 
as genetic make-up. In a case control study, cases and controls may have been 
drawn from different subpopulations. Bias due to population stratification can occur 
in any population study in which cases and controls are not matched for their 
genealogical history. A way to minimalize the possibility of admixture is the use of 
genetically homogeneous populations.   
 
The clinical, biochemical and sonographical characteristics provide a basis for 
investigation of the genetic origins of PCOS by indicating key candidate 
endocrine/metabolic pathways which are controlled by known genes. This is the 
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rationale for using the candidate gene approach in this disorder (Table 1). Genes 
involved in the pathway of androgen production and metabolism include amongst 
others CYP 17 encoding the major regulator 17-α-hydroxylase/17-20-lyase (Carey 
et al., 1994; Gharani et al., 1996; Witchel et al., 1998), CYP 19 encoding P450 
aromatase (responsible for the conversion of androgens to estrogens) (Urbanek et 
al., 1999) and CYP11A encoding the cholesterol side-chain cleavage enzyme 
(Gharani et al., 1997; Urbanek et al., 1999; Diamanti-Kandarakis et al., 2000). Also 
considered are CYP21 and the androgen receptor (Urbanek et al., 1999; Escobar-
Morreale et al., 1999; Mifsud et al., 2000). 
 
 
TABLE 1 Studies of candidate genes in PCOS (Adapted from Legro, R.S., and Strauss, J.F. (2002) 
Molecular progress in infertility: polycystic ovary syndrome. Fertil. Steril., 78, 569-576).  
 
Metabolic pathway  
 
Gene name  Comments 
 
Steroid hormone synthesis and 
action 
 
Aromatase 
 
No association (Urbanek et al., 
1999)   
 17 α-Hydroxy-lyase/17,20-
Lyase  
Possible association  
(Carey et al., 1994; Gharani et 
al., 1996; Witchel et al., 1998) 
 Cholesterol side-chain cleavage 
enzyme 
Weak significant association 
(Gharani et al., 1997; Urbanek 
et al., 1999; Diamanti-
Kandarakis et al., 2000) 
 21-Hydroxylase  Significant association 
(Escobar-Morreale et al., 1999) 
 Androgen Receptor 
 
Possible association  (Urbanek 
et al., 1999; Mifsud et al., 2000) 
 
Carbohydrate metabolism/fuel 
homeostasis 
Leptin  No association (Oksanen et al., 
2000) 
 Leptin receptor  No association (Oksanen et al., 
2000)  
 Insulin receptor gene  Significant association  for 
nearby genes (Urbanek et al., 
1999; Tucci et al., 2001) 
 Insulin gene Possible association 
(Waterworth et al., 1997; 
Urbanek et al., 1999) 
 
Gonadotropin action and 
regulation 
LH β-subunit  No association with PCOS (Elter 
et al., 1999) 
 FSH β-subunit No association (Conway et al., 
1999) 
 Activin binding protein 
 
Possible linkage (Urbanek et al., 
1999) 
  
  
In recent years there has been a great deal of interest in the metabolic associations 
of PCOS as characterised by a distinct form of insulin resistance (Dunaif, 1999). In 
addition to mutations in the insulin gene variable number tandem repeat (Ins-
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VNTR) and the insulin receptor gene, the secretory products of adipose tissue 
including leptin and resistin (Urbanek et al., 2003) also promote insulin resistance 
and have been considered as candidates for PCOS genes (Moller, 2000). An 
additional pathway which needs to be considered in identifying potential candidate 
genes is the regulation and action of gonadotropins. A number of genes have been 
shown to be involved in follicle development (i.e. follistatin gene, LH and its 
receptor, FSH and its receptor). Moreover, recent observations have shown that 
the FSH receptor (FSHR) genotype is associated with different requirements for 
exogenous FSH in in-vitro fertilization (IVF) patients (Perez et al., 2000). In women 
with normogonadotropic normo-estrogenic anovulatory infertility the response of 
the ovary upon exogenous FSH administration varies considerably (van Santbrink 
and Fauser, 1997; Coelingh Bennink et al., 1998). A less sensitive FSH receptor 
might be responsible for the increased FSH threshold (i.e the dose at which the 
first follicle  ≥ 10 mm emerges) in these women which is only surpassed during 
clomiphene citrate or gonadotropin induction of ovulation. Therefore, it might be 
hypothesized that differences in the FSHR genotype might be found in women with 
anovulatory infertility. 
 
1.4  Phenotype and treatment outcome  
 
1.4.1  Treatment modalities 
Medical induction of ovulation using clomiphene citrate (CC) as first line and 
exogenous gonadropins as second line form the classical ovulation induction 
treatment algorithm in WHO II anovulatory infertility. CC is generally applied as first 
line treatment in these women, due to low costs and minor chances of side effects 
or complications. Traditionally, exogenous gonadotropins are considered second 
line therapy in case of failure to ovulate or conceive following CC. The final step of 
treatment strategy is IVF. Major complications during gonadotropin ovulation 
induction and IVF include OHSS (Golan et al., 1989), multiple pregnancies 
(Schenker et al., 1981), and a high rate of early pregnancy wastage (Shoham et 
al., 1991).  
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Figure 3 Schematic presentation of the WHO II anovulatory infertility treatment algorithm. 
 
A schematic presentation of the present treatment strategy and possible treatment 
outcome has been depicted in Figure 3. In this section, the ovulation induction and 
IVF protocols used in daily clinical practice will be described in brief. Additionally, 
alternative treatment modalities will be mentioned.  
 
Generally, CC treatment is initiated between day 3 and day 5 after a spontaneous 
or progestagen-induced withdrawal bleeding. CC interference with estrogen 
negative feedback may be held responsible for stimulating follicle growth due to 
rising serum FSH levels (Jacobson et al., 1968; Kerin et al., 1985). The starting 
dose is 50 mg/day, orally, for 5 subsequent days after initiation of menstruation. 
Daily doses are increased by 50 mg in the subsequent cycle to increase the 
endogenous FSH rise and induce follicle maturation. The highest recommended 
CC dose is 150 mg/day which generally is used in the subsequent cycle after a 
given WHO II patient persists to remain anovulatory following 100 mg of CC. If 
ovulation occurs, the CC dose used should remain unaltered for subsequent 
cycles.  
 
Since their introduction into clinical practice in 1958, exogenous gonadotropin 
preparations play a central role as the second line modality for ovulation induction 
in WHO II patients who fail to ovulate or conceive during the previous anti-estrogen 
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medication (Schwartz and Jewelewicz, 1981; Lunenfeld et al., 1985; Fauser and 
van Heusden, 1997). The aim of this treatment is to approach normal conditions as 
closely as possible; i.e. maturation and ovulation of a single dominant follicle and 
subsequent singleton pregnancy.  
Treatment regimens which involve a stepwise increase in dosages of 
gonadotropin during follicular development (‘step-up regimens’) are frequently used 
clinically. The conventional step-up regimen employed relatively high initial doses 
of gonadotropins leading to high rates of multiple pregnancies (36%) and the 
potentially life-threatening OHSS (14%) (Dor et al., 1980). The subsequently 
introduced ‘low-dose step-up’ regimen is associated with considerably lower 
complication rates (White et al., 1996), and this regimen is now employed in most 
European centres.  
Studies of the endocrine physiology of normal follicular development have 
highlighted the essential unphysiological nature of step-up regimens (van Santbrink 
et al., 1995a). In an attempt to mimic physiology more closely in anovulatory 
women, a stimulation regimen has been developed which involves reducing 
(instead of increasing) the dose of gonadotropins administered during the period of 
follicular development (van Santbrink and Fauser, 1997). In a small prospective 
randomized trial, the low-dose step-down and the low-dose step-up regimen gave 
comparable clinical outcomes. However, in the step-down group, a substantially 
reduced stimulation period was required with a more physiological late-follicular 
FSH serum profile resulting in an increased number of mono-follicular stimulation 
cycles (van Santbrink and Fauser, 1997). On the other hand, it has been shown 
that monitoring of a step-down cycle may need more experience and skills 
compared with a low-dose step-up regimen (van Santbrink and Fauser, 2003). 
 
In-vitro fertilization (IVF) is the final treatment for WHO II anovulatory infertility. This 
is the least explored area in terms of understanding ovarian response during 
treatment and prediction of treatment outcome (complications and live birth) partly 
due to lack of prospective follow-up studies (Dor et al., 1992; Urman et al., 1992). 
Previous studies comparing IVF treatment outcome in PCOS versus controls have 
shown that more oocytes could be retreived, but with a reduced proportion of 
oocytes fertilized. Despite reduced overall fertilization, IVF pregnancy rates in 
PCOS patients appear to be comparable to normo-ovulatory women (Dor et al., 
1990; Urman et al., 1992; Homburg et al., 1993).  
At present, the most commonly used ovarian stimulation regimen in IVF for 
patients with anovulatory infertility includes pituitary down-regulation with a GnRH 
agonist in a long protocol which makes use of co-administration of high dose 
exogenous gonadotropins. This approach to ovarian stimulation involves a 
complex expensive treatment protocol and intensive monitoring, while the risk of 
developing complications (i.e OHSS and multiple pregnancies) remains.   
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Over the past 10 years, increased attention has focused towards alternative 
treatment options such as the insulin-sensitizing agents (Nestler et al., 2002; 
Glueck et al., 2002; Lord et al., 2003), aromatase inhibitors (Mitwally and Casper, 
2001) or laparoscopic surgery of the ovaries (Farquhar et al., 2001). Diet and 
exercise may also be a different approach in restoring the ovarian abnormality and 
should be combined with most of the treatment strategies to increase the chance of 
spontaneous or stimulated ovulation and conception (Hollmann et al., 1996; Clark 
et al., 1998). Treatment with the insulin-sensitizing agents has already been shown 
to be successful in terms of ovulation and pregnancy rates (Lord et al., 2003). For 
the other treatment modalities it can be concluded that although initial studies are 
promising, their role in every day clinical practice remains uncertain until data from 
prospective follow-up studies become available regarding large series of well-
defined patient groups. 
 
1.4.2 Prediction of treatment outcome 
Clinical characteristics have proven to be predictive of ovulation induction (CC and 
gonadotropin) treatment outcome in women with WHO II anovulatory infertility 
(Imani et al., 1998; Imani et al., 1999; Imani et al., 2002a; Imani et al., 2002b; 
Eijkemans et al., 2003). Since these characteristics appear to be related to ovarian 
dysfunction they might discriminate between patients with favourable or 
unfavourable chances following gonadotropin ovulation induction and IVF. Finally, 
the identification of factors predicting the ovarian response to fertility treatment may 
help us unravel the complex etiology involved in anovulatory infertility.   
 
1.5 Study objectives 
 
The present thesis is focussing on the heterogeneity of phenotype expression in 
women suffering from WHO II anovulatory infertility and PCOS.  
First, we have evaluated whether AMH can be used as a marker for the 
extent of ovarian dysfunction in women with normogonadotropic anovulation. 
Furthermore, we will assess whether AMH might be helpful in elucidating the 
pathofyiology of disturbed follicle dynamics as found in women with PCOS.  
Secondly, the clinical entity WHO II anovulation (including PCOS), 
characterised by its heterogeneous presentation, has an important focus in the 
present thesis. The use of OCP has been shown to alter the clinical, endocrine and 
sonographic characteristics associated with anovulatory infertility. Additionally, 
another objective is to study the influence of the use of OCP on PCOS phenotype 
expression.   
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Thirdly, PCOS seems to cluster in families with a complex pattern of 
inheritance. In the present thesis the candidate gene approach is followed to 
identify a possible gene involved. The candidate gene study was performed in a 
well-defined population of WHO II patients. We chose the gene for follicle-
stimulating hormone receptor (FSHR), since the FSHR genotype is associated with 
different requirements for exogenous FSH.  
Finally, shifting the paradigm from diagnosis to prognosis, the optimal 
treatment for a given WHO II patient may be defined, rendering treatment 
strategies more patient tailored. Ultimately, the identification of factors predicting 
the ovarian response to ovulation induction and IVF might add to our 
understanding of mechanism involved in ovarian dysfunction in these patients. 
Considering this approach, the prediction of outcome in gonadotropin ovulation 
induction strategies and IVF in WHO II patients will be amongst the scope of the 
present thesis.  
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2.1 Anti-Müllerian Hormone (AMH) serum concentrations in normo-ovulatory 
and anovulatory women of reproductive age.  
 
Abstract 
 
Anti-Müllerian hormone (AMH) inhibits the recruitment of primordial follicles into the 
pool of growing follicles. Since serum AMH concentrations correlate with the 
number of antral follicles as well as age, it may be used clinically as an endocrine 
marker for ovarian ageing. In normogonadotropic anovulatory infertile women 
(World Health Organization class II) the number of early antral follicles is usually 
increased. To investigate whether AMH concentrations are increased, serum levels 
in 128 WHO II women were compared to those in 41 normo-ovulatory 
premenopausal women of similar age.  
Serum AMH concentrations are significantly (P < 0.001) elevated in WHO II 
patients (median: 7.6 µg/L [range: 0.1-40.0]) compared to controls (median: 2.1 
µg/L [0.1-7.4]). In 106 patients presenting with polycystic ovaries (PCO) (≥ 12 
follicles/ovary measuring 2-9 mm and/or an ovarian volume > 10 mL) AMH levels 
are elevated (9.3 µg/L [1.8-40.0]) compared to 22 patients without PCO (6.4 µg/L 
[0.1-22.1]) (P < 0.0001). In WHO II patients AMH concentrations correlate with 
features characteristic for polycystic ovary syndrome (PCOS) such as LH 
concentrations (r = 0.331; P = 0.0001), testosterone levels (r = 0.477; P = 0.0001), 
mean ovarian volume (r = 0.421; P = 0.0001) and the number of ovarian follicles (r 
= 0.308; P = 0.0001). AMH levels correlated well with age in WHO II patients (r = -
0.248; P = 0.002) as well as in controls (r = -0.465; P = 0.005). However, the 
relative decline in AMH with age is less pronounced in WHO II patients. In a subset 
of patients no significant correlation was found between AMH serum 
concentrations and the FSH response dose, the duration of stimulation and the 
total number of ampoules of FSH used. 
In conclusion, serum AMH concentrations are elevated in WHO II women, 
especially in those patients exhibiting PCO. Since AMH concentrations correlated 
well with other clinical, endocrine and ultrasound markers associated with PCOS, 
AMH may be used as a marker for the extent of the disease. A less pronounced 
AMH decrease over time in these women may suggest retarded ovarian ageing. 
The latter hypothesis however, should be confirmed by longitudinal studies. 
 
2.1.1 Introduction 
 
The dimeric glycoprotein anti-Müllerian hormone (AMH), also referred to as 
Müllerian- inhibiting substance (MIS), is a member of the transforming growth 
factor ß (TGFß) superfamily (Cate et al., 1986). During fetal sex differentiation, 
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AMH is produced by Sertoli cells in the male, in which it induces degeneration of 
the Müllerian ducts (Munsterberg and Lovell-Badge, 1991). In females, AMH is 
expressed only postnatally by the ovary, and until recently its function in the female 
reproductive tract was unknown (Hirobe et al., 1994; Durlinger et al., 2002b).  
Female AMH null mice were reported to be fertile and produced normal-
sized litters (Lyet et al., 1995). However, ovaries of AMH null mice as well as 
female mice heterozygous for the AMH null mutation, contained less primordial 
follicles and more growing follicles, compared with their wild-type littermates 
(Durlinger et al., 1999). In addition, AMH was able to inhibit the initiation of 
primordial follicle growth in cultured neonatal mouse ovaries (Dürlinger et al., 1999) 
and stimulate growth of rat preantral follicles (McGee et al., 2001). Hence, AMH 
appears to regulate early follicle development directly. Furthermore, the absence of 
AMH has been shown to enhance follicle-stimulating hormone (FSH) induced 
follicle growth in female mice (Durlinger et al., 2001). 
Recently, serum AMH levels have been shown to decrease over time in 
young normo-ovulatory women, whereas other markers associated with ovarian 
ageing did not change during this time interval (de Vet et al., 2002). Although AMH 
concentrations did correlate with age and FSH, AMH serum levels were most 
strongly associated with the number of antral follicles. Therefore, AMH might 
represent a sensitive marker for ovarian ageing (Fanchin et al., 2003a). Indeed, it 
has been shown that poor response during in-vitro fertilization (IVF), indicative of a 
diminished ovarian reserve (Beckers et al., 2002), is associated with reduced 
baseline serum AMH concentrations (Seifer et al., 2002; van Rooij et al., 2002).  
Chronic anovulation constitutes a major (20-25%) proportion of infertile 
couples (The ESHRE Capri Workshop Group, 1995; van Santbrink et al., 1997). 
According to the World Health Organization (WHO), approximately 80% of patients 
suffering from chronic anovulation present with serum FSH levels within the normal 
range, along with normal endogenous estrogen activity. These women are 
classified as having normogonadotropic normo-estrogenic anovulatory infertility, 
more commonly referred to as WHO class II (Rowe et al., 2000). Since etiologic 
factors underlying this condition may vary from one patient to another, WHO II 
anovulatory women including those with polycystic ovary syndrome (PCOS) 
constitute a notoriously heterogeneous population (Laven et al., 2002). In WHO II 
patients the number of small antral follicles is generally increased due to disturbed 
dominant follicle selection (Fauser, 1994). Because AMH is predominantly 
expressed by small follicles in mice (Durlinger et al., 2002b) as well as in the 
human (Fanchin et al., 2003b), AMH serum concentrations may be increased in 
patients with polycystic ovaries (PCO). Indeed, in PCOS patients exhibiting the 
classical features of the syndrome, AMH levels were found to be elevated, 
compared with normal controls (Cook et al., 2002). The current study was 
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designed to evaluate AMH as a clinically relevant marker for the extent of ovarian 
dysfunction in WHO II anovulatory women, with or without PCO. 
 
2.1.2 Materials and methods 
 
Subjects 
The local Medical Ethics Review Committee approved this study, and informed 
consent was obtained from all participants. Included in the study were 128 patients 
attending our fertility clinic between 1994 and 1999 with; (a) infertility, (b) 
oligomenorrhea (interval between periods > 35 days) or amenorrhea (absence of 
vaginal bleeding for at least 6 months), (c) serum FSH concentrations within 
normal limits (1-10 IU/L) (Schipper et al., 1998), (d) positive withdrawal bleeding 
after progestagen administration in case of amenorrhea, and (e) age between 19 
and 41 years. Standardized initial screening (clinical investigation, transvaginal 
ultrasound (TVS), and fasting blood withdrawal) was performed on a random day 
between 9-11 AM, irrespective of the interval between blood sampling and the 
preceding bleeding, as previously described (Imani et al., 1999). A subgroup of 
these patients was diagnosed as PCOS due to hyperandrogenemia and an 
increased follicle number and/or ovarian volume. Hyperandrogenemia was defined 
as an elevated (> 4.5) free androgen index (FAI) (testosterone (T) x 100/sex 
hormone-binding globulin (SHBG)). Similarly, an increased follicle number was 
defined as ≥ 12 follicles/ovary measuring 2-9 mm and the ovarian volume was 
considered to be increased above 10 mL (van Santbrink et al., 1997).  
For sonographic imaging we used a 6.5 MHz vaginal transducer (model 
EUB-415, Hitachi Medical Corp., Tokyo, Japan). The ovaries were localized and 
scanned as described previously (Pache et al., 1991). Ovarian volume, stroma 
echogenicity (arbitrarily scored from 1 to 3 per ovary), and the mean follicle number 
were assessed as described earlier (van Santbrink et al., 1997). Women exhibiting 
PCO had either an increased ovarian volume (> 10 mL) or an increased number of 
follicles (≥ 12 follicles measuring 2-9 mm in at least one ovary). 
The control group consisted of 41 healthy volunteers selected by 
advertisement and paid for participation as previously published (Schipper et al., 
1998). Inclusion criteria were a regular menstrual cycle (26-30 days), 20-36 years 
of age, normal body mass index (BMI) (18-25 kg/m2), and no previous use of 
medication or oral contraceptives during at least 3 months before the study. 
Transvaginal ultrasound (TVS) and blood sampling was performed during the early 
follicular phase (cycle day 3, 4, or 5). 
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Ovulation induction treatment  
In a subgroup of WHO II women (those who failed to ovulate or conceive following 
clomiphene citrate treatment) gonadotropin treatment was commenced within 3 to 
5 days after initiation of a spontaneous or progestagen-induced withdrawal 
bleeding. Patients received daily s.c. injections of recombinant FSH (Gonal-F®, 
Ares-Serono, Geneva, Switzerland). During all first cycles a low-dose step-up 
protocol was used with a starting dose of FSH of one ampoule (75 IU) per day. The 
daily dose was increased by ½ ampoule if ovarian response (at least one follicle of 
at least 10 mm) was absent after 14 days. Thereafter the dose was increased by ½ 
ampoule every 7 days if required. The FSH response dose was defined as the 
dose at which an ovarian response was observed (Imani et al., 2002a). In case a 
sufficient ovarian response was observed, the dose was kept constant until 
administration of 5,000 IU human chorionic gonadotropin (hCG) (Profasi®, Ares-
Serono, Geneva, Switzerland). 
 
Hormone assays 
Blood samples were obtained by venepuncture and processed within 2 hours after 
withdrawal. Serum was stored at -20°C and assayed for AMH, LH, FSH, 
androstenedione (AD), T, SHBG, inhibin B, and estradiol (E2). Serum AMH levels 
were assessed using an ultra-sensitive immuno-enzymometric assay 
(Immunotech-Coulter, Marseilles, France), as described elsewhere (de Vet et al., 
2002). The limit of detection (defined as blank +3 SD of the blank) amounted to 
0.05 µg/L. For quality control, samples of pooled serum with high and low levels of 
AMH were assayed in all separate assays. Intra- and interassay coefficients of 
variation were less then 5% and 8%, respectively. 
Serum levels of LH, FSH, and SHBG were measured using luminescence 
based immuno assays (Immulite, Diagnostic Products Corp., Los Angeles, CA, 
USA) whereas serum E2, T, and AD levels were measured using coated tube 
radioimmunoassays (RIAs) provided by the same supplier. Intra- and interassay 
coefficients of variation were less than 5% and 15% for LH, less than 3% and 8% 
for FSH, less than 8% and 11% for AD, less than 3% and 5% for T, less than 5% 
and 7% for E2, and less than 4% and 5% for SHBG, respectively.  
 Dimeric inhibin B levels were assessed using an immuno-enzymometric 
assay obtained from Serotec (Oxford, UK), as described previously (Schipper et 
al., 1998). The detection limit of the assay, defined as the amount of inhibin 
equivalent with the signal of the blank +3 SDs of this signal, was 3.4 ng/L. Intra- 
and interassay coefficients of variation for inhibin B were less than 9% and 15%, 
respectively. 
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Statistical analysis was performed using a commercially available software 
package (SPSS, SPSS Inc., Chicago, IL, USA). Data were analyzed for normal 
distribution. Data are presented as the mean ± SD if distributed normally or 
otherwise as the median and range. To determine differences between groups, 
Mann-Whitney or Kruskal-Wallis tests were used if data were not normally 
distributed. In case data were normally distributed, Student’s t test or ANOVA was 
used. Correlations were expressed as Spearman’s correlation coefficients. 
Regression statistics were applied to assess the differences in decline of 
parameters in time. A P level ≤ 0.05 was considered to be statistically significant. 
 
2.1.3 Results  
 
General clinical characteristics, endocrine data as well as ultrasound findings in 
controls and patients are summarized in Table 1. Briefly, patients were comparable 
with control subjects as far as age was concerned. Endocrine parameters in control 
subjects were all well within the normal range for regularly cycling women. Similarly 
ultrasound scans revealed normal follicle counts in both ovaries in these 
volunteers.  
WHO II patients were either oligo- or amenorrheic, with a median cycle 
duration of 75 days, being significantly different (P < 0.001) from controls. The BMI 
was significantly different in WHO II women, compared with controls (P < 0.01). 
WHO II women presented with elevated LH and T and more PCO on ultrasound 
scanning.  
AMH levels were significantly (P < 0.001) different between controls (median 
2.1 µg/L; range 0.1-7.1 µg/L) and WHO II patients (median 7.6 µg/L; range 0.1-
40.0 µg/L).  When WHO II women were categorized into those with and without 
PCO (≥ 12 follicles measuring between 2 and 9 mm and/or and ovarian volume > 
10 mL), AMH levels were significantly higher (9.3 µg/L; range 1.8-40.0 µg/L) in 
PCO patients compared with non-PCO (6.4 µg/L; range 0.1-22.1 µg/L; P < 0.001) 
and controls (2.1 µg/L; range 0.1-7.1 µg/L; P < 0.001) (Figure 1).  
There was a significant (r = -0.465; P < 0.002) negative correlation between 
age and AMH levels in control subjects. Similarly, a significant negative correlation 
was found in WHO II patients (r = -0.248; P < 0.001). The decrease in AMH levels 
with increasing age was significantly (P < 0.001) different in WHO II patients, 
compared with controls (Figure 2).  
In WHO II patients, AMH levels were significantly correlated with cycle 
duration (r =  0.203; P < 0.05), LH (r = 0.331; P < 0.001), T (r = 0.477; P < 0.001), 
AD (r = 0.321; P < 0.001), FAI (r = 0.224; P < 0.01), mean ovarian volume (r = 
0.421; P < 0.001), and mean follicle number (r = 0.308; P < 0.001) but not with 
inhibin B levels (Figure 3).  
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TABLE 1 Clinical, endocrine and ultrasound parameters (median and range) in normo-ovulatory control 
subjects compared to normogonadotropic normo-estrogenic anovulatory infertile women (WHO II). 
 Controls 
(n = 42) 
WHO II 
(n= 128) 
Clinical  parameters   
Age (years) 29.9 (20.6 - 35.6) 28.9 (19.3 - 40.8) 
BMI (kg/m2) 21.5 (18.8 - 24.3) 25.9 (22.1 - 39.8)a 
Cycle duration (days) 28 (25 - 31) 75 (35 - 183c)b 
   
Endocrine parameters   
LH (IU/L) 3.1 (1.0 - 6.7) 7.0 (1.1 - 23.5)a 
FSH (IU/L) 6.1 (3.3 - 10.0) 5.5 (2.3 - 10.0) 
E2 (pmol/L) 153 (64 - 404) 241 (73 - 864) 
Inhibin B (ng/L) 113 (12 - 213) 129 (21 - 430) 
T (nmol/L) 1.5 (0.5 - 2.9) 2.5 (0.7 - 6.5)a 
AD (nmol/L) NA 14.1 (4.0 - 49.3) 
FAI (100 X T/SHBG) NA 5.9 (1.4 - 29.3) 
   
Ultrasound parameters   
Mean number of follicles (both ovaries)  14 (6 - 28) 24 (2 - 45)a 
Ovarian volume (mL)(per ovary) NA 10.5 (2.5 - 22.9) 
   
 
a P < 0.01 
b P < 0.001  
c Indicating amenorrhea.  
NA = not assayed. 
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In 79 WHO II patients who previously failed clomiphene citrate ovulation 
induction (75%), data with regard to ovulation induction outcome using 
gonadotropins were available. There was no significant correlation between AMH 
serum levels and the FSH response dose, being defined as the dose of exogenous 
FSH at which the first follicle of 10 mm or larger emerged (r = -0.147; P < 0.200; 
data not shown). Similarly, there was no correlation between AMH serum 
concentrations and the duration of stimulation (in days) or the total number of 
ampoules FSH used (data not shown).  
 
2.1.4 Discussion 
 
The present study clearly shows that AMH levels are increased in 
normogonadotropic anovulatory infertile patients. The subgroup of WHO II women 
exhibiting polycystic ovaries presents with the highest AMH serum levels. 
Furthermore, it seems that AMH levels correlate with the extent of ovarian 
dysfunction in these women, as represented by elevated LH or T levels and an 
increased follicle number and/or ovarian volume as established on ultrasound. 
Finally, it might be hypothesized that the age of menopause is delayed in these 
anovulatory women, which might be a direct consequence of elevated intra-ovarian 
AMH production due to an increased number of AMH producing units.  
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Figure 1 Box and whisker plots 
depicting the AMH serum 
levels in normogonadotropic  
anovulatory infertile women 
with polycystic ovaries (PCO) 
and those without (non-PCO), 
compared with normo-
ovulatory controls. Solid lines 
inside boxes depict the median 
AMH level, whereas the upper 
and lower limits of the boxes 
and whiskers indicate 75th, 25th 
and 95th, and 5th percentiles. 
 
New markers for ovarian dysfunction and their clinical implications 
 
 
39
 
 
 
On histological examination it has been shown that PCO exhibit the same 
number of primordial follicles, whereas the number of developing and subsequent 
atretic follicles was doubled, compared with normo-ovulatory controls (Hughesdon, 
1982). Despite the increased number of developing follicles, inhibin B serum levels 
(a marker for small developing follicles) were normal in WHO II patients, 
suggesting an increased number of atretic follicles (Laven et al., 2001a). It appears 
that follicle development is arrested in PCOS at the stage were dominant follicle 
selection occurs under normal conditions (Pache et al., 1992b; Schoot et al., 1993; 
Chandrasekher et al., 1995; van Dessel et al., 1999). Follicle maturation arrest 
during later stages of development may lead to a build up of many immature 
follicles, which in it self could explain increased AMH levels. Hence, it might be 
anticipated that the increased number of follicles, which are generally present in 
PCO, are the source of increased AMH production (Cook et al., 2002).  
 
A
M
H
 ( µµ µµ
g/
L)
 
 
Age (yrs) 
 
60 
 
40 
 
30 
 
20 
 
10 
 
0 
 
40 
 
30 
 
20 
 
10 
 
0 
 50 
 
Figure 2 Individual serum AMH 
concentrations versus age in 128 
WHO II anovulatory infertile patients 
(closed dots), compared with 41 
normo-ovulatory controls (open dots). 
Note the differences (in AMH 
concentration and slope) between the 
regression lines of WHO II and 
controls.  
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Because AMH constitutes a marker for the number of small follicles, its 
correlation with ovarian volume and the number of follicles present in the ovary, is 
not surprising. PCO as observed during ultrasound constitute a sensitive marker 
for the extent of ovarian dysfunction in anovulatory women as well as for ovulation 
induction outcome (Imani et al., 2002b; Jonard et al., 2003). Although AMH serum 
levels were the highest in anovulatory patients with prominent PCO, women 
without PCO also exhibited elevated levels. In the female, AMH is solely 
synthesized by granulosa cells of preantral and small antral follicles (Durlinger et 
al., 2002b). Apparently, smaller follicles, which are not readily detected on 
ultrasound, do significantly contribute to serum AMH levels. Therefore, AMH might 
even constitute a more sensitive marker of ovarian dysfunction in WHO II patients 
than PCO on ultrasound. Indeed, AMH serum levels correlated well with other 
parameters indicative for the extent of ovarian dysfunction such as elevated LH 
and T concentrations.  
Unfortunately, AMH serum concentrations were not significantly correlated 
with outcome parameters of ovulation induction using gonadotropins in those 
women who previously failed clomiphene citrate ovulation induction. Similarly, 
pregnancy rates and miscarriage rates were similar in patients with moderately and 
severely elevated AMH serum levels. Hence, elevated AMH serum levels are not 
associated with adverse treatment outcome indicating a limited predictive power of 
AMH levels in these patients. It seems therefore that the clinical relevance of AMH 
serum concentrations is limited in women in whom clomiphene citrate ovulation 
induction previously failed. 
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Figure 3 Scatter plot depicting the relationship between the individual AMH serum 
concentrations and LH, T, and the mean follicle number respectively, in WHO II anovulatory 
women. Correlation coefficients, Spearman ranks (r), and their respective significance levels 
(P) are shown in the upper right corner. 
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In PCOS patients, aromatase activity may be decreased, because follicles 
from PCO do not produce large amounts of E2. It has been shown that follicular 
fluid has a potent inhibitory effect on E2 production in PCOS (Agarwal et al., 1996; 
Schipper et al., 1997). This follicular fluid derived inhibitor decreases aromatase 
activity by suppressing the P450 aromatase mRNA expression in follicles of PCOS 
patients (Jakimiuk et al., 1998). Because AMH serum concentrations do correlate 
with serum levels of T, AD, and SHBG and only weakly with E2 concentrations, it 
might be speculated that AMH might constitute this follicular fluid derived inhibitory 
factor. Indeed, exogenous AMH did inhibit the biosynthesis of aromatase in 
cultured rat granulosa cells (di Clemente et al., 1994). Moreover, in PCOS women 
an inverse relationship between E2 and AMH serum levels has been previously 
established (Cook et al., 2002). 
A surprising finding constitutes the difference in relative decline in AMH 
serum levels with increasing age between normal controls and WHO II patients, 
suggesting that the latter group might reach menopause later in life. Because AMH 
levels correlate with the number of early antral follicles, which might in turn 
represent the size of the resting pool of follicles, AMH may constitute a marker for 
ovarian ageing (de Vet et al., 2002; van Rooij et al., 2002). Hence, increased intra-
ovarian AMH production in PCO may slow down the process of primordial follicle 
recruitment and thus retard depletion of the primordial follicle pool. Although, it has 
been reported that cycle irregularities and hormonal profiles improve with 
increasing age (Dahlgren et al., 1992; Elting et al., 2000; Bili et al., 2001) data 
regarding the age of menopause in these women are lacking. However, 
menopausal age in these women is difficult to establish because most of them will 
regulate their cycles up to advanced age using oral contraceptive pills. Whether 
AMH can be used as a reliable marker in PCOS should be further substantiated. 
Moreover, the challenging concept of retarded ovarian ageing in PCOS needs 
further confirmation by properly designed longitudinal follow-up studies. 
In conclusion, serum AMH concentrations are elevated in WHO II women, 
which appears to be related to the increased number of small preantral and early 
antral follicles, especially in those patients exhibiting PCO. Because AMH 
concentrations correlated well with other clinical, endocrine and ultrasound 
parameters indicative of ovarian dysfunction in these patients, AMH may constitute 
a novel marker for the extent of the disease. Elevated AMH serum levels in WHO II 
and especially PCOS patients might indicate an increased ovarian reserve. 
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2.2 Changes in anti-Müllerian hormone serum concentrations over time 
suggest delayed ovarian ageing in normogonadotropic anovulatory infertility  
 
Abstract 
 
Anti-Müllerian hormone (AMH), produced by growing preantral and early antral 
ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum 
AMH concentrations are elevated during reproductive life in anovulatory women, 
especially in those patients exhibiting polycystic ovaries (PCO). The current study 
was designed to investigate whether the decrease in AMH serum concentrations 
over time is different comparing women with normogonadotropic anovulation 
(World Health Organization (WHO) group II)(including polycystic ovary syndrome 
(PCOS)) and normo-ovulatory controls.  
AMH serum levels were assessed on 2 occasions in 98 patients suffering 
from WHO II anovulatory infertility as well as in 41 normo-ovulatory premenopausal 
women. Median time interval between both visits was 2.6 years [range: 0.3-9.0] for 
WHO II patients compared to 1.6 years [range: 1.0-7.3] in controls. Serum AMH 
concentrations were significantly (P < 0.0001) elevated at both occasions in WHO 
II patients (AMH1: median = 7.5 µg/L [range: 0.1-35.8] and AMH2: median = 6.7 
µg/L [range: 0.0-30.6]) compared to controls (AMH1: median = 2.1 µg/L [range: 0.1-
7.4] and AMH2: median = 1.3 µg/L [range: 0.0-5.0]). Regression analysis, corrected 
for age, indicated a significant relative decrease in serum AMH concentrations over 
time for both groups (P < 0.001). However, the decline in serum AMH in WHO II 
patients was significantly less compared to controls (P = 0.03).   
The present longitudinal study shows that serum AMH concentrations 
decrease over time both in women presenting with WHO II anovulatory infertility as 
well as in normo-ovulatory controls. The decrease in WHO II patients is less 
pronounced despite distinctly elevated concentrations. This observation may 
suggest retarded ovarian ageing and hence a sustained reproductive life-span in 
these patients. 
 
2.2.1 Introduction 
 
The dimeric glycoprotein anti-Müllerian hormone (AMH), a member of the 
transforming growth factor β (TGF-β) superfamily, is produced exclusively in the 
gonads (Lee and Donahoe, 1993) and is involved in the regulation of growth and 
development (Cate et al., 1986). During male fetal sexual differentiation, AMH (also 
known as Müllerian-inhibiting substance (MIS)) is synthesized by testicular Sertoli 
cells and induces degeneration of the Müllerian ducts (Jost, 1947; Josso et al., 
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1993; Lee and Donahoe, 1993). AMH expression in the ovary starts at the end of 
the third trimester of pregnancy (Rajpert-De Meyts et al., 1999), where it is 
produced in the granulosa cells of early developing follicles (Baarends et al., 1995).   
Ovaries of AMH knock-out mice as well as female mice heterozygous for the 
AMH deletion showed an accelerated exhaustion of the primordial follicle stock 
(Durlinger et al., 1999), suggesting important roles for AMH in depletion of the 
primordial follicle pool. Moreover, AMH was able to inhibit the initiation of primordial 
follicle growth in cultured neonatal mouse ovaries (Durlinger et al., 2002a), and 
AMH has been shown to inhibit follicle-stimulating hormone (FSH) induced follicle 
growth in female mice (Durlinger et al., 2001).  Recent data suggest that AMH 
expression in the human ovary is similar to that observed in mouse and rat 
(Weenen et al., 2004), suggesting important roles for AMH in the regulation of 
human early follicle growth as well.  
AMH serum levels decline with increasing age in normo-ovulatory women 
(de Vet et al., 2002) and are strongly correlated with the number of antral follicles. 
Hence, AMH may be used as a marker for ovarian ageing (de Vet et al., 2002; van 
Rooij et al., 2002; Fanchin et al., 2003a). In fact, poor response during ovarian 
hyperstimulation for in-vitro fertilization (IVF) (indicative of ovarian ageing (Beckers 
et al., 2002)) has been shown to be associated with reduced early follicular phase 
AMH serum concentrations (van Rooij et al., 2002; Seifer et al., 2002; Fanchin et 
al., 2003b).  
Chronic anovulation is a common cause of infertility and it is diagnosed in 
around 20-25% of couples with fertility problems (The ESHRE Capri Workshop 
Group, 1995; Laven et al., 2002). Most of these women present with irregular 
menstrual cycles and normal serum FSH concentrations (World Health 
Organization [WHO] Group II) (Rowe et al., 2000). Recent data have shown that 
serum levels of AMH are elevated in WHO II and polycystic ovary syndrome 
(PCOS) patients (Cook et al., 2002; Pigny et al., 2003; Laven et al., 2004). 
Moreover, it seems that AMH levels correlate well with the extent of ovarian 
dysfunction in anovulatory women (Laven et al., 2004). Finally, the decline in AMH 
serum levels with increasing age in this cross-sectional data set differs when 
comparing anovulatory women and normo-ovulatory controls (Laven et al., 2004).   
Since AMH constitutes an important regulator of primordial follicle pool 
depletion (Durlinger et al., 1999), an increased intra-ovarian AMH production may 
slow down the process of depletion of the primordial follicle pool. Due to retarded 
exhaustion of the primordial stock of follicles, the age of menopause might be 
delayed in these anovulatory women. The current longitudinal cohort study was 
designed to investigate whether the decrease in AMH serum concentrations over 
time is different comparing women with WHO II anovulation (including PCOS) and 
ovulatory controls.  
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2.2.2 Materials and methods 
 
Subjects 
The local Medical Ethics Review Committee approved this study and informed 
consent was obtained from all participants. Ninety eight patients attending our 
fertility clinic between 1993 and 2003 with: (a) infertility, (b) oligomenorrhea 
(interval between periods > 35 days) or amenorrhea (absence of vaginal bleeding 
for at least 6 months), (c) serum FSH concentrations within normal limits (1-10 
IU/L) (van Santbrink et al., 1997), and (d) between 16 and 41 years of age were 
included in the present study. A subgroup of these patients was diagnosed as 
having PCOS due to hyperandrogenism and/or polycystic ovaries (PCO) on 
ultrasound (The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop 
group, 2004b). PCO were diagnosed in the case of an increased follicle count (> 
11 follicles in one or both ovaries) and/or an increased ovarian volume (> 10.0 mL) 
of at least one ovary (Balen et al., 2003). All WHO II women participated in 
previously published studies (Imani et al., 1998; Imani et al., 1999; Mulders et al., 
2003a; Mulders et al., 2003b). 
 The control group consisted of 41 normo-ovulatory women, as described 
before (de Vet et al., 2002). All control women participated in previous studies 
between 1993 and 1999 (van Santbrink et al., 1995a; Schipper et al., 1998; 
Hohmann et al., 2001). Inclusion criteria were regular menstrual cycle (26-30 
days), 20-36 years of age, body mass index (BMI) (19-26 kg/m2), absence of 
endocrine disorders or any other relevant disease, and no use of medications or 
oral contraceptives during the 3 months prior to the start of the study.  
For the anovulatory patients, repetitive standardized screening (clinical 
investigation, fasting blood withdrawal and transvaginal sonography (TVS)), was 
performed on a random day between 9 and 11 AM, as previously described (Imani 
et al., 1998). For each individual anovulatory patient, the length of the interval 
between visits is dependent on the time between each step of the treatment 
regimen (Imani et al., 1998). For the normo-ovulatory controls, repetitive TVS and 
blood sampling were performed during the early follicular phase (cycle day 3, 4, or 
5) (de Vet et al., 2002). For each control, the interval length between visits is 
dependent on the time between participation in both studies (de Vet et al., 2002).  
 
Hormone assays 
Blood samples were obtained by venepuncture and processed within 2 hours after 
withdrawal, as described previously. Serum was stored at -20°C until assayed. The 
hormone assays used have all been described elsewhere (Imani et al., 1998; de 
Vet et al., 2002). Serum AMH levels were measured by using an ultra-sensitive 
enzyme-linked immunosorbent assay (Immunotech-Coulter, Marseilles, France, as 
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described elsewhere (Long et al., 2000)). This assay uses the same components 
as the normal assay, but some procedural adaptations result in increased 
sensitivity, making it possible to determine lower serum concentrations of AMH as 
they exist in women. Intra- and interassay coefficients of variation were less than 
5% and 15% for LH, less than 3% and 8% for FSH, less than 8% and 11% for 
androstenedione (AD), less than 3% and 5% for testosterone (T), less than 5% and 
7% for estradiol (E2), less than 4% and 5% for sex hormone-binding globulin 
(SHBG), less than 9% and 15% for inhibin B, and less than 5% and 8% for AMH, 
respectively (Imani et al., 1998; de Vet et al., 2002).  
 
Data analysis  
Results are presented as the mean ± SD if distributed normally, or otherwise as the 
median and range. To assess differences between groups, Mann-Whitney or 
Kruskal-Wallis tests were used. Associations between different parameters were 
assessed by Spearman’s rank correlation coefficient. To establish whether 
variables changed over time, the Wilcoxon matched pairs signed rank sum test 
was used. To determine the rate of change over time, regression analysis was 
used. After log-transformation, the ratio (value visit 2:visit 1) of variables was 
plotted against the time interval between visit 1 and 2. The relative decline per year 
was introduced in the present analysis since ovarian follicle depletion occurs at a 
constant rate of proportional decline for women under 38 years of age (Faddy et 
al., 1992). A possible difference in rate of decline between WHO II and controls 
was tested for in the analysis. All regression analyses were corrected for age. Data 
were analysed using the commercially available software package SPSS (Chicago, 
IL, USA). A P value of 0.05 was chosen as the threshold level for statistical 
significance. 
 
2.2.3 Results 
 
Clinical, endocrine and ultrasound characteristics during the first assessment in the 
WHO II and normo-ovulatory control group are summarized in Table 1. During the 
second assessment, BMI (P < 0.001), cycle duration (P < 0.001), serum E2 
concentrations (P < 0.001) and mean number of follicles (P < 0.001) were 
significantly elevated in WHO II patients when compared with the controls. Age (P 
= 0.03) and serum FSH concentrations (P < 0.001) were significantly elevated 
during the second assessment for the normo-ovulatory controls. Serum T 
concentrations decreased significantly (P < 0.001) over time for the WHO II 
patients (T1: median = 2.4 nmol/L (range: 0.3-6.8); T2: median = 2.1 nmol/L (range: 
0.5-4.6)).  
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Serum AMH concentrations were significantly (P < 0.001) elevated on both 
occasions in WHO II patients (AMH1: median = 7.5 µg/L (range: 0.1-35.8) and 
AMH2: median = 6.8 µg/L (range: 0.0-30.6)) compared with controls (AMH1: median 
= 2.1 µg/L (range: 0.1-7.4) and AMH2: median = 1.3 µg/L (range: 0.0-5.0)) (Figure 
1). Levels of AMH were negatively correlated with age at visit 1 (WHO II: r = -0.30, 
P = 0.003; controls: r = -0.47, P = 0.002) and visit 2 (WHO II: r = -0.25, P = 0.01; 
controls: r = -0.57, P < 0.001) (Figure 2). Additionally, associations between AMH 
and mean follicle number are shown for both groups at visit 1 and visit 2 (Figure 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A statistical analysis on the serum levels of AMH from participants in whom 
levels at both visits were assessed within 2 years after withdrawal was performed 
to exclude bias due to longterm storage (Lee et al., 1996). A one-sample t-test 
showed a significant decrease in AMH levels. Storage time did not significantly 
influence the slopes of the regression lines of follicle number compared with AMH 
level. The slope of the regression line for follicle number versus AMH serum levels 
was 0.36, 0.30 and 0.29 in groups with a storage time of 2 years, 2-3 years and > 4 
years, respectively (P = 0.8). 
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Figure 1 The left panel shows box-and whiskers-plots depicting the AMH levels in 98 
women with WHO II anovulation and 41 normo-ovulatory women at two different (visit 1 and 
visit 2) assessments. The right panel shows box-and whiskers-plots depicting the AMH 
levels for both groups by age category Solid lines inside boxes depict the median AMH level, 
whereas the upper and lower limits of the boxes and whiskers indicate 75th, 25th, 95th, and 5th 
percentiles. 
 
New markers for ovarian dysfunction and their clinical implications 
 
 
47
 
 
 
 
 
 
 
 AMH serum levels declined in both groups (Figure 3). The rate of decline, 
as shown by the regression lines, in WHO II patients differed significantly from 
controls (P = 0.03) (Figure 3). The regression coefficient (β) (representing the 
logarithm of 1 minus the relative decrease per year) for the normo-ovulatory 
controls was -0.16, compared to only -0.08 for women with WHO II anovulation. 
This implies a yearly decrease in AMH concentrations of 15% of the level of the 
year before in controls, compared to only 8% in WHO II women. Since there was a 
significant difference in age between the WHO II women and the controls, age was 
corrected for in the regression model. Correction for possible differences in age did 
not change either the data or the outcome. Figure 4 shows the fitted curves for the 
decline of AMH serum levels (mean (95% confidence interval (CI))) over time for 
both groups.  
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Figure 2 Scatter plots depicting the correlations between the individual AMH serum 
concentrations versus age and number of follicles, respectively, in 98 women with WHO II 
anovulation and 41 normo-ovulatory women at visit 1 (closed circles) and visit 2 (open circles). 
Spearman’s correlation coefficients and corresponding P values are depicted. 
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TABLE 1 Clinical, endocrine and ultrasound characteristics (medians with (range)) during the first 
assessment in 98 patients with WHO II anovulatory infertility compared with 41 normo-ovulatory 
controls. 
 WHO II  
anovulation 
Normo-ovulatory  
controls 
P value 
Clinical parameters    
Age (years) 27.4 (16.1 - 41.3) 29.9 (19.6 - 35.6) 0.04 
BMI (kg/m2) 27.9 (17.7 - 50.6) 22.3 (18.8 - 27.3) < 0.001 
Cycle duration (days) 93 (13 - 199a) 28 (25 - 31) < 0.001 
Endocrine parameters    
FSH (IU/L) 4.4 (0.1 - 15.7) 6.2 (3.3 - 13.5) < 0.001 
LH (IU/L) 6.8 (0.1 -  24.4) NA  
E2 (pmol/L) 207 (44 - 1137) 153 (64 - 404) < 0.001 
Inhibin B (ng/L) 102 (1 - 621) 113 (12 - 213) 0.9 
Testosterone (nmol/L) 2.4 (0.3 - 6.8) NA  
FAI (100 x T/SHBG) 5.5 (0.5 - 27.8) NA  
AMH (µg/L) 7.5 (0.1 - 35.8) 2.1 (0.1 - 7.4) < 0.001 
Ultrasound parameters    
Mean number of follicles 
(both ovaries) 
29 (5 - 84) 15 (6 - 28) < 0.001 
    
 
a Indicating amenorrhea.  
NA = not available. 
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There were no significant differences in the rate of change of AMH between 
the WHO II women with and without PCOS (data not shown).  
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Figure 3 Scatter plot 
depicting the change of 
the ratio of AMH (value 
visit 2:visit 1), in relation 
to the time interval 
between visit 1 and visit 2 
in 98 women with WHO II 
anovulation (closed 
circles, solid line) and 41 
normo-ovulatory women 
(open circles, dotted line). 
The decline in serum 
AMH over time was 
significantly less in WHO 
II patients (P = 0.03).  
 
Figure 4 Serum levels of AMH in 
relation to age in 98 women with WHO 
II anovulation and 41 normo-ovulatory 
women. Solid lines indicate the fitted 
regression line. Shaded areas indicate 
the 95% confidence intervals around 
the fitted lines. Note the difference in 
the decline of the regression lines 
between WHO II women and normo-
ovulatory controls. The intersection 
with the cut-off value of AMH 
(arbitrarily defined as 0.2 µg/L) of 
WHO II women and normo-ovulatory 
controls was 74 and 42 years 
respectively. 
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2.2.4 Discussion  
 
The present data once more show that AMH serum concentrations are increased 
in women with normogonadotropic normo-estrogenic anovulatory infertility 
compared with normal controls with regular menstrual cycles. Similar results in a 
previous publication from our group were based on a cross-sectional set of data 
(Laven et al., 2004). However, the current longitudinal analysis indicates for the 
first time that serum AMH concentrations decline less rapidly over time in women 
with WHO II anovulatory infertility compared with normo-ovulatory controls. This 
may indicate a sustained reproductive life-span in these anovulatory patients.  
 Polycystic ovaries (PCO) differ from normal ovaries in that follicle 
development is arrested at the stage where dominant follicle selection would have 
taken place under normal conditions (Pache et al., 1992b; van Santbrink et al., 
1995a; Fauser and van Heusden, 1997). Upon histological examination, it has 
been shown that the number of developing and subsequently atretic follicles was 
doubled compared with normo-ovulatory controls (Hughesdon, 1982; Webber et 
al., 2003). Moreover, the number of primordial follicles per section did not differ 
between women with and without PCO (Hughesdon, 1982; Webber et al., 2003). 
However, since the total ovarian volume is increased in PCO, it might be 
speculated that the primordial follicle pool is enlarged in these women. Indeed, 
recent histological studies using more sophisticated morphometric techniques 
suggest that the increased density of small preantral follicles in PCO possibly 
could result from a higher initial population of primordial follicles (Webber et al., 
2003). Alternatively, the rate of follicle depletion in women with PCO may also 
vary. At present, evidence regarding dissimilarities involved in regulation of 
ovarian ageing in women with and without PCO is lacking. However, data 
currently available suggest that the intrinsic ovarian abnormality associated with 
abberant follicular dynamics in the PCO might cause a reduced rate of atresia 
(Webber et al., 2003).  
Menopause represents the clinical hallmark of follicle pool exhaustion and 
the definitive end of reproductive life. In addition, the commencement of 
menopause at an earlier age is associated with an earlier initiation of subfertility, 
sterility and transition to cycle irregularity, and vice versa (te Velde and Pearson, 
2002). For normo-ovulatory women, it has been demonstrated that menstrual cycle 
irregularities associated with increasing age are dependent on the number of 
remaining follicles (Richardson et al., 1987). The basis of ovarian ageing in women 
is depletion of the primordial follicle pool (Richardson et al., 1987; Nikolaou and 
Templeton, 2003). Critical aspects involved in the process of ovarian ageing are 
the number of primordial follicles present in the initial stock and the factors that 
regulate the rate of loss of this stockpile (Wise et al., 1996). It seems likely that the 
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ovary is the predominant pacemaker in reproductive ageing (te Velde et al., 1998; 
te Velde and Pearson, 2002). Studies in mice suggested an important role of AMH 
in depletion of the primordial follicle pool (Durlinger et al., 1999; Durlinger et al., 
2002a). AMH, produced in growing ovarian follicles, has been shown subsequently 
to be an excellent marker for ovarian ageing (de Vet et al., 2002; Seifer et al., 
2002; Fanchin et al., 2003a). Recently, AMH levels were found to be elevated in 
anovulatory and PCOS patients compared with normal controls (Cook et al., 2002; 
Pigny et al., 2003; Laven et al., 2004).  
In anovulatory women for whom the number of all classes of follicles 
including the total number of primordial follicles seems to be increased (Pache et 
al., 1992a; Webber et al., 2003), the age-related menstrual cycle irregularities (Kok 
et al., 2003) and follicle pool exhaustion might occur later. Moreover, it may be 
speculated that the process of ovarian ageing is indeed delayed in women with 
PCO, since levels of AMH, an important inhibitor of primordial follicle pool depletion 
(Durlinger et al., 1999), are increased. Indeed, cross-sectional data have 
suggested that women with PCOS may reach menopause at a later age (Dahlgren 
et al., 1992). Furthermore, it has been reported previously that cycle irregularities 
improve with increasing age (Dahlgren et al., 1992; Elting et al., 2000; Bili et al., 
2001), possibly associated with a decrease in the follicle cohort size (Elting et al., 
2003). Although no information is available regarding the age of menopause in 
women with WHO II anovulation, it has been shown in a cross-sectional study that 
advanced age is associated with lower LH and androgen levels in this group (Bili et 
al., 2001), as could be confirmed for the androgens in the current longitudinal 
study. Both oocyte quantity and quality dictate the subsequent reproductive events 
including decrease of fertility, increased abortion rate, the end of fertility, the 
beginning of cycle irregularity and, when almost no follicles are left the occurrence 
of menopause (te Velde et al., 1998). As a consequence, it might be hypothesized 
that women with WHO II anovulatory infertility when compared with normo-
ovulatory controls still might be able to conceive at an advanced age. However, 
from this point of view oocyte quality is not taken into account. Finally, the 
possibility that a deviant AMH synthesis or receptor is causally related to PCOS, 
cannot be ruled out at this stage. 
In summary, the current longitudinal study confirms that AMH serum levels 
are elevated in anovulatory women presenting with PCO, and demonstrates for the 
first time that the decline in AMH with age is less pronounced compared with 
controls. Considering important and well documented roles of intra-ovarian AMH in 
the pace of follicle pool depletion and resulting female reproductive ageing, it may 
be proposed that the reproductive life span is extended in PCOS. Nevertheless, 
most women included in the present analysis have not yet reached the age of 
menopause. In order to substantiate further a delayed exhaustion of the primordial 
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stock in women with WHO II anovulation, collection of additional follow-up data is 
required.  
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3.1 Influence of oral contraceptive pills on phenotype expression in women 
with polycystic ovary syndrome  
 
Abstract 
 
Polycystic ovary syndrome (PCOS) is characterised by a heterogeneous 
phenotype including chronic anovulation, hyperandrogenism and polycystic 
ovaries. It has been shown that the use of oral contraceptive pills (OCP) alters 
clinical, endocrine and sonographic features characteristic for the syndrome. The 
genetic and environmental homogeneity of women descendant from a founder 
population provides the opportunity to assess the sole effect of OCP on phenotype 
expression of PCOS.  
All patients with normogonadotrophic anovulatory infertility (World Health 
Organization, group II), descendant from a restricted area as identified by ZIP 
codes, underwent a standardised clinical, sonographic and endocrine screening. 
The previous diagnosis WHO II anovulation could be reconfirmed for a total 
number of 101 women. At present, a total of 81 (80%) women could be diagnosed 
as having PCOS (according to the revised 2003 criteria). From these women a total 
of 54 (67%) did not use OCP, whereas 27 (33%) did. Corrected for age, the latter 
group presented with significantly decreased serum concentrations of estradiol (E2) 
(P < 0.001), progesterone (P) (P = 0.02), 17-hydroxyprogesterone (17-OH-P) (P < 
0.001), testosterone (T) (P = 0.04) and androstenedione (AD) (P = 0.01). Serum 
concentrations of cortisol (P < 0.001) and sex hormone-binding globulin (SHBG) (P 
< 0.001) were significantly decreased in these women. These differences resulted 
in a significantly decreased free androgen index (FAI) (100 x T/ SHBG) for women 
presently on OCP (P < 0.001).  
Use of OCP influences phenotype expression (the observable trait) of 
individual women known to suffer from PCOS by reducing hyperandrogenism. 
Despite taking OCP, women diagnosed in the past as PCOS, still fulfilled the 
revised 2003 criteria for the syndrome, as PCO morphology was still present. 
Hence, it may be suggested that PCOS women presenting with PCO may suffer 
from a more severe form of the syndrome. Moreover, the present study suggests 
that it is permitted to rely on historical data regarding diagnosis of PCOS for 
women presently on the OCP since its cardinal features appear to be relatively 
constant. Hence, OCP use does not appreciably affect the PCOS phenotype. 
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3.1 Introduction 
 
Polycystic ovary syndrome (PCOS) is the most common anovulatory disorder in 
women (Rowe et al., 2000). Besides oligo- or amenorrhea its cardinal features are 
hyperandrogenism and polycystic ovary morphology (Laven et al., 2002; The 
Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group, 2004). 
Since many underlying causes might lead to a similar clinical phenotype, this 
condition constitutes a notoriously heterogeneous patient group. A clear familial 
clustering can be observed in PCOS, suggesting that genetic factors are involved 
in its etiology. Although previous studies suggested an autosomal dominant 
pattern of inheritance (Lunde et al., 1989; Carey et al., 1993; Legro et al., 1998; 
Govind et al., 1999) more recent research indicates that a complex mode of 
inheritance is more likely (Hague et al., 1988; Legro and Strauss, 2003). The high 
prevalence of affected individuals and the wide range of related phenotypes 
involved in PCOS might be explained by the interaction of a small number of key 
genes with environmental factors (Franks et al., 2001).  
Some genes for complex conditions, such as PCOS, are expected to be 
more easily identified in isolated populations compared to a general outbred 
population (Wright et al., 1999). As a consequence of drift and founder effects, a 
large number of patients in isolated populations have likely inherited the disease 
susceptibility from a common genetic ancestor (Te Meerman et al., 1995). Hence, 
the number of genes possibly involved in PCOS might be reduced in such a 
population. Although there is an ongoing debate whether genetically isolated 
populations are more suitable than outbred populations for genetic association 
studies, several studies in isolates have been successful (Kuokkanen et al., 1997; 
Leppavuori et al., 1999; Aouizerat et al., 1999; Stefansson et al., 2002).   
The oral contraceptive pill (OCP) is commonly used in the treatment of 
menstrual irregularities and hyperandrogenism in women with PCOS (Morin-
Papunen et al., 2003). OCP has been shown to inhibit significantly the ovarian 
androgen production and to increase serum androgens binding capacity by 
increasing sex hormone-binding globulin (SHBG) (Falsetti and Galbignani, 1990; 
Coenen et al., 1996; Dahlgren et al., 1998). Apart from these positive effects, OCP 
slightly decreases insulin sensitivity (Skouby et al., 1987; Godsland et al., 1992) 
and for this reason their use may augment the already impaired glucose 
metabolism of women with PCOS (Dunaif, 1999). Additionally, OCP appears to 
alter the sonographic profile of women with PCOS (Falsetti et al., 2001). Hence, 
the use of oral contraceptives affects clinical, endocrine and sonographic 
parameters characteristic for the disease, and complicates diagnosis of PCOS.  
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In order to perform a genetic association study, PCOS patients derived from 
an isolated population were recruited. At present, a number of these women uses 
OCP for contraceptive purposes and control of cycle irregularities. The genetic and 
environmental homogeneity offers an opportunity to assess the influence of OCP 
on phenotype expression in a genetically and environmentally homogeneous 
population.  
 
3.1.2 Materials and methods 
 
Patient recruitment and screening  
The local Medical Ethics Review Committees of all participating hospitals approved 
this study and informed consent was obtained from all participants.  
All previously diagnosed PCOS patients descendant from a restricted area in 
the south of the Netherlands were permitted to participate in the study. The 
individuals were selected by means of their ZIP code and a previous assessment 
of endocrine features (1994-2002). Medical charts of the identified individuals were 
handsearched. In case the diagnosis WHO II anovulation or PCOS was confirmed, 
based upon a clinical, endocrine and sonographic evaluation performed in the past 
(The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group, 
2004), women were recruited to participate. Subsequently the clinician involved in 
the study contacted the patient. Only after the subject had signed the informed 
consent the study started.  
All participants underwent a randomly performed clinical, sonographic and 
endocrine screening in order to reconfirm the diagnosis of WHO II anovulation and 
PCOS (The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop 
group, 2004) in a standardised fashion (Imani et al., 1998). In case of use of OCP 
the screening was performed on the last day of the pill free interval (Van Heusden 
and Fauser, 2002). Clinical screening parameters included cycle history (age at 
menarche, duration and (ir)regularity of the cycle nowadays and in the past, use of 
orally administered contraceptives, use of other cycle - intervening medication, 
treatment of infertility). A familial questionnaire was completed concerning 
oligoamenorrhea, hirsutism, type II diabetes, cardiovascular disease, premature 
baldness in males, and subfertility. The following parameters were mapped by 
physical examination: weight, length, waist and hip circumference, extent of 
hirsutism (Ferriman Gallwey score (FG score) (Ferriman and Gallwey, 1961)), 
markers of insulin resistance (acanthosis nigricans (Burke et al., 1999)), BMI 
(kg/m²) and waist-to-hip ratio (WHR). Through transvaginal sonography (TVS) the 
ovarian volume (mL) and the total number of follicles (both ovaries) (Balen et al., 
2003) were assessed.  
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Hormone assays 
Blood samples, obtained by venepuncture, were processed within 2 hours after 
withdrawal and stored at -20˚C until assay. Endocrine screening (fasting levels) 
included serum assays for cortisol, prolactin (PRL), thyroid-stimulating hormone 
(TSH), FSH, LH, estradiol (E2), testosterone (T), androstenedione (AD), 
dehydroepiandosterone (DHEA), dehydroepiandosterone-sulphate (DHEAS), 
SHBG, progesterone (P), 17-hydroxyprogesterone (17-OH-P), inhibin B, anti-
Müllerian hormone (AMH), glucose and insulin. The free androgen index (FAI = 
testosterone (T) x 100/sex hormone-binding globulin (SHBG)) could be calculated 
subsequently. Serum FSH, LH, PRL, cortisol, TSH, AD, DHEAS, SHBG, and 
insulin were assessed by using a chemiluminescent immunoassay (Immulite; 
Diagnostic Products Corp., Los Angeles, CA). E2 and T were measured by using 
coated tube radioimmunoassay kits (Diagnostic Products Corp., Los Angeles, CA). 
Serum DHEA was measured by using a radioimmunoassay (Diagnostic 
Laboratories, Webster, Texas). All other assays have been described previously 
(Lamberts et al., 1987; Imani et al., 1998; Imani et al., 1999; de Vet et al., 2002).  
 
Data analysis 
Data were tested for normality of distribution. Results are presented as the mean ± 
SD in case distributed normally or otherwise as the median and range. To assess 
differences between groups Chi square or Mann-Whitney tests were used. Data 
were analysed using the commercially available software package SPSS (Chicago, 
IL, USA). A P value of 0.05 was chosen as threshold level for statistical 
significance. 
 
3.1.3 Results 
 
From the restricted area defined by zip code the computer selected a total of 1602 
women who all had undergone a previous endocrine assessment in any of the 
participating hospitals. All medical records were handsearched for criteria fitting the 
diagnosis WHO II anovulation (N = 252). Subsequently, a total of 118 women 
agreed to participate in the current analysis. A total of 17 women did not fulfil the 
criteria to confirm WHO II anovulation at present (i.e. no discernable WHO 
category (N=10), WHO I anovulation (N=1), WHO III anovulation (N=3) and 
increased serum prolactin (N=3)).  
The diagnosis WHO II anovulation could be reconfirmed for 101 women. A 
total of 81 (80%) women suffered from PCOS (according to the revised 2003 
criteria) (The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop 
group, 2004). From these women a total of 54 (67%) did not use OCP, whereas 27 
Chapter 3 
 
 
 
58
(33%) women did. Clinical, endocrine and sonographic characteristics of these 
PCOS patients are summarized in Table 1.  
 
TABLE 1 Clinical, endocrine and sonographic characteristics of 81 PCOS women, separately for those 
presently without or with the use of OCP.  * P value corrected for difference in age. 
 
No OCP 
(n = 54) 
OCP  
(n = 27) 
P value 
Clinical parameters    
Age (years) 34.7 ± 5.8 30.8 ± 5.6  0.005 
Menarche (years) 12.9 ± 1.8 13.3 ± 1.9 0.4* 
Cycle duration (history)(days) 70 ± 59 74 ± 51 0.9* 
Time to first liveborn pregnancy (months) 29.0 ± 25.3 23.1 ± 14.3 0.1* 
BMI (kg/m2) 29.5 ± 8.4 27.1 ± 7.3 0.3* 
Waist-to-hip ratio 0.88 ± 0.11 0.84 ± 0.07 0.4* 
Ferriman Gallwey Score 8 ± 5 7 ± 4 0.5* 
Endocrine parameters    
Cortisol (nmol/L) 360 ± 127 531 ± 202 < 0.001* 
LH (IU/L) 7.9 ± 9.0 3.5 ± 2.6 0.1* 
FSH (IU/L) 6.5 ± 11.1 5.3 ± 2.7 0.5* 
E2 (pmol/L) 327 ± 263 136 ± 64 0.001* 
P (nmol/L) 7.6 ± 12.7 1.3 ± 2.3 0.02* 
17-OH- P (nmol/L) 3.5 ± 3.2 1.2 ± 0.9 < 0.001* 
T (nmol/L) 1.3 ± 0.7 1.0 ± 0.7 0.04* 
AD (nmol/L) 9.1 ± 4.2 7.3 ± 3.4 0.01* 
DHEA (nmol/L) 43.5 ± 25.7 43.7 ± 18.1 0.4* 
DHEAS (µmol/L) 3.98 ± 1.81 3.53 ± 1.59 0.08* 
SHBG (nmol/L) 37.6 ± 20.5 92.2 ± 64.5 < 0.001* 
FAI (100 x T/SHBG) 4.4 ± 2.9 1.4 ± 1.0 < 0.001* 
Glucose:Insulin ratio 0.77 ± 0.55 0.61 ± 0.43 0.2* 
Ultrasound parameters    
Mean ovarian volume/ovary (mL)  7.3 ± 3.3 10.0 ± 13.9 0.6* 
Mean follicle number/ovary (n) 15 ± 6 14 ± 6 0.3* 
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TABLE 2 Clinical, endocrine and sonographic characteristics of 37 women for whom the past diagnosis 
of PCOS could be reconfirmed in the present study, separately for those presently without or with OCP.  
 
No OCP 
(n = 27) 
OCP 
(n = 10) P value 
Clinical parameters    
Age (years) 33.4 ± 4.5 31.0 ± 4.5 0.2 
Menarche (years) 12.9 ± 1.8 13.5 ± 2.6 0.5 
Cycle duration (history)(days) 84 ± 70 88 ± 61 0.9 
Time to first liveborn pregnancy (months) 30.9 ± 29.5 25.3 ± 8.5 0.4 
BMI (kg/m2) 31.3 ± 9.8 29.9 ± 9.6 0.7 
Waist-to-hip ratio 0.87 ± 0.11 0.85 ± 0.07 0.5 
Ferriman Gallwey Score 7 ± 5 8 ± 6 0.7 
Endocrine parameters     
Cortisol (nmol/L) 344 ± 126 634 ± 226 0.003 
LH (IU/L) 6.0 ± 4.1 2.9 ± 2.4 0.03 
FSH (IU/L) 4.8 ± 2.3 5.6 ± 1.9 0.3 
E2 (pmol/L) 287 ± 160 128 ± 55 < 0.001 
P (nmol/L) 6.5 ± 12.0 2.0 ± 3.9 0.3 
17-OH- P (nmol/L) 3.6 ± 4.0 1.4 ± 1.1 0.01 
T (nmol/L) 1.2 ± 0.6 1.1 ± 0.6 0.4 
AD (nmol/L) 9.3 ± 4.5 7.6 ± 2.9 0.3 
DHEA (nmol/L) 41.9 ± 21.3 52.5 ± 17.9 0.2 
DHEAS (µmol/L) 3.8 ± 1.9 3.7 ± 1.6 0.9 
SHBG (nmol/L) 34.3 ± 19.9 112.8 ± 75.0 0.009 
FAI (100 x T/SHBG) 4.8 ± 3.2 1.4 ± 0.9 < 0.001 
Glucose:Insulin ratio 0.70 ± 0.55 0.44 ± 0.18 0.04 
Ultrasound parameters     
Mean ovarian volume/ovary (mL)  7.6 ± 3.6 5.8 ± 2.8 0.2 
Mean follicle number/ovary (n) 17 ± 6 17 ± 3 0.6 
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Age was significantly different (P = 0.005) comparing women without (mean±SD: 
34.7±5.8 years) and with the use of OCP (mean±SD: 30.8±5.6 years). Corrected 
for age women taking OCP had significantly increased serum concentrations of 
cortisol (P < 0.001) and SHBG (P < 0.001). Serum concentrations of E2 (P < 
0.001), P (P = 0.02), 17-OH-P (P < 0.001), T (P = 0.04) and AD (P = 0.01) were 
significantly decreased. These differences resulted in a significantly decreased FAI 
for women currently taking OCP (mean±SD: 1.4±1.0) compared to women without 
(mean±SD: 4.4±2.9) (P < 0.001). Figure 1 shows the distribution of hirsutism, 
hyperandrogenism and polycystic ovaries in women with PCOS presently without 
and with OCP, respectively.  
In the present study it was possible to compare the diagnosis PCOS 
(according to the revised 2003 criteria) as set in the past and at present for a total 
of 41 women. The diagnosis could be reconfirmed for a total of 37 women. One 
participant did not fulfil the PCOS criteria in the past, however at present she did. 
For a total of 3 women the diagnosis PCOS could not be reconfirmed (2 of them 
were presently taking OCP). At the time of first diagnosis in the local hospital none 
of these women were on OCP. Clinical, endocrine and sonographic characteristics 
of the women for whom the diagnosis PCOS could be reconfirmed are summarized 
in Table 2. A total of 27 (73%) women did not use OCP at present whereas 10 
(27%) of them did. Women taking OCP had significantly increased serum 
concentrations of cortisol (P = 0.003) and SHBG (P < 0.001). Serum 
concentrations of LH (P = 0.030), E2 (P < 0.001), 17-OH-P (P = 0.012), FAI (P < 
0.001) and the G:I ratio (P =  0.035) were significantly decreased for those using 
OCP. Figure 2 shows the distribution of hirsutism, hyperandrogenism and 
polycystic ovaries in women with PCOS presently without and with OCP, 
respectively.  
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Figure 1 Distribution of hirsutism (FG score ≥ 8), hyperandrogenism (FAI ≥ 4.5) and 
polycystic ovaries (PCO) in women with PCOS, presently without (n = 54) and with (n = 27) 
OCP. Figures given outside and inside circles are percentages of women within the 
specified subgroup. Figures between parentheses are numbers of patients within the 
specified subgroup.   
 
 
 
Figure 2 Distribution of hirsutism (FG score ≥ 8), hyperandrogenism (FAI ≥ 4.5) and 
polycystic ovaries (PCO) in women for whom the past diagnosis PCOS could be 
reconfirmed in the present study, separately for those currently without (n = 27) and with (n 
= 10) OCP. Figures given outside and inside circles are percentages of women within the 
specified subgroup. Figures between parentheses are numbers of patients within the 
specified subgroup.   
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Finally, clinical, endocrine and sonographic characteristics of the 54 PCOS patients 
without OCP participating in the present study were compared to PCOS controls. 
All controls (n=361) visited the infertility outpatient clinic of the Erasmus Medical 
Center and participated in previous studies (Laven et al., 2002; Eijkemans et al., 
2003). Age (P < 0.001), serum concentrations of T (P < 0.001), AD (P < 0.001), 
and mean ovarian volume (P < 0.001) were significantly different between both 
groups. Corrected for age the control group still had significantly increased serum 
concentrations of T (P < 0.001), AD (P < 0.001) and an increased ovarian volume 
(P < 0.001). The presence of polycystic ovaries (P = 0.6) and obesity (P = 0.6) was 
equally distributed between both groups. PCOS controls suffered significantly more 
often from amenorrhea (P = 0.02) and hyperandrogenism (P = 0.004). Figure 3 
shows the distribution of obesity, hyperandrogenism and polycystic ovaries in 
PCOS women descendant from the founder population and the PCOS controls, 
respectively.  
 
 
 
PCO 
85% (n = 46) 
Hyperandrogenism 
41% (n = 22)  
PCOS founder 
(n = 54) 
Obesity 
50% (n = 27) 
11% 
(n = 16) 19%
(n = 20) 
6% 
(n = 13) 
19% 
(n = 10) 
PCO 
88% (n = 319) 
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(n = 361) 
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46% (n = 167) 
Hyperandrogenism 
62% (n = 224) 
 
 
 21%
(n = 182) 
9% 
(n = 139) 
29%
(n = 106) 
8%
(n = 134) 
Figure 3 Distribution of obesity (BMI > 27), hyperandrogenism (FAI ≥ 4.5) and polycystic 
ovaries (PCO) separately for PCOS women descendant from the founder population (n = 54) 
and PCOS controls (n = 361). Figures given outside and inside circles are percentages of 
women within the specified subgroup. Figures between parentheses are numbers of women 
within the specified subgroup.   
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3.1.4 Discussion  
 
In the present analysis it could be established that the use of the OCP influences 
phenotype expression in women known to suffer from PCOS. Parameters 
characteristic for the extent of the disease such as hyperandrogenism are less 
severe for those women using OCP. This is shown for women who could be 
diagnosed as having PCOS (according to the revised criteria) at present, as well as 
for those for whom the past diagnosis could be reconfirmed currently (Table 1 and 
2).  Moreover, women still fulfilled the PCOS criteria despite taking OCP. These 
data suggest that OCP use does not appreciably affect the PCOS phenotype, 
despite the observed decrease in hyperandrogenism. 
OCP are frequently used for the long-term management of women with 
PCOS (Cagnacci et al., 2003). The reasons for OCP use in PCOS are 
contraception, protection against the development of endometrial hyperplasia, 
control of irregular cycles and suppression of excessive androgen secretion to 
control hirsutism and acne (The ESHRE Capri Workshop Group, 2001; Morin-
Papunen et al., 2003). Indeed, the OCP reduces the amount of androgens 
produced by the ovary, causes a decrease of the free androgen fraction and leads 
to reduction of peripheral androgen effects (Cagnacci et al., 2003). After cessation 
of OCP use the original PCOS features usually return within a few months (The 
ESHRE Capri Workshop Group, 2001). 
Administration of the OCP in women with PCOS has been shown to significantly 
suppress ovarian androgen synthesis and to increase serum androgens binding 
capacity (Falsetti and Pasinetti, 1995; Dahlgren et al., 1998). Hence, treatment with 
the OCP significantly reduces serum concentrations of both total and free 
androgens (Dahlgren et al., 1998; Gjonnaess, 1999). In terms of anti-androgenicity, 
OCP containing cyproterone acetate (a specific anti-androgen) or a 3rd generation 
progestin are mostly used (Cibula et al., 2001; Mastorakos et al., 2002). A 
combination of ethinyl estradiol (EE) and cyproterone acetate however, is effective 
in reducing hirsutism, but may decrease insulin sensitivity (Venturoli et al., 1999; 
Morin-Papunen et al., 2000). In addition, an OCP containing a 3rd generation 
progestin significantly decreases androgen production and concentrations without 
reducing insulin sensitivity (Cibula et al., 2002). In the present study the free 
androgen index was significantly decreased for women using OCP. However, 
ultrasonographic evaluation showed the presence of polycystic ovaries (PCO) and 
hence these women still fulfilled PCOS criteria.  
Apart from the aforementioned positive effects on androgen production and 
free androgen levels, the OCP is believed to slightly deteriorate insulin sensitivity 
(Skouby et al., 1987; Kasdorf and Kalkhoff, 1988), and for this reason their use 
may aggravate the already impaired glucose metabolism in women with PCOS. 
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OCP does induce impairment of glucose tolerance and does elevate insulin levels 
in healthy women, but these effects depend largely on the dose of estrogen and 
the dose and type of progestin (Godsland et al., 1992). However, studies 
evaluating the role of the OCP on glucose tolerance or insulin sensitivity in women 
with PCOS have generated conflicting results (Korytkowski et al., 1995; Dahlgren 
et al., 1998; Morin-Papunen et al., 2000; Cibula et al., 2002; Morin-Papunen et al., 
2003). Differences in outcome are primarily based on the various methods used to 
assess glucose intolerance (insulin resistance or hyperinsulinaemia) as well as the 
difference in the estrogen/progestin components. Moreover, it has been shown that 
the magnitude and variability of the metabolic effects observed with OCP use are 
primarily dependent on the progestin component (Spellacy, 1982; Godsland et al., 
1992). In the current study, no differences are observed in the fasting 
glucose/insulin ratio of PCOS women with or without the use of OCP. However, 
when comparing women for whom the diagnosis PCOS could be reconfirmed the 
glucose/insulin ratio is significantly reduced for those using OCP. Indeed, the 
current observation may suggest an increased sensitivity to develop glucose 
intolerance for women with PCOS when taking oral contraceptives.  
It has been suggested that the use of oral contraceptives as a consequence 
of suppressed ovarian function results in reduction of ovarian dimension and follicle 
number, as assessed by abdominal ultrasound examination, in adolescents with 
hyperandrogenism (Venturoli et al., 1988). Additionally, the presence of polycystic 
ovaries significantly decreased after a long term treatment (60 cycles) with OCP in 
adults with PCOS (Falsetti et al., 2001). On the other hand, it is shown that 
polycystic ovary morphology is restored after cessation of therapy (Falsetti et al., 
2001). However, in the current study women taking OCP still present with PCO. 
These dissimilarities may exist due to differences in ultrasound examination and 
duration of treatment with OCP. Moreover, polycystic ovaries appear to be a 
relatively constant feature comparing women presently without or with OCP use 
(Figure 1 and 2).  Indeed, these data may suggest that women with polycystic 
ovary appearance may suffer from a more severe disease condition (Imani et al., 
1998; Laven et al., 2002; Mulders et al., 2003a).   
Finally, even after correction for age, the PCOS phenotype in women 
descendant from the founder population seems to be associated with less 
increased serum levels of androgens. As a consequence, the frequency of 
hyperandrogenism is decreased in women participating in the present study when 
compared to a PCOS control group with a heterogeneous genetic background. 
Hence, for the former group it could be hypothesized that genes involved in 
androgen metabolism are less probably involved in the development of the 
disease. However, these suggestions need to be interpreted with caution.  
Use of OCP influences phenotype expression (the observable trait) of 
individual women known to suffer from PCOS by reducing hyperandrogenism. 
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Despite taking OCP, women diagnosed in the past as PCOS, still fulfilled the 
revised 2003 criteria for the syndrome, as PCO morphology was still present. 
Hence, it may be suggested that PCOS women presenting with PCO may suffer 
from the most stubborn form of the syndrome. Moreover, the present study 
suggests that it is permitted to rely on historical data regarding diagnosis of PCOS 
for women presently on the OCP since its cardinal features appear to be relatively 
constant. In addition, OCP use does not appreciably affect the PCOS phenotype. 
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4.1 Follicle-stimulating hormone receptor polymorphism in women with 
normogonadotropic anovulatory infertility. 
 
Abstract 
 
In the present cross-sectional study the incidence of different FSH receptor (FSHR) 
genotypes in normogonadotropic anovulatory infertile women (WHO II) and normo-
ovulatory controls was assessed. Furthermore, the FSHR genotypes were 
correlated with baseline characteristics and ovarian responsiveness during 
ovulation induction in women with WHO II anovulatory infertility.  
Thirty normo-ovulatory controls were compared to 148 WHO II women. In 
WHO II patients and controls a standardized evaluation including: cycle history, 
body mass index and transvaginal ultrasound scanning of ovaries was performed. 
Fasting blood samples were obtained for endocrine evaluation. Ovarian 
responsiveness to FSH in WHO II women was assessed during ovulation induction 
and DNA was analyzed to determine the FSHR genotype. 
The Thr/Thr 307 genotype was significantly less (52% vs 23%; P < 0.05) and 
the Ser/Ser 680 polymorphism was significantly more prevalent (40% vs 16%; P < 
0.05) in WHO II patients compared to controls. WHO II patients with the Ser/Ser 
680 polymorphism presented with higher median FSH serum levels (5.2 IU/L; 
range 2.4-9.7) compared to the Asn/Asn 680 (4.6 IU/L; range 1.4-5.8) and Asn/Ser 
680 (4.5  IU/L; range 1.8-9.7) variants (P < 0.05). However, ovarian 
responsiveness to FSH was similar comparing different polymorphisms in 
anovulatory women. 
WHO II patients exhibit a different FSHR genotype compared to normo-
ovulatory controls and although this is associated with increased baseline FSH 
serum levels altered ovarian sensitivity to exogenous FSH during ovulation 
induction could not be established.   
 
4.1.1 Introduction 
 
Follicle-stimulating hormone (FSH) plays a crucial role during folliculogenesis by 
stimulating granulose-cell estrogen production through induction of aromatase 
activity (Fauser and van Heusden, 1997). The action of FSH is mediated by the 
FSH receptor, which belongs to the large family of G-protein-coupled receptors. 
These receptors are characterized by a transmembrane domain consisting of 
seven membrane transversing α-helices connected by three extracellular and three 
intracellular loops (Simoni et al., 1997; Themmen and Huhtaniemi, 2000). The FSH 
receptor gene is located at chromosome 2p21 to 16 (Simoni et al., 1997; Themmen 
and Huhtaniemi, 2000; Simoni et al., 2002).   
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Several naturally occurring mutations in the FSH receptor gene have been 
found. In a sample of Finnish women with hypergonadotropic ovarian dysgenesis, 
a loss-of-function mutation was found that resulted from a (Ala189Val) missense 
mutation that segregated perfectly with the phenotype (Aittomaki et al., 1995). 
Patients with the lowest remaining FSH receptor activity have hypergonadotropic 
primary amenorrhea with atrophic ovaries (Aittomaki et al., 1995), whereas carriers 
of mutations that less severely affect receptor function present with secondary 
normal-sized ovaries, and follicular development up to the antral stage (Beau et al., 
1998; Tapanainen et al., 1998; Touraine et al., 1999; Themmen and Huhtaniemi, 
2000). However, inactivating mutations of the FSH receptor are rarely found in 
premature ovarian failure (POF) (Layman et al., 1998; Takakura et al., 2001; 
Doherty et al., 2002).  
The only activating FSH receptor mutation was identified in a 
hypophysectomized man who remained fertile despite undetectable gonadotropin 
levels (Gromoll et al., 1996). Symptoms of activating FSH receptor mutations might 
resemble the phenotype of patients with McCune-Albright disease (Laven et al., 
2001b). In these patients, the constitutive activation of Gsα leads to symptoms of 
combined luteinizing hormone (LH) and FSH hyperactivity. In addition, enlarged 
ovaries with multiple cysts have been described in women with FSH-producing 
pituitary tumours (Christin-Maitre et al., 1998). 
Recently, two polymorphisms of the FSH receptor gene have been identified. 
One is located in the extracellular domain at position 307, occupied either by 
alanine (Ala) or threonine (Thr). The second one is located in the intracellular 
domain at position 680, occupied either by asparagine (Asn) or serine (Ser). Both 
polymorphic sites are within exon 10 and give rise most frequently to two discrete 
allelic variants of the FSH receptor: Thr307/Asn680 and Ala307/Ser680 (Perez et 
al., 2000; Simoni et al., 2002). No distinct differences could be found in the 
distribution of these two allelic variants in infertile men or women compared with 
normal persons (Conway et al., 1999; Simoni et al., 1999). 
From the combination of the two polymorphisms in both positions, two more 
allelic variants are possible: Thr307/Ser680 and Ala307/Asn680. Their frequency 
distribution in persons of different ethnic background has not been systematically 
analyzed. Whether FSH receptor polymorphisms have pathophysiologic 
significance with regard to ovarian dysfunction or ovarian response to stimulation is 
uncertain. Some investigators did not find differences in the distribution of these 
polymorphisms in polycystic ovary syndrome (PCOS) and POF (Conway et al., 
1999; Tong et al., 2001), whereas others did (Sudo et al., 2002). 
In normogonadotropic normo-estrogenic anovulatory infertility (World Health 
Organization (WHO) class II), the response of the ovary to exogenous FSH 
administration varies considerably among patients (van Santbrink and Fauser, 
1997; Coelingh Bennink et al., 1998). In a recent study, the individual FSH 
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response dose for gonadotropin induction of ovulation in anovulatory infertile 
women could be predicted on the basis of initial screening characteristics, such as 
the initial FSH serum level (Imani et al., 2002a). Recent observations in patients 
undergoing in-vitro fertilization (IVF) suggest that the FSH receptor genotype is 
associated with different requirements for exogenous FSH (Perez et al., 2000).  
 We analyzed the frequency distribution of the two FSH receptor 
polymorphisms and their combination into four discrete allelic variants and 
compared their occurrence in normogonadotropic anovulatory infertile women with 
that in normo-ovulatory controls of different ethnic origin. In addition, we studied the 
correlation between the observed FSH receptor genotype and the response to 
exogenous FSH for ovulation induction in normogonadotropic anovulatory infertile 
women.  
 
4.1.2 Materials and methods 
 
Patients 
This study was conducted as a part of a research line that was approved by the 
Institutional Review Board of the Erasmus Medical Center. Informed consent was 
obtained from all participants. 
We included 148 white Dutch patients who attended our infertility outpatient 
clinic between 1994 and 1999. No immigrants (persons of Mediterranean, Latin 
American, or southeast Asian origin) were included.  
Inclusion criteria for patients were infertility, oligomenorrhea (interval 
between periods  > 35 days) or amenorrhea (absence of vaginal bleeding for at 
least 6 months), serum FSH concentrations within normal limits (1 to 10 IU/L) (van 
Santbrink et al., 1997; Schipper et al., 1998), positive withdrawal bleeding after 
progestagen administration in patients with amenorrhea, and age 20 to 40 years. 
Standardized initial screening (clinical examination, transvaginal ultrasonography, 
and fasting blood sampling) was performed on a random day between 9 AM to 11 
AM, as described elsewhere (van Santbrink et al., 1997). 
The control group consisted of 30 healthy volunteers selected by 
advertisement and paid for participation, as described elsewhere (Macklon and 
Fauser, 2000). Like the patients, controls were Dutch and not immigrants. Inclusion 
criteria were a regular menstrual cycle (26 to 30 days), age 20 to 35 years, normal 
body mass index (BMI) (18 to 25 kg/m2), no history of endocrine disease, and  no 
use of medication or oral contraceptives for at least 3 months before study entry. 
Transvaginal ultrasonography and blood sampling were performed during the early 
follicular phase (cycle day 3, 4, or 5). The controls are described in detail 
elsewhere (Macklon and Fauser, 2000). 
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Ovulation induction 
In a subgroup of 89 women who failed to ovulate or conceive after clomiphene 
citrate administration, gonadotropin treatment was commenced within 3 to 5 days 
after initiation of spontaneous or progestagen-induced withdrawal bleeding. 
Patients received daily s.c. injections of recombinant (r)FSH (Gonal-F®; Ares-
Serono, Geneva, Switzerland). During all first cycles, a low-dose step-up protocol 
was used with a starting dose of FSH of one ampoule (75 IU) per day. The daily 
dose was increased by 0.5 ampoule if ovarian response (≥ 1 follicle ≥ 10 mm) was 
lacking after 14 days. Thereafter, the dose was increased by 0.5 ampoule every 7 
days if required. The FSH response dose was defined as the dose at which an 
ovarian response was observed. If sufficient ovarian response was observed, the 
dose was kept constant until administration of hCG (Profasi®; Ares-Serono).  
 
Hormone assays 
Blood samples were obtained by venepuncture and processed within 2 hours after 
withdrawal. Serum was stored at -20°C and assayed for LH, FSH, androstenedione 
(AD), testosterone (T), sex hormone-binding globulin (SHBG), inhibin B, estradiol 
(E2) and progesterone (P). Serum LH and FSH were measured by 
immunofluorometric assay (Amerlite; Ortho-Clinical Diagnostics, Amersham, United 
Kingdom), whereas serum E2, P, T, AD, and SHBG levels were measured by 
radioimmunoassay (RIA) provided by Diagnostic Products Corp. (Los Angeles, 
CA), as described elsewhere (Imani et al., 2000). Intra- and interassay coefficients 
of variation were less than 5% and 15% for LH, less than 3% and 8% for FSH, less 
than 8% and 11% for AD, less than 3% and 5% for T, less than 5% and 7% for E2, 
less than 16% and 17% for P, and less than 4% and 5% for SHBG.  
 Dimeric inhibin B levels were assessed by using an immuno-enzymometric 
assay obtained from Serotec (Oxford, United Kingdom), as described elsewhere 
(Schipper et al., 1998). The detection limit of the assay, defined as the amount of 
inhibin equivalent with the signal of the blank plus 3 SDs of this signal, was 3.4 
ng/L. Intra- and interassay coefficients of variation for inhibin B were less than 9% 
and 15%, respectively. 
 
DNA isolation and analysis 
Genomic DNA was obtained from peripheral blood leukocytes, as described 
elsewhere (Gromoll et al., 1996). Polymerase chain reaction amplification of 
fragments of exon 10 encompassing amino acid positions 307 and 680 were 
analyzed by single-stranded conformation polymorphism gel electrophoresis, as 
described elsewhere (Simoni et al., 1999; Gromoll et al., 2000; Simoni et al., 2002). 
The results of single-stranded conformation polymorphism analysis were confirmed 
by direct sequencing of about 10% of randomly chosen DNA samples. 
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Statistical analysis 
Statistical analysis was performed by using a commercially available software 
package (SPSS; SPSS Inc, Chicago, IL). Data were analyzed for normal 
distribution. Data are presented as the mean (±SD) if distributed normally or as the 
median and range if distributed non-normally. To detect differences between 
groups, Mann-Whitney or Kruskal-Wallis tests were used if data were not normally 
distributed. Normally distributed data were subjected to one-way analysis of 
variance. P ≤ 0.05 was considered statistically significant. 
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Figure 1 Distribution of the 
three possible FSH receptor 
genotypes at positions 307 
(A) and 680 (B) in exon 10 
of the FSH receptor gene 
among normogonadotropic 
anovulatory women and 
normo-ovulatory controls. 
The difference in distribution 
between anovulatory 
patients and normo-
ovulatory controls was 
significant for both 
polymorphisms (P < 0.05 for 
position 307 and P < 0.05 for 
position 680). 
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4.1.3 Results 
 
The Ala/Ala 307 variant was found in approximately 16% of controls, whereas the 
Ala/Thr and Thr/Thr variants were found in 32% and 52% of controls. As for the 
polymorphism at position 680, 23% of controls had Asn/Asn, 61% has Asn/Ser, 
and 16% had Ser/Ser.  
In normogonadotropic anovulatory infertile women, the overall frequency 
distribution for polymorphism at position 307 was 20% for Ala/Ala, 57% for Ala/Thr, 
and 23% for Thr/Thr; for polymorphism at position 680, 16% for Asn/Asn, 44% for 
Asn/Ser, and 40% for Ser/Ser. The distribution of both polymorphisms differed 
significantly between anovulatory patients and normo-ovulatory controls (P < 0.01 
for position 307 and P < 0.01 for position 680) (Figure 1). However, the prevalence 
of the combined genotype (polymorphisms at position 307 and 680) did not 
significantly differ (P < 0.09) between controls and anovulatory infertile women 
(Figure 2). 
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Figure 2 The similarity in distribution of several FSH receptor genotypes among 
normogonadotropic anovulatory women and normo-ovulatory controls. Since the 
Ala307/Ser680-Thr307/Asn680 and Ala307/Asn680-Thr307/Ser680 genotype cannot be 
distinguished by the methods used, they are considered together and designated as 
Ala307/Ser680-Thr307/Asn680. 
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Table 1 shows the prevalence of the different alleles of the FSH receptor in 
controls and anovulatory patients. The distribution of alleles did not significantly 
differ between (P = 0.8) or within groups (P = 0.7 in controls and P = 0.9 in 
anovulatory patients).  
Table 2 shows clinical, endocrine, and ultrasonographic variables of 
anovulatory patients with the various FSH receptor polymorphisms. Except for the 
initial serum FSH concentration, no statistically significant differences were found 
among the three polymorphisms for position 307 or 680. The FSH serum 
concentrations were 5.2 IU/L in patients with the Ser/Ser 680 variant; this value 
was significantly higher than FSH serum levels in patients with the Asn/Ser 680 
variant (4.5 IU/L) and those with the Asn/Asn 680 variant (4.6 IU/L). 
Data on ovulation induction were available for 89 (60%) anovulatory women. 
The frequency of polymorphisms at position 307 in clomiphene citrate-resistant 
patients was 16% for those with the Ala/Ala variant, 54% for those with the Ala/Thr 
variant, and 30% for those with the Thr/Thr variant. The frequency of the 
polymorphisms at position 680 in these patients was 9% (Asn/Asn), 40% (Asn/Ser), 
and 51% (Ser/Ser). The frequencies of polymorphisms at position 307 or 680 did 
not differ between clomiphene citrate-resistant patients and those who failed to 
conceive during previous successful ovulation induction with clomiphene citrate. In 
addition, the distribution of different alleles and allelic combinations were similar 
between clomiphene citrate-resistant patients and those who ovulated after 
clomiphene citrate administration (data not shown). 
 
 
TABLE 1 Distribution of allelic FSH receptor variants in normogonadotropic anovulatory patients and 
normo-ovulatory controls. 
  Allele (%)  
Group AS TN AN TS 
Anovulatory patients (n = 148) 126 (43%) 97 (33%) 17 (5%) 56 (19%)a 
Controls (n = 30) 17 (28%) 32 (53%) 2 (3%) 9 (15%) 
 
Note: Data are expressed as numbers of participants (percentage). 
a Differences in distribution of the four distinct alleles between controls and anovulatory patients were 
not statistically significant (P < 0 .8).  
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The FSH response dose could be determined in 77 (87%) of the 89 
clomiphene citrate-resistant patients. There were no statistically significant 
differences among patients with different subtypes of FSH receptor variants for the 
polymorphism at position 307 or 680 in terms of the FSH dose at the beginning of 
the stimulation cycle, the number of ampoules of FSH used, the duration of 
stimulation, the median daily dose of FSH, or the response dose (Table 2). 
Moreover, the number of cancelled cycles (due to poor response or 
hyperstimulation) was the same in all three groups for both receptor 
polymorphisms. 
Patients with polycystic ovaries (defined as an ovarian volume ≥ 10.8 mL, 
mean number of follicles > 10, or mean ovarian stroma score > 3) (van Santbrink et 
al., 1997) and hyperandrogenemia, defined as a free androgen index (T level X 
100/SHBG level) exceeding 4.5, were classified as having PCOS. In 61 women 
with PCOS, a similar distribution as in anovulatory patients was found; this 
distribution differed significantly from that in controls. In patients with PCOS and 
polymorphism at position 307, the overall frequency distribution was 21% for 
position Ala/Ala, 58% for Ala/Thr, and 21% for Thr/Thr; corresponding values for 
anovulatory women without PCOS were 22%, 51%, and 27%, respectively. The 
frequencies among patients with polymorphisms at position 680 and PCOS were 
15% for Asn/Asn, 50% for Asn/Ser, and 35% for Ser/Ser; values in patients with 
this polymorphism but no PCOS were 19%, 38%, and 44%, respectively. For both 
polymorphisms, the distribution differed significantly among anovulatory women 
with PCOS, anovulatory women without PCOS on one hand and normo-ovulatory 
controls on the other hand (P < 0.01 for position 307 and P < 0.01 for position 680). 
Figure 3 summarizes the data for patients with the polymorphism at position 
680. No statistically significant differences in clinical, endocrine, or 
ultrasonographic variables were found among anovulatory women with PCOS, 
anovulatory women without PCOS, and controls. Stimulation characteristics in 
patients with PCOS and those without PCOS were similar (data not shown). 
 
4.1.4 Discussion 
 
We found differences in distribution of the different FSH receptor genotypes 
between normogonadotropic anovulatory patients (those with WHO class II disease 
and PCOS) and normo-ovulatory controls. The FSH receptor variants Ala/Thr 307 
and Ser/Ser 680 were significantly more prevalent among anovulatory women. The 
Thr/Thr 307 polymorphism was significantly more prevalent in controls. Earlier 
reports failed to establish differences in prevalence of FSH receptor genotypes in 
fertile or infertile men (Simoni et al., 1999) and in infertile women (Conway et al., 
1999). 
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Few studies have addressed the distribution of the allelic variants in patients 
with PCOS, and results are conflicting. Two studies revealed no differences in 
prevalence between a limited number of patients with PCOS and normo-ovulatory 
women (Conway et al., 1999; Tong et al., 2001). Recently, Sudo et al. (2002) 
reported a significant increase in the Ala/Thr 307 and Asn/Ser 680 genotype in a 
large cohort of women with PCOS. Because the distribution of the polymorphism at 
position 680 among our normo-ovulatory controls is similar to the previously 
reported incidence in normal women (Conway et al., 1999; Asatiani et al., 2002; 
Sudo et al., 2002), the observed difference in this large cohort of anovulatory 
women and patients with PCOS seems to be real. 
The FSH receptor polymorphism combination Ser/Ser 680 was associated 
with higher basal FSH levels compared with the Asn/Asn 680 and Asn/Ser 680 
variants. This might indicate that the Ser/Ser 680 FSH receptor polymorphism is 
associated with decreased FSH sensitivity. In a recently published prediction 
model, the individual FSH response dose during ovulation induction therapy was 
determined in part by the initial basal FSH serum concentration (Imani et al., 
2002a). Moreover, in normo-ovulatory IVF patients, ovarian response to exogenous 
FSH stimulation was determined by the FSH receptor genotype. Normo-ovulatory 
patients exhibiting the Ser/Ser 680 allelic variant had higher levels of basal FSH 
and required a significantly higher daily FSH dose for successful hyperstimulation 
in a routine IVF/intracytoplasmic sperm injection (ICSI) program (Perez et al., 
2000). 
Controls 
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Figure 3 Distribution of the 
three possible FSH receptor 
genotypes at both positions 
307 and 680 in exon 10 of 
the FSH receptor gene 
among women without the 
polycystic ovary syndrome 
(non-PCOS), women with 
PCOS (PCOS), and normo-
ovulatory controls. The 
distribution of both 
polymorphisms significantly 
differed between women 
with PCOS and those 
without PCOS on one hand 
and controls on the other 
hand.  
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 Similarly, in our study, the highest basal FSH serum levels in anovulatory 
infertile patients were associated with the Ser/Ser 680 allelic variant. However, 
neither the response dose nor the total number of ampoules FSH used or duration 
of stimulation differed among patients with the different FSH receptor genotypes. 
This lack of association between FSH receptor genotype and ovarian sensitivity 
might be due to differences in stimulation protocols. Because ovulation induction 
protocols in anovulatory patients aim for mono-follicular development, the amount 
of exogenous FSH used may be within the physiologic range. In contrast, 
exogenous FSH administered during IVF stimulation protocols extends the 
physiologic range since multi-follicular development is the goal. 
 Because previous in vitro experiments failed to establish significant 
differences in binding characteristics and receptor activation between several FSH 
receptor polymorphisms (Simoni et al., 1999; Sudo et al., 2002), differences in FSH 
receptor activity might become apparent only after supraphysiologic stimulation 
(i.e. IVF stimulation protocols). However, the association between the FSH 
receptor phenotype and the basal FSH serum levels might also be coincidental. 
Moreover, the FSH receptor polymorphism might merely constitute a genetic 
marker for a nearby gene (not the FSH receptor) that increases the risk for 
anovulation. 
 More clinical and experimental data are necessary to establish the exact 
relationship between the dose of exogenous FSH and FSH receptor genotypes. 
Although about 50% of anovulatory infertile patients in our study were clomiphene 
citrate-resistant and not normo-ovulatory, which might make them not readily 
comparable to normo-ovulatory women, a dose dependent relationship between 
the FSH receptor polymorphism and the magnitude of the post-receptor signal 
cannot be ruled out. 
 In conclusion, normogonadotropic anovulatory patients and women with 
PCOS have a different FSH receptor genotype compared with normo-ovulatory 
controls. Despite these differences, FSH receptor genotypes are not associated 
with altered ovarian sensitivity to exogenous FSH during ovulation induction in 
anovulatory patients.  
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5.1 Prediction of chances for success or complications in gonadotropin 
ovulation induction in normogonadotropic anovulatory infertility  
 
Abstract 
 
A prospective follow-up study was designed to investigate whether initial clinical, 
endocrine, and sonographic screening characteristics of women with 
normogonadotropic anovulatory infertility are capable of predicting individual 
outcome of gonadotropin induction of ovulation applying a step-down dose 
regimen.  Previous studies from our group focussed on the prediction of outcome 
from first line CC treatment in these women. It would be of distinct clinical benefit in 
case patient characteristics could also predict individual chances for complications 
(i.e. multi-follicular growth) or success (i.e. ongoing pregnancy) prior to initiation of 
gonadotropin induction of ovulation. 
One hundred and fifty four women attending our infertility unit between 
March 1993 and December 1999 were included in the present study. All these 
women presented with (a) a history of infertility, (b) oligomenorrhea or amenorrhea, 
(c) normal follicle-stimulating hormone (FSH) and estradiol (E2) serum 
concentrations and (d) previously unsuccessful treatment with clomiphene citrate 
(i.e. CC resistant anovulation (CRA) or failure to conceive in 6 ovulatory CC-cycles 
(CCF)). Daily FSH injections were initiated on day 3-5 after a spontaneous or 
progestagen-induced withdrawal bleeding. A dose finding low-dose step-up 
regimen was applied during the first treatment cycle in order to identify the 
individual FSH response dose. In all subsequent cycles a step-down protocol was 
applied with an individually adjusted starting dose.  
The total number of step-down cycles was 441, with 47% of cycles 
presenting with mono-follicular development (1 follicle > 15 mm on the day of 
hCG). Initial serum levels of luteinizing hormone (LH), testosterone (T) and 
androstenedione (AD) were significant predictors in univariate logistic regression 
analysis for the probability of multi-follicular development (P < 0.05). The area 
under the receiver operating characteristic curve (AUC) of the multivariate model 
(including AD and mean follicle number) to predict the chances of multiple 
dominant follicle development was 0.62. FSH treatment resulted in a total of 67 
(44%) ongoing pregnancies with a cumulative ongoing pregnancy rate of 58.3%. 
Comparing those women who did versus those who did not reach an ongoing 
pregnancy in a multivariate Cox regression analysis, initial serum insulin-like 
growth factor-I (IGF-I), T and women’s age entered into the final model (AUC = 
0.67). 
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The individual treatment outcome – both multi-follicular growth and ongoing 
pregnancy - following gonadotropin induction of ovulation may be predicted by 
initial screening characteristics. 
 
5.1.1 Introduction 
 
Chronic anovulation is a common cause of infertility in women. Most of these 
women present with irregular menstrual cycles and normal serum follicle-
stimulating hormone (FSH) concentrations (World Health Organization [WHO] 
group II) (The ESHRE Capri Workshop Group, 1995; Rowe et al., 2000). 
Depending on the criteria used, polycystic ovary syndrome (PCOS) has been 
diagnosed in approximately 60% of these women (van Santbrink et al., 1997; 
Laven et al., 2002).         
Exogenous gonadotropin preparations have been used extensively for 
stimulation of ovarian function since their introduction into clinical practice in 1958 
(Lunenfeld, 2003). During the last two decades, its use in ovulation induction has 
been restricted to anovulatory infertile patients who failed to ovulate or conceive 
during preceding first line clomiphene citrate treatment (Schwartz and Jewelewicz, 
1981; Insler, 1988; Fauser and van Heusden, 1997). Exogenous gonadotropins 
elicit increased ovulation rates (up to 90 %) compared with clomiphene citrate 
(CC), with comparable cumulative conception (van Santbrink et al., 1995b; White et 
al., 1996; Imani et al., 1999). However, FSH treatment is associated with higher 
chances for complications such as ovarian hyperstimulation syndrome (OHSS) and 
multiple pregnancies, especially in PCOS (Wang and Gemzell, 1980; Hamilton-
Fairley and Franks, 1990). As these complications are related to the number of 
developing follicles (Blankstein et al., 1987), adjusted dose regimens along with 
intense monitoring of ovarian response aiming at mono-follicular cycles have been 
implemented (Hamilton-Fairley et al., 1991; van Santbrink et al., 1995b; Balasch et 
al., 1996). Additionally, previous retrospective studies have suggested that 
individual patient characteristics such as luteinizing hormone (LH) concentrations 
(Homburg et al., 1988; Hamilton-Fairley et al., 1991), overweight (Hamilton-Fairley 
et al., 1992; White et al., 1996; Yarali et al., 1999), age (Hamilton-Fairley et al., 
1992) and insulin resistance (Homburg et al., 1996; Fulghesu et al., 1997; Dale et 
al., 1998) may also be involved in chances for complications or success following 
gonadotropin induction of ovulation.  
Distinct individual differences in the amount of FSH required to elicit an 
ovarian response (referred to as the ‘FSH threshold’) may underlay chances for 
hyperresponse and severe complications (Brown, 1978; Fauser and van Heusden, 
1997). Recently, a model based on initial screening characteristics has been 
introduced, to predict the individual ovarian FSH response (threshold) dose for 
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gonadotropin induction of ovulation  (Imani et al., 2002a; van Santbrink et al., 
2002). 
The present prospective follow-up study was designed to investigate 
whether these initial clinical, endocrine, and sonographic screening characteristics 
of women with normogonadotropic anovulatory infertility can also predict individual 
outcome of gonadotropin induction of ovulation applying a step-down dose 
regimen.  Previous studies have focussed on the prediction of outcome from first 
line CC treatment (Imani et al., 1998; Imani et al., 1999; Imani et al., 2000) in these 
women. It would be of distinct clinical benefit if patient characteristics could also 
predict individual chances for complications (i.e. multi-follicular growth) or success 
(i.e. ongoing pregnancy) prior to initiation of second line gonadotropin induction of 
ovulation.     
 
5.1.2 Materials and methods 
 
Subjects 
One hundred and fifty four women attending the infertility unit between March 1993 
and December 1999 were included in the present study. Study approval was 
obtained from the human subjects committee of the Erasmus Medical Center and 
informed consent was obtained from all subjects. Inclusion criteria were [1] 
oligomenorrhea (bleeding interval between 35 days and 6 months) or amenorrhea 
(bleeding interval > 6 months), [2] normal serum FSH (1-10 IU/L), estradiol (E2) (> 
100 pmol/L) (van Santbrink et al., 1995a; Schipper et al., 1998), prolactin (< 44 
µg/L) and thyroid-stimulating hormone (TSH) (0.2-4.2 mU/L) concentrations, [3] 
spontaneous menses or positive bleeding response to progestagen withdrawal, [4] 
body mass index (BMI) (weight divided by square height) > 18 kg/m2, [5] between 
19 and 40 years of age,  [6] previous unsuccessful CC treatment (i.e. anovulation 
during at least three consecutive cycles with an increasing dose up to 150 mg/day 
(CC resistant anovulation (CRA)) or failure to conceive in six ovulatory CC cycles 
(CCF) (Imani et al., 1998; Imani et al., 1999; Imani et al., 2000)), [7] a total motile 
sperm count (TMC = ejaculate volume (mL) × sperm concentration (106/mL) × 
percentage of progressive motile spermatozoa) above 1 million, and [8] a negative 
history for any tubal pathology along with negative antibody test for Chlamydia (C. 
trachomatis IgG and IgA < 1.0) or proven normal tubal patency on 
hysterosalpingography or laparoscopic inspection.  
Standardized initial clinical, sonographic and endocrine screening took place 
prior to administration of exogenous gonadotropins using a low-dose step-up 
regimen, as described before (Imani et al., 1998; Imani et al., 1999; Imani et al., 
2002a; Imani et al., 2002b). Clinical screening included age, duration and type 
(primary versus secondary) of infertility, cycle history, ovarian response to previous 
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CC medication, BMI, waist-to-hip ratio (WHR), any other previous medication 
and/or surgery. Transvaginal sonographic (TVS) screening included assessment of 
the ovarian stroma echogenicity (arbitrarily classified from 1 (normal) to 3 
(markedly increased) per ovary), ovarian volume (mL) and total number of antral 
(2-8 mm) follicles (both ovaries), as described previously (van Santbrink et al., 
1997). Sonographic monitoring was performed by a single observer (BI), using an 
ultrasound machine (model EUB-415, Hitachi Medical Corp., Tokyo, Japan) with a 
6.5 MHz transvaginal transducer. 
Endocrine screening included serum assays for FSH, LH, E2, AD, T, and sex 
hormone-binding globulin (SHBG), as described previously (Imani et al., 1998). In 
addition, serum was also assayed for fasting insulin and glucose, free and total 
insulin-like growth factor-I (IGF-I), IGF binding protein-I (IGFBP-I), IGFBP-III and 
leptin concentrations as described previously (Imani et al., 2000). The method of 
blood withdrawal, the assays used and the intra- and interassay coefficients of 
variation valid for this study have all been previously described (Imani et al., 1999; 
Imani et al., 2000). 
 
Study protocol 
Exogenous FSH, using either daily intramuscular (i.m.) injections of urinary FSH 
(Metrodin HP®, Serono Benelux BV, The Hague, The Netherlands) or 
subcutaneous (s.c.) injections of recombinant FSH (Gonal-F®, Serono Benelux 
BV), was initiated on day 3-5 after a spontaneous or progestagen-induced 
withdrawal bleeding. The treatment protocol and assessment of ovarian response 
have been described before (Imani et al., 2002a).  
Low-dose step-up protocol: During the first cycle a low-dose step-up regimen 
was applied to assess the individual FSH response (threshold) dose (Imani et al., 
2002a) (i.e sonographic visualization of a follicle ≥ 10 mm (Pache et al., 1990; van 
Santbrink et al., 1995b)). The starting dose of FSH was one ampoule (75 IU) per 
day. The first increase in FSH dose by half an ampoule (37.5 IU) per day was 
based on the absence of sonographic visualization of a follicle ≥ 10 mm after 7 
days. If ovarian response remained absent during the following 7 days, the FSH 
dose was increased again (i.e. incremental steps of 37.5 IU/day every 7 days). If 
there was an ovarian response, the exogenous FSH dose was not changed until 
administration of human chorionic gonadotropin (hCG). 
Step-down protocol: Arbitrarily, a dose of half an ampoule (37.5 IU) of FSH 
above the response dose (Imani et al., 2002a) was used, to start the subsequent 
step-down cycle in most patients. Initially, in some patients the starting dose was 
based on BMI alone. The first decrease in dose by half an ampoule (37.5 IU) per 
day was based on visualization of at least 1 follicle ≥ 10 mm in diameter, as 
described previously (van Santbrink and Fauser, 1997). A further dose decrease 
(each time by 37.5 IU/day) was performed every 3 days in case follicular growth 
Chapter 5 
 
 
84
continued, to a minimum dose of one ampoule (75 IU) per day until the day hCG 
could be administered. The initial dose was increased by half an ampoule (37.5 IU) 
per day if ovarian response remained absent after 5 days. If follicular growth 
remained absent over the following 10 days (two incremental steps of 37.5 IU/day), 
further medication was withheld and the cycle was cancelled.  
hCG (Pregnyl®, NV Organon, Oss, The Netherlands) was administered 
intramuscularly as a single dose of 5,000 IU on the day upon which one or two 
follicles ≥ 18 mm could be visualized. If three or more follicles ≥ 16 mm were 
present, stimulation was cancelled. Ovulation after hCG administration was 
assessed by the sonographic signs of collapse of the dominant follicle and mid-
luteal progesterone (P) concentrations above 25 nmol/L. No luteal support was 
provided. 
 
Data analysis 
Data of clinical characteristics in patient groups are presented as means ± SD if 
distributed normally. Otherwise data are presented as median and range.  
Univariate and multivariate logistic regression analyses were used for 
comparison of patients who developed multi-follicular growth (> 1 follicle > 15 mm). 
Because multiple cycles from the same patient were included, the data analysed 
were interrelated. Therefore, P values were corrected by Huber's method (using S-
plus software) to take account of clustering of data (Huber, 1967). Variables that 
had P values lower than 0.10 were candidates for stepwise multi-variable analysis. 
Multivariate analyses for multi-follicular growth were performed using the method of 
backward stepwise selection. The multivariate odds ratio is provided for the factors 
included in the final model. For instance, multivariate odds ratio (95% CI) of serum 
AD = 1.04 (1.02-1.07). The best estimate is that a 1 unit increase in a given 
patient’s AD level increases her odds for multi-follicular growth following 
exogenous gonadotropin induction of ovulation by 4% relatively. There is a 95% 
probability that this increase will be between 2 and 7%. 
Univariate and multivariate Cox regression was used for analysis of ongoing 
pregnancy rates during exogenous gonadotropin induction of ovulation. The 
number of gonadotropin induced cycles was the time variable. Censoring was 
defined as definitive discontinuation of gonadotropin therapy without an ongoing 
pregnancy or end of follow-up. The log rank test has been used to test statistical 
significance in life-table analyses. The prognostic impact of variables was 
expressed as a fecundability ratio, which is equivalent to the hazard ratio in survival 
analysis. Multivariate analyses for cumulative ongoing pregnancy rates were 
performed using the method of forward stepwise selection to gain a better insight in 
the interdependence between initial screening parameters. To build a multivariable 
model, multiple imputation of missing values was used (Little, 1992). Variables that 
had P values lower than 0.10 were candidates for stepwise multivariable analysis.  
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Data were analysed using the commercially available software package 
SPSS (Chicago, IL, USA). A P value of 0.05 was chosen as the threshold level for 
statistical significance. 
 
5.1.3 Results 
 
A total number of 154 patients fulfilled the inclusion criteria and underwent 544 
cycles with exogenous FSH for induction of ovulation. All participating women 
underwent a mean number of 3.5 FSH-stimulation cycles before discontinuing 
treatment. Twenty percent of the women underwent > five cycles. For a total of 103 
women, a low-dose step-up regimen was applied during the first cycle.  In 32% of 
the step-up cycles, multi-follicular growth (> 1 follicle > 15 mm) occurred. In 11% of 
the cycles, no hCG was administered due to potential risks for multiple pregnancy 
and OHSS. The step-down protocol was applied in a total number of 441 cycles. In 
199 (45%) cycles, multi-follicular growth (> 1 follicle > 15 mm) occurred. If there 
were > two follicles > 15 mm (65 cycles: 15%), no hCG was administered due to 
potential risks for multiple pregnancy and OHSS.  
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n dose regim
en. 
 
O
verall 
(n  = 407) 
M
ono-follicular grow
th 
(n = 208) 
M
ulti-follicular grow
th 
(n= 199) 
 
 
P
a 
 
AU
C
b 
 
C
linical param
eters 
 
 
 
 
 
Age (years) 
29.0 ± 4.3 
29.3 ± 4.3 
28.7 ± 4.3 
 
N
S 
- 
Am
enorrhea (%
) 
115 (28) 
53 (26) 
62 (31) 
 
N
S 
- 
BM
I (kg/m
2) 
26.4 ± 5.7 
26.7 ± 5.7 
26.0 ± 5.7 
 
N
S 
- 
W
aist-to-hip ratio 
0.8 ± 0.1 
0.8 ± 0.1 
0.8 ± 0.1 
 
N
S 
- 
C
C
 resistant anovulation (%
) 
192 (50) 
89 (45) 
103 (55) 
 
0.08 
0.55 
Predicted FSH
 response dose (IU
) 
120 ± 46 
117 ± 38 
123 ± 53 
 
N
S 
- 
Endocrine  param
eters 
 
 
 
 
 
LH
 (IU
/L) 
8.3 ± 4.3 
7.8 ± 4.4 
8.8 ± 4.0 
 
0.05 
0.59 
FSH
 (IU
/L) 
5.0 ± 1.5 
5.1 ± 1.6 
4.8 ± 1.4 
 
0.07 
0.55 
E
2  (pm
ol/L) 
254 ± 142 
249 ± 152 
259 ± 130 
 
N
S 
- 
AD
 (nm
ol/L) 
17.2 ± 8.0 
16.0 ± 6.7 
18.5 ± 9.0 
 
0.02 
0.57 
T (nm
ol/L) 
2.8 ± 1.1 
2.6 ± 1.0 
3.0 ± 1.2 
 
0.001 
0.60 
IG
F-I (ng/m
L) 
210 ± 77 
206 ± 79 
214 ± 74 
 
N
S 
- 
Leptin (ng/m
L) 
20.1 ± 15.3 
20.7 ± 15.9 
19.4 ± 14.7 
 
N
S 
- 
U
ltrasound  param
eters 
 
 
 
 
 
Total strom
a score
c 
3.6 ± 1.2 
3.5 ± 1.2 
3.7 ± 1.2 
 
0.06 
0.55 
M
ean ovarian volum
e (m
L)   
11.2 ± 4.9 
11.0 ± 4.9 
11.4 ± 4.8 
 
N
S 
- 
M
ean follicle num
ber  
13.6 ± 5.9 
12.9 ± 6.2 
14.4 ± 5.5 
 
0.08 
0.57 
 a P
 value of univariable logistic regression predicting m
ulti-follicular grow
th, correcting for clustering of cycles w
ithin w
om
en by H
uber's m
ethod. b A
rea under the R
O
C
 curve 
(univariate analysis). c A
rbitrarily defined as one to three per ovary (both ovaries added), as published previously (van S
antbrink et al., 1997).  Footnote: A
 total of 32 cycles 
w
ere excluded from
 analyses because of poor response (i.e. no follicles > 15 m
m
 and no hC
G
 adm
inistered). A
nother tw
o cycles w
ere excluded due to the existence of an 
ovarian cyst.  
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Figure 1 AD concentrations (A), mean follicle number (B), BMI (C) and predicted FSH response 
dose (D) in mono-follicular (n = 208) or multi-follicular (n = 199) cycles during gonadotropin 
ovulation induction applying a step-down regimen in 154 normogonadotropic oligoamenorrheic 
infertile patients for whom previous treatment with clomiphene citrate was unsuccessful. Data are 
presented as box and whisker plots: boxes encompass values between the 25th and the 75th 
percentile, horizontal lines represent median values, and whiskers give the 95% range of values. 
Only initial serum AD and mean number of follicles were included in the final model. 
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Initial serum LH, T and AD were significantly different for patients who developed 
one single dominant versus multiple follicles during ovarian stimulation. The area 
under the ROC curves of univariable logistic regression for the prediction of multi-
follicular growth are depicted in Table 1. Backward stepwise multivariate analyses 
of initial screening characteristics was performed for the prediction of developing 
multi-follicular growth after gonadotropin induction of ovulation using a step down 
regimen (Table 2).  
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Figure 2 Age (A), serum T (B), IGF-I (C), BMI (D), and 
predicted FSH response dose (E) as prognostic factors 
in 154 normogonadotropic anovulatory infertile patients 
who failed to conceive following preceding CC 
medication and were treated with ovulation induction 
applying a step-down dose regimen. Data are 
presented, separately for women who did or did not 
achieve an ongoing pregnancy, as box and whisker 
plots: boxes encompass values between the 25th and 
the 75th percentile, horizontal lines represent median 
values, and whiskers give the 95% range of values. 
Only age, serum T, and IGF-I were included in the final 
model. 
 
Phenotype expression and clinical implications 
 
 
89
Initial serum AD and mean number of follicles were included in the final model 
(Area under the ROC curve = 0.62). The impact of initial screening characteristics 
as a prognostic factor in 154 normogonadotropic anovulatory infertile patients on 
prediction of single dominant follicle development has been depicted in Figure 1.  
Seventy-nine women (51%) conceived. Twelve (15%) miscarried and the 
remaining ongoing pregnancies ended in 60 singleton, five twin, one triplet and one 
quadruplet pregnancy. The differences found in initial parameters between those 
who did or did not have an ongoing pregnancy are depicted in Table 3.  
 
 
TABLE 2 Multivariate analyses of screening parameters for the prediction of developing multi-
follicular growth or ongoing pregnancy following exogenous gonadotropin induction of ovulation in 
women with normogonadotropic anovulatory infertility. 
Prediction of 
multi-follicular 
growth (Logistic 
regression) 
 
  
  
Odds Ratio 95% Confidence Interval 
 AD (nmol/L)      
(range 4.5 -49.3)            
1.04 1.01 - 1.07 
 Number of follicles (n) 
(range 2.0 - 34.5)           
1.04 1.00 - 1.09 
Final model (Area 
under the ROC 
curve) 
 0.62 0.56 - 0.67 
 
Prediction of  
ongoing 
pregnancy (Cox 
regression) 
   
  
Fecundability 
Ratio 
95% Confidence Interval 
 Age (years)   
(range 19.0 - 40.0)         
0.96 0.92 - 1.0 
 T (nmol/L)            
(range 0.6 - 6.8)             
0.71 0.55 - 0.92 
 IGF-I (ng/mL)    
(range 64 - 440)             
1.004 1.001 - 1.007 
Final model (Area 
under the ROC 
curve) 
 0.67 0.57 - 0.77 
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In univariate Cox regression analysis, initial serum T and IGF-I were 
significantly different between patients who did or did not have an ongoing 
pregnancy following gonadotropin induction of ovulation. Multivariate Cox 
regression analyses of screening parameters for prediction of ongoing pregnancy 
following gonadotropin induction of ovulation using a step-down regimen in 154 
anovulatory infertile patients was performed (Table 2). In the final model, the 
multivariate fecundability ratio (95% CI) of age was 0.96 (0.92-1.0). This means 
that a 1 year increase in a given patient’s age reduces her monthly probability of 
ongoing pregnancy following exogenous gonadotropin induction of ovulation by 
4%. The impact of individual screening characteristics on treatment outcome (i.e. 
ongoing pregnancy) is shown in Figure 2.  
Age (cut-off of 30 years), ovarian response during preceding CC medication 
(CRA versus CCF), and initial serum LH concentration (cut-off level of 7.0 IU/L) in 
univariate analyses for cumulative ongoing pregnancy rates are depicted in Figure 
3. The life-table analysis of cumulative ongoing pregnancy rates of the overall 
group of patients is depicted in Figure 3. A cumulative ongoing pregnancy rate of 
58.3% was reached within eight induced cycles.  
  
5.1.4 Discussion 
 
The present study was designed to evaluate whether initial screening 
characteristics may predict treatment outcome of gonadotropin induction of 
ovulation, applying a step-down dose regimen in women with anovulatory infertility 
who failed to ovulate or conceive during previous CC treatment. Although 
gonadotropin ovulation induction has been the focus of a vast number of 
investigators during the last four decades, prospective follow-up studies designed 
to identify screening characteristics capable of predicting treatment outcome are 
extremely scarce. The current study shows for the first time that AD concentrations 
and follicle number as assessed by ultrasound upon initial screening can predict 
the occurrence of multi-follicular cycles (and presumably chances for complications 
such as multiple gestation and OHSS). Secondly, chances for ongoing pregnancy 
can be predicted on the basis of age of the woman, T and IGF-I concentrations.  
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Figure 
3 
Life-table 
analysis 
of 
cum
ulative 
ongoing 
pregnancy 
rates 
in 
154 
norm
ogonadotropic 
oligoam
enorrheic 
infertile 
patients 
w
ho failed to ovulate or conceive 
follow
ing preceding C
C
 m
edication 
and w
ere treated w
ith gonadotropin 
induction 
of 
ovulation. 
O
ngoing 
pregnancy 
rates 
(including 
absolute num
ber of patients at risk 
and num
ber of events (i.e. ongoing 
pregnancies)) are presented for the 
total study group (upper left panel) 
(vertical 
lines 
represents 
95%
 
confidence 
intervals). 
U
nivariate 
analysis 
of 
ongoing 
pregnancies 
are show
n for the follow
ing initial 
screening characteristics: patient's 
age 
(cut-off 
level 
at 
30 
years) 
(upper 
right 
panel), 
ovarian 
response 
to 
preceding 
C
C
 
m
edication 
(C
R
A
 
versus 
C
C
F) 
(low
er left panel) and initial serum
 
LH
 concentrations (cut-off level at 
7.0 
IU
/L) 
(low
er 
right 
panel). 
n 
represents 
the 
initial 
num
ber 
of 
patients at risk.  
P
 = log rank test P
 value. 
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These models might be of clinical importance, since they discriminate 
between women with low or high chances for success (i.e. ongoing pregnancy) or 
complications (i.e. multi-follicular development). The probability to reach a 
conception resulting in an ongoing pregnancy lower than 30% was predicted in 
10% out of the 154 patients. The apparent c–statistic of the model for ongoing 
pregnancy was 0.67, indicating a moderate discriminative ability. For instance, a 
woman with AD concentrations and follicle numbers of respectively 10.0 and 7.0 
has a chance for multi-follicular development of 35%. This is in contrast with a 
chance of 66% for a woman with an AD level of 25.0 and a mean follicle number of 
22.5. In practical terms, this may mean that differences are not large enough for 
practitioners to counsel their patients in terms of multi-follicular growth. It should be 
emphasized that the predictive power is relatively limited with an AUC of the ROC 
curve of 0.62 for prediction of multi-follicular cycles. Moreover, these observations 
need to be confirmed in an independent patient population (external validation) 
before this approach could be introduced in clinical practice.     
Women with PCOS seem to be at risk for multi-follicular development in 
response to gonadotropin stimulation (MacDougall et al., 1992a). The observed 
association between mean follicle number and multiple follicle development 
confirms previous findings applying a low-dose step-up protocol (van der Meer et 
al., 1998). Others recently described a correlation between initial ovarian volume 
and subsequent response (Lass et al., 2002). Indeed, sonographic parameters also 
predict patients remaining anovulatory following CC (Imani et al., 1998). 
As previously reported, ovarian response to CC and initial serum FSH were 
major factors predicting an augmented FSH response dose (Imani et al., 2002a; 
van Santbrink et al., 2002), which may represent the severity of ovarian 
abnormalities in these patients (Imani et al., 2002a). Similar factors also predict 
ovarian response in terms of mono- or multi-follicular development in the current 
study. Women with low levels of initial serum FSH and resistant to CC (CRA) have 
a higher chance of developing multi-follicular growth compared with women with 
normal FSH serum concentrations who failed to conceive during ovulatory CC 
cycles (CCF). On the other hand, the FSH response dose itself is not predictive of 
chances for multiple follicle growth. Further studies regarding the association of 
these factors are required to clarify this issue. Pathophysiological mechanisms 
underlying mono- and multi-follicular development are still unknown. Additional 
studies should also investigate the possible cycle-to-cycle variability in the 
occurrence of multi-follicular development.   
In the current study, CRA patients appear to be more likely to develop 
multiple follicle growth and therefore an increased chance of cancellation of the 
stimulated cycle. However, the present study demonstrates for the first time that 
patients who remain anovulatory following CC have similar chance for ongoing 
pregnancy during gonadotropin induction of ovulation compared with women who 
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failed to conceive despite the preceding CC-induced ovulatory cycles. These 
observations may have important clinical implications, since there seems no 
reason to withhold FSH from these women as second line treatment, as often 
stated. CRA patients have no chance of conception due to persistent anovulation, 
whereas CCF patients ovulate but do not conceive following consecutive ovulatory 
CC-induced cycles, presumably due to impaired cervical mucus quality or 
endometrial receptivity associated with direct anti-estrogenic effects of CC in the 
reproductive tract (Imani et al., 1999). These effects are counterbalanced once 
exogenous FSH preparations are used.  
In the present analysis, a marked impact of initial serum T and IGF-I on 
ongoing pregnancy rates was observed in women with anovulatory infertility. 
Differences in patient selection could possibly explain why these associations were 
not observed by others (White et al., 1996). However, many authors have reported 
that both T (Nelson et al., 1999) and the IGF system (van Dessel et al., 1999) are 
involved in ovarian dysfunction in PCOS. It could be postulated that alterations in 
ovarian androgen synthesis will lead to aberrant folliculogenesis during 
gonadotropin stimulation. The predictive power of initial serum IGF-I was the 
highest. Age entered in the last step of the multivariate analysis. The association of 
advanced age with reduced treatment outcome (i.e. ongoing pregnancy) following 
CC-induced or FSH-induced cycles has previously been reported (McClure et al., 
1993; Imani et al., 2002b), as for many other interventions, including IVF. This may 
be due to an increased incidence of chromosomally abnormal oocytes resulting in 
reduced fertilization and an increased incidence of aneuploid embryos (Macklon et 
al., 2002).   
Surprisingly, the current study suggests that obesity, the main factor involved 
in prediction of exogenous FSH requirement for ovarian response, is not a 
predictor for multi-follicular growth. Moreover, factors associated with obesity such 
as BMI, WHR or serum leptin level also do not predict treatment outcome of 
exogenous FSH induction of ovulation, as previously reported by others (Dale et 
al., 1993; Dale et al., 1998). Weight reduction in women with PCOS may normalize 
insulin resistance, androgen metabolism and improve outcome of ovulation 
induction (Norman et al., 2002). It has also been suggested that the incidence of 
spontaneous miscarriage increases with increasing BMI in women with PCOS 
(Hamilton-Fairley et al., 1992; White et al., 1996). It should be noted, however, that 
some of these conclusions were drawn after inclusion of a selected group of non-
obese women (BMI < 27). Moreover, accurate information regarding preceding CC 
treatment is often lacking. The present analysis does not confirm a possible 
association of increased BMI with pregnancy outcome, as already described by 
others (McClure et al., 1993).        
Initial serum LH concentrations predict chances for multiple follicle 
development but not ongoing pregnancy in the present study. In addition, no 
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significant increase in the chance of spontaneous miscarriages was observed in 
patients with an elevated initial serum LH level. The findings are in contrast with 
retrospective previous reports indicating a higher percentage of miscarriages in 
these patients (Homburg et al., 1988; Balen et al., 1993a). However, the small 
number of miscarriages occurring in most studies preclude definitive conclusions in 
this regard. In addition, in previous studies, initial LH concentrations were not 
predictive for chances of ovulation and conception after CC medication (Imani et 
al., 1998; Imani et al., 1999). 
In summary, the present longitudinal follow-up study demonstrates that 
normogonadotropic anovulatory women who exhibit elevated AD concentrations 
along with an increased number of ovarian follicles prior to ovarian stimulation are 
at an increased risk of multiple follicle development during gonadotropin ovulation 
induction. They exhibit higher chances for cancellation of the FSH-induced cycle. 
Furthermore, this study suggests that gonadotropin ovulation induction should be 
considered as a treatment strategy with high chances of ongoing pregnancy, 
particularly in young patients (both CRA and CCF) who exhibit elevated initial IGF-I 
concentrations and T levels within the normal range. Those women, who are more 
likely to fail to conceive following exogenous FSH stimulation, may benefit from 
alternative treatment modalities such as insulin-sensitizing agents, laparoscopic 
ovarian surgery or assisted reproduction. However, these options should be 
evaluated in future prospective studies.  
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5.2 Patient predictors for outcome of gonadotropin ovulation induction in 
women with normogonadotropic anovulatory infertility: a meta-analysis  
 
Abstract  
 
A systematic review was conducted to determine if initial screening characteristics 
of women with normogonadotropic anovulatory infertility, predict clinically 
significant outcomes of ovulation induction with gonadotropins, and to obtain 
pooled estimates of their predictive value through meta-analysis. Relevant studies 
were identified by a search strategy which consisted of MESH headings and a 
check of bibliographies. Only those studies in which pre-treatment screening 
characteristics (such as body mass index (BMI), serum  luteinizing hormone (LH) 
and androgens, insulin sensitivity and ultrasound appearance of ovaries) were 
related to outcome parameters (such as total amount of FSH administered, 
cancellation, ovulation, pregnancy and miscarriage), were included in this analysis. 
Studies reporting relationships between initial screening characteristics and 
outcome parameters of ovulation induction as measures of association (e.g. Odds 
ratios) were pooled if at least 2 studies report an association. The measures of 
association were pooled using inverse variance weighting.  
Thirteen studies fulfilled the inclusion criteria. A positive association was 
seen in all studies between the level of obesity (definition applied as assessed by 
individual studies) and total amount of FSH administered (Weighted Mean 
Difference (WMD) of 771 IU (95%CI: 700 - 842)). Pooled Odds ratios of 1.86 (95% 
CI: 1.13 - 3.06) and 0.44 (95% CI: 0.31 - 0.61) were found between obesity with 
cancellation and ovulation, respectively. Pooled analysis did not show a significant 
association between obesity and pregnancy rate. The pooled Odds ratio for obese 
versus non-obese women and miscarriage rate was significant (3.05 (95% CI: 1.45 
- 6.44)). Association measures between insulin resistance (definition applied as 
assessed by individual studies) and total amount of FSH administered produced a 
weighted mean difference (WMD) of 351 (95% CI: 73 - 630) IU.  A pooled Odds 
ratio of 0.29 (95% CI: 0.10 - 0.80) was found for insulin resistance with pregnancy 
rate. The pooled Odds ratio for insulin resistance (hyperinsulinemia versus 
normoinsulinemia) and miscarriage rate was not significant. A pooled Odds ratio of 
1.04 (95% CI: 1.01 - 1.07) was found for LH (IU/L) with pregnancy rate. The pooled 
Odds ratio for LH and miscarriage rate was not significant. Finally, pooled analysis 
did not find a significant association between testosterone (T) and pregnancy rate. 
The included studies did not address possible links between initial sonographic 
parameters and treatment outcome. 
This analysis suggests that the most clinically useful predictors of 
gonadotropin ovulation induction outcome in normogonadotropic women are 
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obesity and insulin resistance. These findings might be of clinical relevance since 
they discriminate between women with low or high chances for success. However, 
the best available evidence testing measures of association between screening 
characteristics and treatment outcome is limited. 
 
5.2.1 Introduction 
 
Chronic anovulation presents with amenorrhea or oligomenorhea and can be 
classified on the basis of serum follicle-stimulating hormone (FSH) and estradiol 
(E2) levels. Hypogonadotropic anovulation, low levels of gonadotropins and 
negligible estrogen activity, is also referred to as World Health Organization (WHO) 
group I. Hypergonadotropic anovulation is characterized by elevated gonadotropin 
levels and low E2 (WHO group III)  (Lunenfeld and Insler, 1974; The ESHRE Capri 
Workshop Group, 1995; Rowe et al., 2000). Normogonadotropic anovulation (FSH 
and E2 levels within the normal range) (WHO group II) represents the most 
common form of ovarian dysfunction and is a frequent cause of infertility (Rowe et 
al., 2000; Laven et al., 2002).  
Clomiphene citrate (CC) has been used worldwide as the medication of first 
choice for the treatment of these women, because it is safe, convenient, cheap, 
and reasonably effective. The risk of developing ovarian hyperstimulation 
syndrome (OHSS) and multiple gestation is limited (2-3%) (Imani et al., 1999). 
However, a significant proportion (23%) of women remains anovulatory following 
CC (Imani et al., 1998).  A cumulative pregnancy rate of 73% is reported in 
ovulatory CC women (Imani et al., 1999). 
Induction of ovulation using exogenous gonadotropins is generally indicated 
in patients with normogonadotropic anovulatory infertility who have failed to ovulate 
or conceive during previous CC treatment (Schwartz and Jewelewicz, 1981; 
Lunenfeld et al., 1985; Insler, 1988; Kelly and Jewelewicz, 1990; Franks and 
Gilling-Smith, 1994; Fauser and van Heusden, 1997). Since the early 1960s many 
anovulatory patients have been treated with human menopausal gonadotropin 
(hMG) and human chorionic gonadotropin (hCG) to induce ovulation. This 
treatment modality has been proven to be effective, but the risks of OHSS 
(Stephenson, 1991; Navot et al., 1992) and multiple pregnancies are considerably 
increased (Schenker et al., 1981; Fauser and van Heusden, 1997).  
Recent studies have focused on the prediction of ovulation induction 
outcome based upon initial screening characteristics of WHO II anovulatory infertile 
women (Imani et al., 1998; Imani et al., 1999; Imani et al., 2002b; Mulders et al., 
2003a). It could be demonstrated that some clinical, sonographic, and endocrine 
characteristics are predictive of ovulation and conception during CC treatment 
(Imani et al., 1998; Imani et al., 1999; Imani et al., 2000; Imani et al., 2002b). 
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Outcome parameters of gonadotropin treatment in these women correlated with 
woman’s age, ovarian response to preceding CC medication, body mass index 
(BMI), the mean follicle number assessed by ultrasound, serum levels of FSH, 
testosterone (T), androstenedione (AD), and initial insulin-like growth factor-I (IGF-
I) (Imani et al., 2002a; Mulders et al., 2003a).  
The aim of gonadotropin ovulation induction in anovulatory infertility is 
healthy live birth, preferably from a singleton pregnancy. This is often hard to 
achieve despite the recent introduction of low-dose incremental or decremental 
regimens (Fauser and van Heusden, 1997). An individualized treatment regimen, 
based on valid outcome predictors, might optimize ovulation induction strategies by 
improving the balance between success and complications. The existing literature 
concerning the prediction of outcome is limited and ambiguous. Some studies 
observe significant associations, whereas others fail to do so. Therefore, a 
systematic review was undertaken to establish more firmly which screening 
parameters are predictive of outcome of gonadotropin induction of ovulation.  
 
5.2.2 Methodology 
 
The objectives of this review were to determine whether screening criteria applied 
to women with normogonadotropic anovulatory infertility, predict clinically 
significant outcomes of ovulation induction with gonadotropins, and to obtain 
pooled estimates of their predictive value through meta-analysis.  
 
Criteria for considering studies for this review    
Studies reporting gonadotropin ovulation induction in women with 
normogonadotropic anovulatory infertility (WHO II, including polycystic ovary 
syndrome (PCOS)) were considered for inclusion if they provided specific 
information on: the regimens and type of gonadotropin administered, e.g. standard 
protocol, step-up protocol, step-down protocol, hMG, urinary derived (u)FSH and 
recombinant (r)FSH. The following primary outcome measures were sought: mono-
follicular growth (arbitrarily defined as one follicle > 15 mm on the day of hCG (van 
Santbrink and Fauser, 1997)), total amount of gonadotropins administered on the 
day of hCG in international units (IU), cancellation rate (cycle where there is no 
hCG administered), ovulation rate (as confirmed by an increased serum 
progesterone (P) level (> 20 nmol/L) in the luteal phase), pregnancy rate (per cycle 
or per patient)(defined as a positive urinary pregnancy test) and miscarriage rate 
(sonographic assessment of absence of an intrauterine gestational sac with heart 
beat at 12 weeks amenorrhea). The following screening characteristics were also 
sought: age (years), cycle history (oligo- or amenorrhea), BMI (kg/m2), response 
during previous CC treatment (clomiphene citrate-resistant anovulation 
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(CRA)/clomiphene citrate failure (CCF)), ovarian volume (mL), total number of 
follicles (both ovaries) (Pache et al., 1992a), ovarian stroma echogenicity (Dewailly 
et al., 1994), serum levels of T, AD, luteinizing hormone (LH), LH/FSH, fasting 
insulin and glucose. Inclusion was limited to studies in which outcome parameters 
were related to pre-treatment screening characteristics.   
 
Search strategy for the identification of studies 
Studies reporting the prediction of outcomes following gonadotropin induction were 
initially identified through a handsearch (no specific criteria: papers at hand were 
considered). The wide variety of keywords used in these reports provided the 
foundation for the final search strategy. It consisted of: (1) a Medline search by 
means of MESH headings (in the following order): (follicle stimulating hormone 
[majr] OR menotropins [majr]) AND “female genital diseases and pregnancy 
complications” [majr] and (2) a check of the bibliographies of identified studies. 
 
Identification 
Through the MESH headings search strategy ((follicle stimulating hormone [majr] 
OR menotropins [majr]) AND “female genital diseases and pregnancy 
complications” [majr]) 631 titles were identified (1986 to October 2002). For 474 
titles it was clear that population or intervention did not fulfil the selection criteria. 
To verify whether it was appropriate to exclude such articles based solely on titles, 
one of us (AM) read 10 of the 474 articles. None fulfilled the inclusion justifying this 
identification strategy. The remaining 157 articles were then read by one author 
(AM). Twenty-three studies fulfilled the selection criteria. All of their bibliographies 
were checked. This identified one additional study for inclusion.  
 Twenty-four potentially relevant studies were read by all authors and 13 
were included. There were no disagreements between authors regarding the 
inclusion of studies.   
 
Methods of the review 
The following information was extracted from the potentially relevant studies: study 
characteristics, specified as observational, cohort, cross-over, consecutive or 
randomized, multicentre or not, method of randomization, number of 
patients/cycles (randomized, excluded and analysed), duration, timing and location 
of the study. Patient characteristics were recorded: definition of normogonadotropic 
anovulatory infertility (WHO II including PCOS) (clinical, biochemical, 
ultrasonographic markers or combination of the former), definition and duration of 
infertility, age, investigative work-up, other causes of infertility and previously 
administered treatment(s), in particular whether previous treatment with CC had 
been tried and how CRA or CCF was defined. Finally, the outcome measures and 
their specific definitions were also recorded: total amount of exogenous FSH 
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administered (IU), duration of administration of exogenous FSH (days), the number 
of cancelled cycles, the number of cycles with multi- or mono-follicular growth, the 
number of ovulatory cycles, the number of patients pregnant and not pregnant, 
miscarriage rate, multiple pregnancy rate and OHSS rate. A study had to give 
either a direct measure of association between predictor and outcome variables or 
present data that allowed for the calculation of such a measure. Studies reporting 
relationships between initial screening characteristics and outcome parameters of 
ovulation induction as measures of association (Odds ratio: OR) and studies from 
which measures of association could be derived from the data given were included. 
For example, if a study reported the mean and standard deviation (SD) of an 
outcome variable (e.g. cancellation rate) for obese and for lean women separately, 
the OR of cancellation rate for obesity could be calculated assuming a normal 
distribution of the outcome variable in both groups, by the formula: ln(OR) = 
(meanobese - meanlean)/(pooled variance in obese and lean).  
 
5.2.3 Results 
 
Studies excluded 
Eleven potentially relevant studies were excluded (Table 1). These included 
application of modified stimulation schemes (Norfolk (1, 3, 5) regimen or 
administration of 150 IU every other day) (Ginsburg and Hardiman, 1991; 
Remorgida et al., 1991), application of modified controlled ovarian hyperstimulation 
followed by intrauterine and/or intraperitoneal insemination for PCOS and normo-
ovulatory patients (Zullo et al., 1996), and comparison of  two different stimulation 
regimens for a different subset of patients (repetitive cycles, not equally distributed) 
(Shoham et al., 1991).  
Six studies stated insufficient data to allow analysis: only P levels were noted 
for significant and non-significant prediction of duration of treatment by screening 
parameters (Coelingh Bennink et al., 1998), insufficient data were provided to 
calculate OR (respectively age versus conception) (Ginsburg and Hardiman, 1991), 
no clear statement of the background of LH levels supplied (Hamilton-Fairley et al., 
1991), only data of LH pre-treatment versus ovulation for a subset of patients 
(Polson et al., 1987), no original data of LH levels (separately for pregnant and 
non-pregnant women) (Strowitzki et al., 1994). Finally, data for different subsets of 
patients (WHO I and II) were not provided separately (Fluker et al., 1994). 
In one study (Abdel et al., 1990), Pearson’s correlation statistics showed a 
significant positive correlation between the BMI and the dose of gonadotropins (r = 
0.4666; P < 0.001). This dose correlated negatively with ovarian volume (r = - 
0.1958; P = 0.01). Since these correlation coefficients could not be incorporated in 
the pooled analysis, these data were not included.  
Phenotype expression and clinical implications 
 
 
101
One study (Imani et al., 2002a) provided significant correlations between the 
amount of exogenous FSH required for ovarian response (sonographic 
visualization of a follicle ≥ 10 mm (Pache et al., 1990)) and initial clinical, 
sonographic and endocrine screening characteristics. Four of these parameters 
(i.e. ovarian response to CC medication (CRA), BMI, initial serum levels of FSH 
and free IGF-I) were included in the multivariate model to predict the FSH response 
dose (i.e. the amount of exogenous FSH required for ovarian response). Since this 
study only reported one specific outcome parameter that was not considered in the 
review, this study was excluded from the pooled analysis. 
 
Methodological quality of included studies  
A total of 13 studies were included in the current review (Table 2) (Sagle et al., 
1991; Hamilton-Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993; 
McClure et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; 
Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; 
Vicino et al., 2000). Some researchers performed several studies concerning 
outcome of ovulation induction in the same patient group of interest (Sagle et al., 
1991; McClure et al., 1992; McClure et al., 1993; White et al., 1996). However, 
these studies appeared to include a different subset of patients (Dale et al., 1993); 
Dale et al., 1998) or the focus (screening characteristic versus outcome parameter) 
of the studies was different (Sagle et al., 1991; Hamilton-Fairley et al., 1992; 
McClure et al., 1992; McClure et al., 1993; White et al., 1996).  
 
Description of participants 
The definitions of normogonadotropic anovulatory infertility (WHO II) and PCOS 
varied between centres, as detailed in Table 2. Patients suffering from WHO II 
anovulatory infertility were included (Farhi et al., 1993; Balasch et al., 1996; Yarali 
et al., 1999). The most comprehensive definition of PCOS specified as a 
combination of clinical features (oligoamenorrhea), biochemical parameters 
(increased androgen concentrations) and polycystic appearance of ovaries on 
ultrasound scan (enlarged ovaries with multiple small follicles), was used in a 
number of studies (McClure et al., 1992; Fulghesu et al., 1997; Vicino et al., 2000). 
Various combinations of clinical, biochemical and ultrasonographic findings were 
also used: ultrasound and clinical, or biochemical (Sagle et al., 1991; Hamilton-
Fairley et al., 1992; Dale et al., 1993; Dale et al., 1998; Strowitzki et al., 1998), 
clinical and ultrasound and/or biochemical (McClure et al., 1993), or clinical and 
ultrasound (White et al., 1996). According to these definitions oligoamenorrhea is 
not present in all patients per se (McClure et al., 1992; Dale et al., 1993; Farhi et 
al., 1993; Balasch et al., 1996; Dale et al., 1998; Strowitzki et al., 1998).  
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The extent of the infertility work-up was stated in all studies (Sagle et al., 
1991; Hamilton-Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993; 
McClure et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; 
Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; 
Vicino et al., 2000). This consisted most commonly of a semen analysis and a 
hysterosalpingography and/or laparoscopic inspection. Twelve studies included 
only couples with a normal semen analysis (Sagle et al., 1991; Hamilton-Fairley et 
al., 1992; McClure et al., 1992; Dale et al., 1993; McClure et al., 1993; Farhi et al., 
1993; Balasch et al., 1996; Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 
1998; Yarali et al., 1999; Vicino et al., 2000). In all studies tubal patency (at least 
one open tube) was confirmed (Sagle et al., 1991; Hamilton-Fairley et al., 1992; 
McClure et al., 1992; McClure et al., 1993; Farhi et al., 1993; Balasch et al., 1996; 
White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Vicino et al., 2000). 
In one study, donor sperm (one patient) was used because of co-existing male 
factor infertility (Hamilton-Fairley et al., 1992).  
Except for one study (White et al., 1996), the patients of interest either had 
remained anovulatory after CC treatment, or had failed to conceive despite 
ovulating during CC treatment. A wide variation in the definition of CC resistant 
anovulation and failure was used. In two studies, ovarian wedge resection or 
ovarian electrocauterization had been performed before gonadotropin induction of 
ovulation (Dale et al., 1993; Dale et al., 1998). 
In three studies, patients with increased BMI levels were excluded from 
treatment: BMI > 28 kg/m2 (Hamilton-Fairley et al., 1992; White et al., 1996) and 
BMI > 30 kg/m2 (Sagle et al., 1991). 
 
Description of interventions 
The step-up regimen was applied according to the following protocol: a starting 
dose of 75 IU per day and a first dose increase of 75 IU per day after 5-7 days 
(Farhi et al., 1993). Various alternatives of this protocol were reported (McClure et 
al., 1992; McClure et al., 1993; Fulghesu et al., 1997; Vicino et al., 2000). Others 
used the step-up regimen according to the following protocol: starting dose of 50-
75 IU per day, a first dose increase of 37.5 IU per day after 14 days and a 
subsequent dose increase of 37.5 IU per day  (Sagle et al., 1991; Hamilton-Fairley 
et al., 1992; Dale et al., 1993; Balasch et al., 1996; White et al., 1996; Dale et al., 
1998; Yarali et al., 1999). Strowitzky et al. (1998) utilized a variation of this 
regimen. In some studies the starting dose was adjusted in the subsequent (> 1) 
cycle performed (McClure et al., 1992; Balasch et al., 1996; White et al., 1996; 
Yarali et al., 1999; Vicino et al., 2000).  
The following preparations of gonadotropins were used: hMG (Sagle et al., 
1991; Hamilton-Fairley et al., 1992; McClure et al., 1992; Farhi et al., 1993; White 
et al., 1996), uFSH (Sagle et al., 1991; Hamilton-Fairley et al., 1992; McClure et al., 
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1992; Dale et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; 
Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; 
Vicino et al., 2000) and rFSH (Strowitzki et al., 1998; Yarali et al., 1999). Only one 
study compared gonadotropin-only treatment (uFSH/hMG) with a combined 
regimen (hMG and the concomitant administration of a GnRH agonist) (Farhi et al., 
1993). Besides gonadotropin induction of ovulation, electrocautery was also 
performed in one study (Vicino et al., 2000). 
 
Description of outcome measures 
In six studies the number of cycles with mono-folllicular development was not 
reported (McClure et al., 1992; McClure et al., 1993; Farhi et al., 1993; White et al., 
1996; Fulghesu et al., 1997; Vicino et al., 2000). The definition of mono-follicular 
growth varied from one follicle > 15 mm (Dale et al., 1998) and one follicle > 17 mm 
(Balasch et al., 1996) in diameter on the day of hCG. In five studies the definition 
used was not clearly stated (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale 
et al., 1993; Strowitzki et al., 1998; Yarali et al., 1999). Only seven studies reported 
the number of cycles with mono-follicular growth (Sagle et al., 1991; Hamilton-
Fairley et al., 1992; Dale et al., 1993; Balasch et al., 1996; Dale et al., 1998; 
Strowitzki et al., 1998; Yarali et al., 1999). 
The total amount of gonadotropins administered per cycle (Sagle et al., 
1991; McClure et al., 1992; Dale et al., 1993; McClure et al., 1993; Farhi et al., 
1993; White et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 
2000) or the mean total quantity of gonadotropins to induce ovulation or achieve 
follicular maturation (Hamilton-Fairley et al., 1992; Balasch et al., 1996; Fulghesu 
et al., 1997; Dale et al., 1998) was provided for all studies in ampoules or IU. For 
one study (McClure et al., 1992) the total amount of gonodotropins administered 
was deduced from a figure illustration. A conversion to IU was made for those 
studies reporting the total dose in ampoules (Sagle et al., 1991; Hamilton-Fairley et 
al., 1992; Farhi et al., 1993; White et al., 1996; Strowitzki et al., 1998; Vicino et al., 
2000).  
Criteria for cycle cancellation were based on the number of follicles 
developed and/or serum E2 levels. In five studies, cycles were cancelled in case of 
multi-follicular growth (≥ 4 follicles ≥ 15 mm) (Sagle et al., 1991; Hamilton-Fairley et 
al., 1992; Dale et al., 1993; White et al., 1996; Dale et al., 1998; Yarali et al., 1999). 
In four studies, cycles were cancelled because of multi-follicular growth or absence 
of response (Balasch et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino 
et al., 2000). Finally, three studies cancelled treatment cycles based on multi-
follicular growth and/or increased serum E2 levels (McClure et al., 1992; McClure et 
al., 1993; Farhi et al., 1993). One study did not provide information on criteria for 
cycle cancellation (Fulghesu et al., 1997). Only nine studies reported the number of 
cancelled cycles (Sagle et al., 1991; McClure et al., 1992; Dale et al., 1993; 
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Balasch et al., 1996; White et al., 1996; Dale et al., 1998; Strowitzki et al., 1998; 
Yarali et al., 1999; Vicino et al., 2000). 
Criteria for ovulation were based on the assessment of serum P levels 
(Hamilton-Fairley et al., 1992; Dale et al., 1993; White et al., 1996; Dale et al., 
1998; Yarali et al., 1999), or ultrasound (Strowitzki et al., 1998) or both (Sagle et 
al., 1991; Fulghesu et al., 1997; Vicino et al., 2000). Four studies did not provide 
information concerning confirmation of ovulation (McClure et al., 1992; McClure et 
al., 1993; Farhi et al., 1993; Balasch et al., 1996). A total of 11 studies reported the 
number of ovulatory cycles (Sagle et al., 1991; Hamilton-Fairley et al., 1992; 
McClure et al., 1992; Dale et al., 1993; Farhi et al., 1993; Balasch et al., 1996; 
White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; 
Vicino et al., 2000). 
Explicit details of the definition of pregnancy were given by using serum hCG 
(Sagle et al., 1991; Strowitzki et al., 1998; Yarali et al., 1999), ultrasound (Balasch 
et al., 1996; Vicino et al., 2000), serum hCG and ultrasound (Hamilton-Fairley et 
al., 1992; McClure et al., 1993) or ultrasound and/or histological verification (Dale 
et al., 1993; Dale et al., 1998). Two studies specifically stated the presence of a 
clinical pregnancy (Sagle et al., 1991; Yarali et al., 1999). Finally, one study only 
provided data on the definition of a clinical pregnancy (i.e. intrauterine gestational 
sac and fetal heart beat) (Vicino et al., 2000).  In four studies the definition of 
pregnancy was not stated (McClure et al., 1992; Farhi et al., 1993; White et al., 
1996; Fulghesu et al., 1997). Pregnancy rate (per cycle and per patient) was 
provided for all studies except one (McClure et al., 1993).  
The definition of miscarriage, spontaneous abortion or ongoing pregnancy 
rate was not clearly stated in seven studies (Farhi et al., 1993; Balasch et al., 1996; 
White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; 
Vicino et al., 2000). In two studies the definition of early pregnancy loss was stated 
(Sagle et al., 1991; Hamilton-Fairley et al., 1992). In four studies the definition of 
miscarriage was based on the division in first and second trimester abortions 
(McClure et al., 1992; Dale et al., 1993; McClure et al., 1993; Dale et al., 1998). 
Data on miscarriage rates were stated in all studies except one (Vicino et al., 
2000). 
 
Description of screening characteristics related to treatment outcome 
Except for one (Sagle et al., 1991), all studies stated data of age (means ± SD) for 
patients. In only four studies exact data of cycle history (i.e. oligomenorrhea or 
amenorrhea) for all patients were mentioned (Sagle et al., 1991; Hamilton-Fairley 
et al., 1992; Farhi et al., 1993; Balasch et al., 1996).  
Details of BMI levels for patients were given in nine studies (Dale et al., 
1993; McClure et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 
1996; Fulghesu et al., 1997; Dale et al., 1998; Yarali et al., 1999; Vicino et al., 
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2000). Some studies divided patients into non-obese (lean) and obese (BMI > 25 
kg/m2 (Hamilton-Fairley et al., 1992; Dale et al., 1993; White et al., 1996; Fulghesu 
et al., 1997; Dale et al., 1998), BMI > 27 (Vicino et al., 2000), or probably BMI > 30 
(Yarali et al., 1999)). One study (Strowitzki et al., 1998) described patients as lean 
or obese without any further information. The fraction of obese (BMI > 25) and non-
obese patients was calculated where only continuous data of BMI were provided 
(McClure et al., 1992; Farhi et al., 1993; White et al., 1996), assuming a normal 
distribution. 
In nine studies, CRA was defined as anovulation during at least 3 
consecutive cycles with an increasing dose up to at least 150 mg/day for a period 
of 5 days (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Dale et al., 1993; Farhi 
et al., 1993; Balasch et al., 1996; Dale et al., 1998; Strowitzki et al., 1998; Yarali et 
al., 1999; Vicino et al., 2000). One study decreased the threshold for CRA to 100 
mg/day (Fulghesu et al., 1997). In one study the dose for CRA was not clearly 
stated (McClure et al., 1992). CCF was defined as failure to conceive after at least 
6 ovulatory CC cycles (McClure et al., 1992; Farhi et al., 1993; Fulghesu et al., 
1997; Strowitzki et al., 1998; Yarali et al., 1999). One study decreased the number 
of cycles for CCF to 3 (Balasch et al., 1996). In two other studies the number of 
ovulatory cycles to fulfil the criteria for CCF were not stated (Dale et al., 1993; Dale 
et al., 1998). In two studies (McClure et al., 1993; Strowitzki et al., 1998), patients 
were said to be (un)responsive or resistant to CC, however the dose as well as the 
duration of CC treatment were not stated. In only six studies the exact number of 
patients suffering from CRA and CCF were mentioned (Sagle et al., 1991; 
Hamilton-Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993; McClure et al., 
1993; Vicino et al., 2000).  
The definition of polycystic ovaries was based on the Adams criteria (i.e. 
increased number of follicles and either an increased ovarian volume or increased 
stromal area or both) (Sagle et al., 1991; Hamilton-Fairley et al., 1992; Farhi et al., 
1993; White et al., 1996; Dale et al., 1998; Strowitzki et al., 1998; Vicino et al., 
2000),  or based on the presence of an increased number of follicles and/or ovarian 
stroma (McClure et al., 1992; McClure et al., 1993). Others did not report (clear) 
information on the definition of polycystic ovaries (Dale et al., 1993; Balasch et al., 
1996; Fulghesu et al., 1997; Yarali et al., 1999). In seven studies the number of 
patients with polycystic ovaries was stated (Sagle et al., 1991; Hamilton-Fairley et 
al., 1992; Dale et al., 1993; Farhi et al., 1993; White et al., 1996; Dale et al., 1998; 
Strowitzki et al., 1998).  
Details of baseline T levels were provided in nmol/L (Sagle et al., 1991; 
Hamilton-Fairley et al., 1992; Dale et al., 1993; Fulghesu et al., 1997; Dale et al., 
1998) or converted to SI units when expressed as ng/mL (Farhi et al., 1993; 
Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000). Data regarding AD 
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levels were provided in nmol/L (Dale et al., 1993; Fulghesu et al., 1997; Dale et al., 
1998; Vicino et al., 2000) or converted to SI units (Vicino et al., 2000).  
Details concerning baseline LH levels for patients or subgroups of patients 
were provided in IU/L in eight studies (Sagle et al., 1991; Hamilton-Fairley et al., 
1992; Dale et al., 1993; Farhi et al., 1993; Fulghesu et al., 1997; Dale et al., 1998; 
Strowitzki et al., 1998; Vicino et al., 2000) or converted when expressed as mIU/mL 
(Vicino et al., 2000). Baseline LH/FSH ratios were provided by eight studies (Sagle 
et al., 1991; Farhi et al., 1993; Balasch et al., 1996; Fulghesu et al., 1997; Dale et 
al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000). 
Dale et al. (1998) assessed insulin resistance and glucose tolerance by 
means of a continuous infusion of glucose with CIGMA (continuous infusion of 
glucose with model assessment) model assessment test. Fulghesu et al. (1997) 
classified patients as hyperinsulinemic or normoinsulinemic based on the 
insulinemic response to glucose load (OGTT). Both studies (Fulghesu et al., 1997; 
Dale et al., 1998) provided data of fasting glucose (nmol/L) and insulin levels 
(mIU/L). Conversion to IU units was performed where necessary.  
 
Pooling of data 
Data from studies reporting relationships between initial screening characteristics 
and outcome parameters of ovulation induction as measures of association (OR) 
were pooled if at least two studies reported an association of similar screening 
parameter and outcome characteristic. The measures of association were pooled 
using the inverse of the variance as weight. Heterogeneity was tested for using the 
Q statistic as defined by DerSimonean and Laird, which has a χ² distribution with df 
= [number of pooled studies - 1] (DerSimonian and Laird, 1986). Random effects 
estimates were calculated using the likelihood method described by Hardy and 
Thompson (Hardy and Thompson, 1998), when at least three studies were 
available. Association measures were extracted from studies for the following 
outcome parameters: total amount of FSH administered (Table 3), cancellation rate 
(Table 4), ovulation rate (Table 5), pregnancy rate (Table 6 and 7) and miscarriage 
rate (Table 8). 
 
Results of pooling 
A total number of seven studies reported an association (all positive) between 
obesity and total amount of gonadotropins administered (IU) (Figure 1) (Hamilton-
Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993; Fulghesu et al., 1997; 
Dale et al., 1998; Strowitzki et al., 1998; Vicino et al., 2000). The weighted mean 
difference (WMD) (obese versus non-obese) for total dose used was 771 (95% CI: 
700 - 842) IU. Significant heterogeneity was detected between studies (P < 0.001). 
The random effects estimate of the difference between obese and non-obese 
patients was 629 (95% CI: 317 - 931) IU. Two studies reporting on insulin 
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resistance versus total amount of FSH administered (Fulghesu et al., 1997; Dale et 
al., 1998) produced a WMD (hyperinsulinemic versus normoinsulinemic) of 351 
(95% CI: 73 - 630) IU.  
 Four studies reported an association between obesity and cancellation rate 
(Dale et al., 1993; Dale et al., 1998; Strowitzki et al., 1998; Vicino et al., 2000) 
(Figure 2). The pooled OR (obese versus non-obese) was 1.86 (95% CI: 1.13 - 
3.06). Despite conflicting directions of association, the test for heterogeneity was 
not significant (P = 0.2).  
Four studies (Hamilton-Fairley et al., 1992; Strowitzki et al., 1998; Yarali et 
al., 1999; Vicino et al., 2000) reported an association between obesity and 
ovulation rate, with a pooled OR (obese versus non-obese) of 0.44 (95% CI: 0.31 - 
0.61) (Figure 3).The test for heterogeneity was not significant (P = 0.4). Two 
studies (Sagle et al., 1991; White et al., 1996) reported an association between LH 
and ovulation rate. Pooling of the results was not possible because one studied 
reported LH as continuous variable (Sagle et al., 1991) and the other provided data 
of LH in two categories (White et al., 1996). Association measures for respectively 
T (White et al., 1996) and insulin resistance (Fulghesu et al., 1997) with ovulation 
were calculated from the data provided.   
Pregnancy was analyzed per cycle and per patient. Four studies reported an 
association (three positive and one negative) between obesity and pregnancy rate 
per cycle, pooled OR (obese versus non-obese) 1.13 (95% CI: 0.70 - 1.84) 
(Hamilton-Fairley et al., 1992; Dale et al., 1993; Strowitzki et al., 1998; Vicino et al., 
2000). The test for heterogeneity was not significant (P = 0.4). Five studies 
reported an association (two positive and three negative) between obesity and 
pregnancy rate per patient (Hamilton-Fairley et al., 1992; Farhi et al., 1993; White 
et al., 1996; Strowitzki et al., 1998; Vicino et al., 2000). The pooled OR (obese 
versus non-obese) was 1.22 (95% CI: 0.77 - 1.93). The test for heterogeneity was 
not significant (P = 0.16). Three studies (Farhi et al., 1993; White et al., 1996; 
Vicino et al., 2000) reported an association between T and pregnancy rate per 
patient. The pooled Odds ratio (per nmol/L) was 0.94 (95% CI: 0.80 - 1.09). Four 
studies (Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Vicino et al., 
2000) reported an association between LH and pregnancy rate per patient (Figure 
4). The pooled OR (per IU/L) was 1.04 (95% CI: 1.01 - 1.07). The test for 
heterogeneity was not possible in the latter two cases. Association measures 
between insulin resistance and pregnancy rate per cycle as well as per patient 
(Fulghesu et al., 1997; Dale et al., 1998) were calculated. Both studies (Fulghesu 
et al., 1997; Dale et al., 1998) reported a negative association between insulin 
resistance and pregnancy rate, with pooled OR (hyperinsulinemic versus 
normoinsulinemic) of 0.29 (95% CI: 0.10 - 0.80) and 0.24 (95% CI: 0.08 - 0.74).  
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during gonadotropin induction of ovulation in norm
ogonadotropic anovulatory infertility (see also Figure 1).  
 
Study 
N
 
(cycles)
M
ean IU
 (SD
) 
 M
ean difference in IU
 (95%
 C
I) 
 
 
 
O
besity
a 
T 
LH
 
Insulin resistance
b 
Balasch et al. (1996) 
534 
1185 (900) 
- 
- 
- 
- 
D
ale et al. (1993) 
66 
1702 (925) 
759 (346 - 1172) 
- 
- 
741 (290 - 1192) 
D
ale et al. (1998) 
70 
1611 (949) 
449 (46 - 852) 
- 
- 
- 
Farhi et al. (1993) 
195 
1979 (1027) 
- 
- 
- 
- 
Fulghesu et al. (1997) 
52 
1462 (638) 
263 (-59 - 585) 
- 
- 
113 (-241 - 466) 
H
am
ilton-Fairley et al. (1992) 
405 
1360 (719) 
1013 (848 - 1177) 
- 
- 
- 
M
cC
lure et al. (1992) c, d 
181 
1483 (640) 
892 (706 - 1079) 
- 
- 
- 
M
cC
lure et al. (1993) 
- 
- 
- 
- 
- 
- 
Sagle et al. (1991) 
75 
1269 (475) 
- 
- 
- 
- 
Strow
itzki et al. (1998) 
116 
1110 (567) 
33 (-173 - 238) 
- 
- 
- 
Vicino et al. (2000) 
107 
1444 (578) 
908 (801 - 1014) 
- 
- 
- 
W
hite et al. (1996) 
429 
1140 (785) 
- 
- 
- 
- 
Yarali et al. (1999) 
96 
1145 (762) 
- 
- 
- 
- 
 Pooled estim
ates 
 2326 
 1358 
 
 - 
 - 
 - 
 - 
                           W
eighted m
ean difference (W
M
D
) (95%
 C
I) 
 
771 (700 - 842) 
- 
- 
351 (73 - 630) 
  
R
andom
 effects m
odel 
629 (317 - 931) 
 
- 
- 
- 
  
Test for heterogeneity 
 
P < 0.001 
- 
- 
- 
 
Footnotes: a  O
besity versus total am
ount of gonadotropins adm
inistered expressed as: w
eighted m
ean difference (W
M
D
) in IU
: W
M
D
 based on 
obese versus non-obese patients (applied cut-off varied from
 study to study: range 25-30 kg/m
2). 
b  Insulin resistance versus total am
ount of 
gonadotropins adm
inistered expressed as: w
eighted m
ean difference (W
M
D
) in IU
: W
M
D
 based on hyperinsulinem
ic versus norm
oinsulinem
ic 
patients (applied definition varied betw
een studies). c Total dose in IU
 deducted from
 figure illustration: data not stated in results/table (M
cC
lure et 
al.,1992). d O
nly ovulatory cycles included for the present analysis (i.e. total am
ount of gonadotropins adm
inistered) (M
cC
lure et al.,1992). 
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fe
ct
s 
O
R
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5%
 C
I) 
1.
86
 (1
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06
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en
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= 
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 b
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 p
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 b
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 p
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 c
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TA
B
LE 7 P
ossible clinical and endocrine features involved in the observed pregnancy rate per patient during gonadotropin induction of ovulation in  
resistant norm
ogonadotropic anovulatory infertility
 (see also Figure 4). 
 Study 
 
 
N
 patients 
 
M
ean N
 cycles 
per patient 
 N  
pregnancies (%
) 
 
 
O
R
 (95%
 C
I) 
 
 
 
 
  
O
besity
a 
T  
LH
  
Insulin resistance
b 
B
alasch et al. (1996) 
234 
2.3 
93 (40%
) 
- 
- 
1.07 (1.06 - 1.16) 
- 
D
ale et al. (1993) 
50 
1.3 
12 (24%
) 
- 
- 
- 
0.10 (0.02 - 0.56) 
D
ale et al. (1998) 
42 
1.7 
16 (38%
) 
- 
- 
- 
- 
Farhi et al. (1993) 
89 
2.2 
35 (39%
) 
2.95 (1.09 - 7.96) c 
0.90 (0.73 - 1.12) 
1.00 (0.96 - 1.04) 
- 
Fulghesu et al. (1997) 
34 
1.5 
11 (32%
) 
- 
- 
- 
0.44 (0.10 - 1.92) 
H
am
ilton-Fairley et al. 
(1992) 
100 
4.1 
45 (45%
) 
2.25 (0.89 - 5.67) 
- 
- 
- 
M
cC
lure et al. (1992)   
71 
3.2 
45 (63%
) 
- 
- 
- 
- 
M
cC
lure et al. (1993) 
- 
- 
- 
- 
- 
- 
- 
S
agle et al. (1991) 
30 
2.5 
10 (33%
) 
- 
- 
- 
- 
S
trow
itzki et al. (1998) 
68 
1.7 
21 (31%
). 
0.59 (0.21 - 1.69) 
- 
- 
- 
V
icino et al. (2000) 
21 
5.1 
8 (38%
) 
0.39 (0.06 - 2.70) 
0.95 (0.70 - 1.29) 
0.73 (0.35 - 1.53) 
- 
W
hite et al. (1996)  
91 
4.7 
49 (54%
) 
0.79 (0.35 - 1.80) c 
1.0 (0.73 - 1.37) 
1.01 (0.96 - 1.08) 
- 
Yarali  et al. (1999) 
51 
1.9 
21 (41%
) 
- 
- 
- 
- 
Pooled estim
ates 
881 
2.7 
366 
- 
- 
- 
- 
 
Fixed effectsO
R
 (95%
 C
I) 
1.22 (0.77-1.93) d 
0.94 (0.80 -1.09) e 
1.04 (1.01 -1.07) f 
0.24 (0.08 - 0.71) 
  
  
Test for heterogeneity
 
P = 0.16 
- 
- 
- 
 
Footnotes: a O
R
 based on obese versus non-obese patients (applied cut-off varied from
 study to study: range 25- 30 kg/m
2). b O
R
 based on hyperinsulinem
ic versus norm
oinsulinem
ic patients (applied definition varied  
betw
een studies). c Farhi et al. (1993) and W
hite et al. (1996) both provide continuous data of B
M
I for pregnant versus non-pregnant w
om
en: assum
e B
M
I is norm
ally distributed am
ong pregnant versus non-pregnant  
patients: calculate the fraction obese and non-obese patients (2x2 table constructed): indirect calculation of O
R
 (based on num
ber of patients): 2.95 and 0.79 respectively. d S
econd best analysis perform
ed (per patient),  
because not all studies provided data per cycle: analysis based on obese versus non-obese patients (applied cut-off varied from
 study to study: range 25-30 kg/m
2): obesity versus pregnancy rate expressed as: O
R
. e For T  
levels expressed as SI units (nm
ol/L) pooled analysis w
as perform
ed (Farhi et al., 1993; W
hite et al., 1996; V
icino et al., 2000). f For LH
 levels expressed as S
I units (IU
/L) pooled analysis w
as perform
ed (Farhi et al., 1993;  
B
alasch et al., 1996; W
hite et al., 1996; V
icino et al., 2000). 
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Difference in total amount administered (IU) for obese versus non-obese women  
 
Figure 1 Association measures between obesity and total amount of gonadotropins administered (IU) for 
ovulation induction in normogonadotropic anovulatory infertility (median and 95% CI). The weighted mean 
difference (WMD) was generated using inverse variance weighting. Heterogeneity was tested for and 
random effects estimates were calculated using the likelihood method as described by Hardy and 
Thompson (1998). 
Odds ratio of cancellation rate for obese versus non-obese women  
 
Figure 2 Four studies reported an association between obesity and cancellation rate. The pooled OR 
and 95% CI (obese versus non-obese) was calculated by inverse variance weighting.  
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Random effects OR 0.43 (0.29 - 0.71) 
Fixed effects OR 0.44 (0.31 - 0.61) 
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Odds ratio of ovulation rate for obese versus non-obese women  
 
Figure 3 Four studies reported an association between obesity and ovulation rate, with a 
pooled OR and 95% CI (obese versus non-obese) generated calculated by inverse 
variance weighting. Note: the range of the x-axis is different from Figure 2. 
 
 
Odds ratio of pregnancy rate (per patient) for LH (per IU/L) 
 
Figure 4 Association measures between LH (per IU/L) and pregnancy rate per patient was 
provided by a total number of 4 studies. The pooled OR and 95% CI (obese versus non-obese) 
was calculated by inverse variance weighting.  
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Four studies reported an association between obesity and miscarriage rate 
(Figure 5) (Hamilton-Fairley et al., 1992; McClure et al., 1993; White et al., 1996; 
Strowitzki et al., 1998). The pooled OR (obese versus non-obese) was 3.05 (95% 
CI: 1.45 - 6.44). The test for heterogeneity was not significant (P = 0.17). Two 
studies (McClure et al., 1993; White et al., 1996) reported an association between 
LH and miscarriage rate. The pooled OR (per IUl/L) was 1.013 (95% CI: 0.95 - 
1.08). Two studies (Fulghesu et al., 1997; Dale et al., 1998)  reported an 
association between insulin resistance and miscarriage rate. The pooled OR 
(hyperinsulinemic versus normoinsulinemic) was 1.75 (95% CI: 0.30 - 10.3). An 
association of age (McClure et al., 1993) versus T (White et al., 1996) and 
miscarriage rate was calculated from the data provided.   
None of the studies provided a measure of association between CRA/CCF 
or the presence of polycystic ovaries and treatment outcome. 
In summary, significant associations were found for the total amount of FSH 
administered, cancellation rate, ovulation rate and miscarriage rates with BMI. 
Furthermore, significant associations were found for the total amount of FSH and 
pregnancy rate with insulin resistance. 
 
Random effects OR 3.11 (1.55 - 5.95) 
Fixed effects OR 3.05 (1.45 - 6.44) 
White et al. (1996) 
Strowitzky et al. (1998) 
McClure et al. (1993) 
Hamilton - Fairley et al. (1992) 
0 5 
 
10 
 
50 
 
Odds ratio of miscarriage rate for obese versus non-obese women 
 
Figure 5 Four studies reported an association between obesity and miscarriage rate. The pooled OR and 
95% CI (obese versus non-obese) was calculated by inverse variance weighting. Note: the range of the x-
axis is different from Figure 2. 
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5.2.4 Discussion 
 
This systematic review and meta-analysis demonstrates how few studies have 
provided measures of association between screening characteristics in women with 
normogonadotropic anovulatory infertility and gonadotropin ovulation induction 
treatment outcome. The studies included used various criteria for patient inclusion 
and intervention and are prone to bias. The best available evidence suggests that 
obesity and insulin resistance are both associated with adverse treatment 
outcomes, including increased FSH requirements, increased cancellation and 
miscarriage rates and most importantly decreased ovulation and pregnancy rates. 
Obesity frequently coincides with normogonadotropic anovulation and 
represents an important clinical feature associated with PCOS (Laven et al., 2002). 
Differences in pharmacokinetic characteristics of gonadotropin preparations 
(Mannaerts et al., 1993) as well as the amount of exogenous gonadotropins 
required to achieve follicular maturation (Hamilton-Fairley et al., 1992; McClure et 
al., 1992; Dale et al., 1993; Vicino et al., 2000; Imani et al., 2002a) related to body 
weight, have been reported. Obesity is associated with reduced circulating levels of 
sex hormone-binding globulin (SHBG), mildly elevated androgen levels (Poretsky 
et al., 1999) and hyperinsulinemia (Norman et al., 2002). Insulin resistance 
(associated with PCOS as well (Dunaif, 1999)) is also related to the total amount of 
gonadotropins administered, as previously reported (Homburg et al., 1996).  
So far, the impact of obesity on the cycle cancellation rates in women with 
anovulatory infertility has not been convincingly established. However, the impact 
of obesity on ovulation rates was previously mentioned by several authors 
(Hamilton-Fairley et al., 1992; Yarali et al., 1999; Vicino et al., 2000). The present 
meta-analysis explicitly shows that obese women are less likely to ovulate following 
gonadotropin ovulation induction and therefore suggests that ovarian dysfunction in 
these women is more severe. However, differences in absorption and distribution 
of exogenous FSH may also be involved (Mannaerts et al., 1993). Weight reduction 
may normalize insulin resistance and androgen metabolism (Kiddy et al., 1992; 
Holte et al., 1995) and may significantly improve menstrual abnormalities, 
ovulation, and fertility rates (Norman et al., 2002).  
Obesity does not seem to be associated with decreased pregnancy rates, as 
previously reported (Hamilton-Fairley et al., 1992; Dale et al., 1993; White et al., 
1996; Strowitzki et al., 1998; Vicino et al., 2000). It should be noted that some of 
these conclusions were drawn based on studies of a selected group of non-obese 
women (i.e. BMI < 27 kg/m2). The current analysis, however, shows an increased 
incidence of spontaneous miscarriage with increasing BMI in women with PCOS. 
This finding has been reported before (Hamilton-Fairley et al., 1992). The present 
analysis, though, shows that all other studies are in line with this observation. This 
result again stresses the importance of weight reduction. Likewise, it has been 
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described that the incidence of spontaneous miscarriage increases with decreasing 
insulin sensitivity (Dale et al., 1993). However, the small number of miscarriages 
precludes definitive conclusions in this regard. Along these lines, it has been 
suggested that insulin-sensitizing agents also reduce miscarriage rates (Glueck et 
al., 2001).  
Hyperandrogenism is considered to be a key feature in PCOS and 
constitutes a hallmark for the diagnosis (Dunaif et al., 1992). Intra-ovarian inhibitors 
of FSH action (such as the IGF system) (Schipper et al., 1997; van Dessel et al., 
1999) might possibly promote follicle maturation arrest and concomitantly ovarian 
hyperandrogenism (Giudice, 1999). Hyperandrogenism has proven to be a 
powerful predictor for the response to ovulation induction, emphasizing its 
significance for ovarian dysfunction in these women (Imani et al., 1998; Imani et al., 
1999; Imani et al., 2000; Imani et al., 2002a; Imani et al., 2002b; Mulders et al., 
2003a). The impact of these biologically plausible factors involved in ovarian 
dysfunction in normogonadotropic anovulation, such as serum androgens and free 
IGF-I, unfortunately could not be scrutinized in the current analysis, because of 
lack of data.  
Elevated LH levels are frequently encountered in PCOS, but this is not a 
mandatory diagnostic of PCOS (Laven et al., 2002). Although it was previously 
reported that elevated serum LH concentrations were associated with increased 
miscarriage rates on the basis of retrospective studies (Howles et al., 1986; Balen 
et al., 1993b; Watson et al., 1993), prospective data do not support the concept 
that elevated LH is implicated in ovarian dysfunction and ovulation induction 
outcome (Imani et al., 2002b). The present analysis, however, shows a small but 
significant association of elevated serum LH with increased pregnancy rates. 
Upon pelvic ultrasound, ovaries of women with normogonadotropic 
anovulation might be enlarged (Puzigaca et al., 1991; Pache et al., 1992a), contain 
an increased number of follicles (Obhrai et al., 1990; Jonard et al., 2003), and 
exhibit an increased density of ovarian stroma (Dewailly, 1997). It has been shown 
that the value of these sonographic parameters as a screening test to predict 
endocrine abnormalities characteristic of PCOS is limited (van Santbrink et al., 
1997). In addition, sonographic parameters are predictive of patients remaining 
anovulatory following CC (Imani et al., 1998). Others recently described a 
correlation between initial ovarian volume or mean follicle number and subsequent 
response applying gonadotropin induction of ovulation (van der Meer et al., 1998; 
Lass et al., 2002; Mulders et al., 2003a). These findings could not be reconfirmed 
in the current analysis since none of the included studies reported sufficient data to 
perform the analysis.  
The association of advanced age with reduced treatment outcome following 
CC- or FSH-induced cycles, as previously reported (McClure et al., 1993; Imani et 
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al., 2002b; Mulders et al., 2003a), could not be confirmed by the present meta-
analysis because of lack of data.  
In summary, the current results are perhaps somewhat disappointing. 
However, this should not be too surprising as most studies did not intend to predict 
treatment outcome by patient characteristics. The possibility that some conclusions 
from this analysis may be affected by the repetitive inclusion of data cannot be 
completely discarded. However, we believe that such effects, if they exist, are 
minor. In addition, pooling of the original data files rather than the published data 
might also have resulted in slightly different outcomes. Principally, the association 
between initial clinical screening parameters (reflecting the extent of ovarian 
dysfunction in normogonadotropic anovulatory infertility) and treatment outcome 
deserves further attention. In addition, more individualized ovulation induction 
treatment algorithms may subsequently be developed. For the future, there is a 
need to standardize the definitions of ovulation induction treatment outcome in 
women with normogonadotropic anovulatory infertility (including PCOS). Live birth 
from a singleton pregnancy following gonadotropin induction of ovulation could 
then be more effectively achieved by treatment strategies individually tailored on 
the basis of initial screening characteristics.  
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5.3 IVF outcome in WHO II anovulatory infertility (including polycystic ovary 
syndrome) following previous unsuccessful ovulation induction  
 
Abstract  
 
This follow-up study represents in-vitro fertilization (IVF) treatment characteristics 
and outcomes in women with World Health Organization (WHO) group II 
anovulatory infertility after previous unsuccessful ovulation induction compared to 
controls. Furthermore, the possibility of initial screening parameters of these 
anovulatory women to predict IVF outcome was examined.  
Twenty six patients with WHO II anovulatory infertility who failed to establish 
a live birth following previous induction of ovulation (using clomiphene citrate as 
first line and follicle-stimulating hormone (FSH) as second line) were compared 
with 26 IVF patients with tubal infertility matched for age, treatment period and 
treatment regimen. The WHO II patients underwent 49 IVF cycles, whereas the 
normo-ovulatory controls underwent 46 cycles. In WHO II patients 15 cycles were 
cancelled compared to 6 cycles in controls (P = 0.04). Cycles were predominantly 
cancelled due to insufficient response (P = 0.04). In case the cycle was cancelled, 
body mass index (BMI) was significantly higher (P < 0.001) in WHO 2 women 
compared to controls. Overall live birth rates were comparable (P = 0.9).  
Obese women suffering from WHO II anovulatory infertility are at an 
increased risk to have their IVF cycle cancelled due to insufficient response. Once 
oocyte retrieval is achieved live birth rates are comparable to controls.  
 
5.3.1 Introduction 
 
Chronic anovulation is a common cause of infertility. Most anovulatory women 
have irregular menstrual cycles and normal serum FSH concentrations (World 
Health Organization (WHO) group II) (The ESHRE Capri Workshop Group, 1995; 
Rowe et al., 2000). Depending on the criteria used, polycystic ovary syndrome 
(PCOS) is diagnosed in approximately 60-70% of these women (van Santbrink et 
al., 1997; Laven et al., 2002).  
When classical induction of ovulation (including clomiphene citrate as first 
line and exogenous gonadotropins as second line treatment) fails to result in 
pregnancy, in-vitro fertilization (IVF) has proven to be a feasible therapeutic option 
(Shulman and Dor, 1997). Previous studies comparing IVF treatment outcome in 
PCOS versus controls have shown that more oocytes could be retrieved, but with a 
reduced proportion of oocytes fertilized. These observations suggest that an 
increased number of immature oocytes are recruited (Dor et al., 1990; Urman et 
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al., 1992; Homburg et al., 1993). Moreover, both mature and immature oocytes of 
PCOS patients show reduced fertilization rates, presumably due to endogenous 
hormonal imbalance (Dor et al., 1990; Urman et al., 1992). Despite reduced overall 
fertilization, IVF pregnancy rates in PCOS patients appear to be comparable to 
normo-ovulatory women (Dor et al., 1990; Urman et al., 1992; Homburg et al., 
1993).  
These findings should be interpreted with caution, however, because of 
possible confounding factors. First of all, pituitary down-regulation by gonadotropin-
releasing hormone (GnRH) agonist co-treatment, associated with overall increased 
pregnancy rates following IVF (Hughes et al., 1992; Homburg et al., 1993), was not 
uniformly applied (Dor et al., 1990; Urman et al., 1992). Furthermore, some reports 
compared IVF treatment outcome in patients with and without polycystic ovaries 
(PCO) (Owen et al., 1991; MacDougall et al., 1993). Subjects involved did not 
necessarily suffer from anovulatory infertility, and therefore it does not seem 
appropriate to extrapolate these findings to women who suffer from PCOS. Other 
potential confounders might constitute the inclusion of patients in whom, besides 
PCOS, additional factors such as tubal infertility or oligospermia (Salat-Baroux et 
al., 1988; Dale et al., 1991) were involved, or there were uncertainties regarding 
previous ovulation induction strategies (Dor et al., 1990; Tanbo et al., 1990; 
Homburg et al., 1993). These above mentioned factors, along with the limited 
patient numbers and the absence of proper controls (Tanbo et al., 1990; Dor et al., 
1992; Urman et al., 1992) seriously hamper interpretation of these studies.  
The present study was designed to compare IVF treatment characteristics 
(such as amount of FSH administered, number of oocytes retrieved, cancellation 
rates and fertilization rates) along with clinical outcomes in women suffering from 
normogonadotropic anovulatory infertility versus controls. Women with WHO II 
infertility, originating from a large series of consecutive women all prospectively 
followed from the initiation of fertility work-up, were matched with a control group 
consisting of women with tubal infertility. Distinct variability in individual patient 
characteristics might be indicative for IVF outcome in women with 
normogonadotropic anovulatory infertility, as was previously shown for ovulation 
induction strategies using either clomiphene citrate (Imani et al., 1998; Imani et al., 
1999; Imani et al., 2000; Imani et al., 2002b) or gonadotropins (Imani et al., 2002a). 
Therefore, clinical, sonographic and endocrine screening characteristics possibly 
predicting stimulation characteristics or IVF outcome were also examined.  
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5.3.2 Materials and methods 
 
Study population 
Between February 1993 and May 1999, a consecutive series of 240 women with 
WHO II anovulatory infertility visiting the fertility outpatient clinic were included in 
the present prospective follow-up study (Imani et al., 1998; Imani et al., 1999; Imani 
et al., 2000; Imani et al., 2002a; Imani et al., 2002b). The local Medical Ethics 
Review Committee approved this study, and informed consent was obtained from 
all participants. All 240 women started with induction of ovulation using clomiphene 
citrate as a first line treatment. A total of 57 (24%) and 71 (30%) were found to 
suffer from CC resistant anovulation (CRA) and CC failure (CCF), respectively. 
Subsequently, a total of 84 women from the initial cohort underwent gonadotropin 
induction of ovulation as second line therapy. In 44 women, an ongoing pregnancy 
was achieved. Finally, a total of 26 women underwent IVF following unsuccessful 
classical ovulation induction and were included in the present analysis. Inclusion 
criteria were: [1] oligomenorrhea (bleeding intervals between 35 days and 6 
months) or amenorrhea (bleeding interval > 6 months), [2] serum FSH and E2 
concentrations within normal limits (van Santbrink et al., 1995a), [3] normal serum 
prolactin and thyroid-stimulating hormone concentrations, [4] spontaneous menses 
or positive bleeding response to progestagen withdrawal, [5] BMI (body mass index 
(kg/m2)) > 18 kg/m2, [6] age between 25 and 40 years, [7] total motile sperm count 
[TMC = ejaculate volume (mL) × sperm concentration (106/mL) × percentage of 
progressive motile spermatozoa] > 1 x 106, [8] a negative history for any tubal 
pathology along with negative antibody test for chlamydia or proven normal tubal 
patency upon hysterosalpingography or laparoscopic inspection, and [9] failure to 
establish either ovulation or live birth following ovulation during previous induction 
of ovulation.  
For each subject undergoing IVF one normo-ovulatory control patient 
matched for age, period of IVF treatment (1995-2000) and a similar GnRH agonist 
long protocol as co-treatment for ovarian stimulation was included in the present 
study. All had a history of regular menstrual cycles (between 25 and 32 days). 
These matched controls suffered from tubal infertility (bilateral occluded tubes) as 
their indication for IVF.  
 
Initial screening 
Initial standardized clinical, sonographic and endocrine screening of women with 
oligo-amenorrhea was performed at intake as previously described (Imani et al., 
1998; Imani et al., 1999; Imani et al., 2000; Imani et al., 2002a; Imani et al., 2002b). 
Clinical screening parameters recorded were age, duration and type (primary 
versus secondary) of infertility, cycle history, BMI, waist-to-hip ratio (WHR). During 
subsequent transvaginal sonography (TVS) ovarian stroma echogenicity, ovarian 
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volume (mL) and total number of follicles, were assessed as previously described 
(Pache et al., 1992a; van Santbrink et al., 1997). Endocrine screening included the 
assessment of FSH, luteinizing hormone (LH), estradiol (E2), androstenedione 
(AD), testosterone (T), sex hormone-binding globulin (SHBG), 
dehydroepiandrosterone-sulphate (DHEAS), fasting insulin and glucose, free and 
total insulin-like growth factor-I (IGF-I), IGF binding protein-I (IGFBP-I), IGFBP-III, 
inhibin B and leptin serum levels, as previously published (Imani et al., 1998; Imani 
et al., 1999; Imani et al., 2000; Imani et al., 2002b). The hormone assays used and 
the intra- and interassay coefficients of variation valid for this study have all been 
described previously (Imani et al., 1998; Imani et al., 1999; Imani et al., 2000). 
 
Preceding ovulation induction treatment regimen  
The treatment protocol, assessment of ovarian response and conception have 
been described previously (Imani et al., 1998; Imani et al., 1999; Imani et al., 2000; 
Imani et al., 2002a; Imani et al., 2002b). In brief, CC doses were 50 mg/day, 
starting on cycle day 3 for 5 subsequent days after a spontaneous or progestagen-
induced withdrawal bleeding. In the case of absent ovarian response, daily doses 
were increased to 100 and 150 mg in subsequent cycles. All patients with 
normogonadotropic anovulation trying to conceive were said to be CRA if they 
remained anovulatory during at least 3 consecutive cycles. CCF was defined as 
failure to conceive despite having 6 ovulatory cycles during the preceding CC 
treatment. In case of CRA or CCF, gonadotropin induction of ovulation was applied 
as second line therapy. Exogenous FSH was initiated on days 3-5 after a 
spontaneous or an induced withdrawal bleeding. During the first cycle, a low-dose 
step-up regimen using either daily intramuscular (i.m.) injections of urinary (u)FSH 
(Metrodin HP®, Serono Benelux BV, The Hague, The Netherlands) or 
subcutaneous (s.c.) injections of recombinant (r)FSH (Gonal-F®, Serono Benelux 
BV) was used to assess the individual FSH response (threshold) dose (i.e. 
sonographic visualization of a follicle ≥ 10 mm) (Imani et al., 2002a). During all 
subsequent cycles, a step-down protocol was performed. No significant differences 
in outcome between urinary and recombinant FSH were observed (data not 
shown). 
 
IVF treatment regimen and monitoring of ovarian response  
In those women suffering from amenorrhea or severe oligomenorrhea, pituitary 
down-regulation was initiated randomly. In the remaining patients and controls 
pituitary down-regulation was achieved by administering the GnRH agonist 
triptorelin (0.1 mg daily s.c., Decapeptyl®, Ferring Nederland BV, Hoofddorp, The 
Netherlands) starting one week before the expected menses (Beckers et al., 2000). 
In all patients ovarian stimulation was commenced after two weeks of GnRH 
agonist use.  
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Different preparations of urinary FSH (i.m.) or recombinant FSH (s.c.) have 
been used (Humegon®, NV Organon, Oss, The Netherlands; Metrodin HP®, 
Serono Benelux BV; Puregon®, NV Organon). Multiple follicle development was 
induced with daily injections at an initial dose of 150 up to 450 IU (depending on 
previous response). The daily dose was adjusted according to the ovarian 
response as assessed by serial ultrasound scans. On the day ≥ 3 follicles > 15 mm 
were present and the leading follicle reached a diameter ≥ 18 mm, a single bolus of 
human chorionic gonadotropin (hCG) (Pregnyl®, NV Organon) (5,000 IU or 10,000 
IU) was administered (Beckers et al., 2000). Transvaginal ultrasound-guided 
oocyte retrieval was performed within 32-36 hours. After fertilization, a maximum of 
two embryos was transferred after 3-5 days of culture (Huisman et al., 2000). 
Remaining embryos of sufficient quality were cryopreserved.  
Luteal phase support, either hCG (Pregnyl®, NV Organon) (1,500 IU s.c. on 
the day of oocyte retrieval and 2, 4, and 6 days after oocyte retrieval) or micronized 
progesterone (Progestan®, NV Organon) (600 mg/day administered vaginally) was 
given from the day of oocyte retrieval (van der Gaast et al., 2002). 
Cycles were cancelled if there was insufficient response (the presence of no 
more than two dominant follicles) as assessed by ultrasound. Hyperresponse was 
defined as the presence of multiple dominant follicles (The ESHRE Capri 
Workshop Group, 1996). In the latter case, the cycle was cancelled because of the 
risk of ovarian hyperstimulation syndrome (OHSS). The severity of OHSS was 
assessed according to previously published guidelines (Navot et al., 1992). A 
biochemical pregnancy was defined as a positive urinary pregnancy test 
(Clearview®: hCG > 25 IU/L, Unipath Limited, Bedford, Bedfordshire, United 
Kingdom) performed at least 17 days after oocyte retrieval. An ongoing pregnancy 
was defined as sonographic assessment of intrauterine gestational sac with 
positive heartbeat. Live birth rate was defined as the number of live born babies 
per 26 patients. 
 
Data analysis 
All patients were followed either until their first pregnancy or until discontinuation of 
therapy. Data of clinical and IVF treatment characteristics in both patient groups 
are presented as means ± SD if distributed normally. Otherwise data are presented 
as median and range. Comparisons between the groups were performed using a 
Student’s t test, Mann-Whitney U test or χ²-test. Cumulative conception rates were 
analysed with the Kaplan-Meier method, as were cumulative live birth rates. 
Censoring was defined either as definitive discontinuation of therapy without 
conception or end of follow-up period. The log rank test was used for statistical 
comparison in Kaplan-Meier analyses.  
Student’s t test and χ²-test were used to compare initial screening 
parameters of cycles in WHO II women who respectively did and did not undergo 
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oocyte retrieval. Women with multiple treatment cycles will occur more than once in 
this analysis. When they have repetitive cancellation of cycles this may potentially 
lead to biased results. Association between screening characteristics and 
stimulation characteristics was assessed by Spearman’s correlation. Multiple linear 
regression was used for multivariable analysis, with amount of FSH administered 
as a continuous outcome variable. Initial screening variables that were significant in 
univariable analyses were entered into the multiple regression model in a forward 
stepwise fashion.  
Student’s t test and χ²-test were also used to compare initial screening 
parameters between the women with WHO II infertility included in the initial cohort 
and the WHO II women who finally underwent IVF.  
Data were analysed using a commercially available software package 
(SPSS, Chicago, IL, USA). A P value of 0.05 (two-tailed) was considered as the 
threshold level for statistical significance.  
 
5.3.3 Results  
 
Twenty-six patients with anovulatory infertility (WHO II) fulfilled the inclusion criteria 
and subsequently underwent 49 IVF cycles. The control group consisted of 26 (46 
cycles) normo-ovulatory women suffering from tubal infertility matched for age, 
treatment period, and treatment regimen. Clinical as well as IVF treatment 
characteristics of both groups are summarized in Table 1. In WHO II patients 15 
cycles (31%) were cancelled, compared with only six cycles (13%) in the control 
group (P = 0.04). Cycles were cancelled either due to insufficient response (WHO 
II: 25% (n = 12), controls: 7% (n = 3); P = 0.04) or hyperresponse (WHO II: 4% (n = 
2), controls: 4% (n = 2); NS). Only a few cycles were cancelled because of 
intercurrent disease (WHO II: 2% (n = 1), controls: 2% (n = 1); NS). In patients in 
whom the cycle was cancelled, BMI was significantly higher (P < 0.001) in WHO II 
women compared with controls (32.3 versus 22.7 kg/m2).  
Chapter 5 
 
 
134
TABLE 1 IVF characteristics (mean ± SD) of women with normogonadotropic anovulatory infertility 
(WHO II) after unsuccessful preceding classical ovulation induction versus matched control IVF patients.  
 
 
 
* median (range). a Only for non-cancelled cycles. b Day of hCG. c Definition based upon morphology 
score (i.e. stage of development, amount of fragmentation, presence of degeneration and amount of 
granulation) as previously published (Huisman et al., 2000).  
 WHO II  
infertility 
Tubal 
infertility 
P value 
 (N = 26 patients) (N = 26 patients)  
Clinical characteristics    
Age  (years) 34.9 ± 3.2 34.8 ± 3.5 NS 
% Primary infertility (n) 62 (16) 69 (18) NS 
BMI  (kg/m²)  26.5 ±  6.2  25.0 ± 5.2  NS 
Total motile sperm count  183  (1 - 681)* 50 (1 - 4000)* NS 
    
    
 (N = 49 cycles) (N = 46 cycles)  
Stimulation characteristics    
No. of cancelled cycles (%) 15 (31) 6 (13) 0.04 
Duration of stimulation (days)a 11.4 ± 2.8 11.7 ± 2.5 NS 
Total amount of  FSH administered (IU)a 1946 ± 720 2100 ± 909 NS 
    
Late follicular phase ovarian 
folliclesa,b 
   
Total no. of follicles (≥ 10 mm)  15.6 ± 7.4  11.9 ± 5.6  0.02 
No. of follicles 10-13 mm  11.4 ± 6.7  8.5 ± 5.4  0.04 
No. of follicles 14-17 mm  3.8 ± 1.9 3.4 ± 1.4 NS 
No. of follicles ≥ 18 mm  1.1  ± 1.1 1.2 ± 0.9 NS 
Gamete and embryo characteristics    
No. of oocytes retrieved 11.8 ± 7.8 10.9 ± 5.9 NS 
 % normal fertilization    50 ± 27 62 ± 26 NS 
No. of 2 PN embryos 5.8 ± 3.9 6.4 ± 3.7 NS 
 % embryo transfer with 1-2 good quality 
embryos (n)c  
45 (13) 67 (25) NS 
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The differences found in initial parameters between WHO II patients who did 
and did not undergo oocyte retrieval are depicted in Table 2. Briefly, BMI was 
significantly different (P = 0.003) in those women that succeeded until oocyte 
retrieval and the ones who did not. The analysis on first IVF cycles gave similar 
results. BMI, SHBG and IGFBP-I were significantly different. The differences for 
FAI (free androgen index: T x 100/SHBG) and DHEAS were of the same 
magnitude, but not of statistical significance. Univariate analysis showed that the 
total amount of exogenous FSH (IU) administered correlated with BMI, serum 
levels of SHBG, FAI, DHEAS and IGFBP-I (Table 3).  
 
 
TABLE 3 Spearman’s correlation coefficients of initial clinical and endocrine screening  
characteristics of the overall group of anovulatory infertile patients (n = 26) with the  
total amount of FSH (IU) administered. 
 
                                       Total amount of FSH (IU) administered 
   
  ra 
 
      No. of cyclesb 
 
 
BMI (kg/m²) 
 
 
0.38c 
 
48 
 
SHBG (nmol/L)  - 0.47c 48  
FAI (T x 100/SHBG)  0.34d 48  
DHEAS (µmol/L)  0.56c 48  
IGFBP-I (ng/mL)  - 0.50c 36  
 
a Univariate analysis (step 0).  
b Cancelled and non-cancelled combined. 
c P < 0.01. 
d P < 0.05. 
Note: Only variables significant in univariate analysis were used in multivariate analysis. Forward 
stepwise multivariate analyses of initial screening characteristics for prediction of total amount of 
FSH (IU) administered. All analyses were corrected for BMI, to test whether an association exists 
between screening characteristics and total amount of FSH (IU), independent from BMI. In this 
analysis only DHEAS remained significant (P < 0.01). The adjusted R2 of the final model (including 
BMI and DHEAS) = 0.54. 
 
Subsequently, a multivariable analysis of initial screening characteristics for 
prediction of total amount of FSH (IU) administered in the overall group of 
anovulatory infertile patients was performed. All analyses were corrected for BMI, 
to test whether an association exists between screening characteristics and total 
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amount of FSH (IU), independent from BMI. In this analysis, only DHEAS remained 
significant (P < 0.01). The adjusted R2 of the final model (including BMI and 
DHEAS) = 0.54.      
Patients with anovulatory infertility achieving oocyte retrieval developed 
significantly more dominant follicles on the day of hCG administration compared 
with controls (P = 0.02). However, the oocyte recovery rates were comparable 
(Table 1). The correlations between the total amount of exogenous FSH (IU) 
administered versus the total number of follicles or BMI in 26 WHO II women and 
their controls are depicted in Figure 1. There were three cases of OHSS in the 
group with WHO II infertility whereas only one patient in the control group showed 
signs of OHSS (NS).  
 
 
TABLE 4 Pregnancy and live birth rates as percentage (absolute numbers in parentheses) of women 
with normogonadotropic anovulatory infertility (WHO II) after unsuccessful preceding classical ovulation 
induction versus matched control IVF patients.  
         WHO II infertility 
            (26 patients) 
       Tubal infertility 
          (26 patients) 
P value 
Clinical pregnancies/cycle 33 (16/49) 26 (12/46) 0.5 
Clinical pregnancies/oocyte retrieval 47 (16/34) 30 (12/40) 0.1 
Clinical pregnancies/embryo transfer 55 (16/29) 32 (12/38) 0.05 
Implantation rate/embryo 36 (20/56) 19 (14/74) 0.03 
Miscarriages 38 (6/16) 17 (2/12) 0.2 
Live birth/cycle 16 (8/49) 15 (7/46) 0.9 
Multiple pregnancies (twins) 50 (5/10) 30 (3/10) 0.4 
 
IVF treatment outcome in both groups is summarized in Table 4. In WHO II 
patients, a total of 16 cycles (55%) resulted in a biochemical pregnancy compared 
with 12 (32%) cycles in the control group (P = 0.05). In the WHO II group, six 
biochemical pregnancies (38%) resulted in a miscarriage, compared with only two 
(17%) in the control group (P = 0.2). WHO II women with an ongoing pregnancy did 
not have lower levels of initial serum LH (P = 0.6) or seemed to be less obese (P = 
0.1) (data not shown). Cumulative conception rates (after three cycles) in WHO II 
subjects were 68 and 54% for those with tubal infertility (P = 0.5). Similarly, the 
cumulative live birth rates were almost identical for both groups (38 versus 31%)(P 
= 0.9) (Figure 2).  
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Figure 1 Scatter plots depicting the correlations between the total amount of exogenous FSH (IU) 
administered versus the total number of dominant (≥ 10 mm) follicles on the day of hCG or BMI in 26 
women with WHO II infertility and tubal infertility. Open circles represent patients who underwent oocyte 
retrieval. Closed circles represent patients whose cycle was cancelled. Spearman’s correlation 
coefficients and corresponding P values are depicted. 
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No significant differences were found in initial screening characteristics 
between the WHO II women included in the initial cohort and those who finally 
underwent IVF (mean values for BMI, T, AD and mean ovarian volume are 
respectively 26.8 versus 27.3, 2.4 versus 2.6, 15.2 versus 16.9 and 9.8 versus 
12.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2 Life-table analysis of cumulative conception rates and cumulative live birth rates  
 in 26 women with normogonadotropic anovulatory infertility and 26 controls with tubal  
 infertility that underwent IVF.   
 
 
5.3.4 Discussion 
The present study demonstrates that cancellation rates during ovarian stimulation 
and the total number of late follicular phase follicles on the day of hCG (especially 
those of 10-13 mm in size) in the non-cancelled cycles were increased following 
IVF in women with WHO II anovulatory infertility after previous unsuccessful 
ovulation induction. In these women, obesity was correlated with an increased 
number of cancelled cycles (unexpectedly, mostly due to insufficient ovarian 
response) together with an increased amount of exogenous FSH administered. 
However, the numbers of retrieved - and normally fertilized - oocytes, as well as 
clinical and ongoing pregnancy rates, were not significantly different comparing 
women with WHO II anovulatory infertility and matched controls suffering from 
tubal infertility. Anovulatory women tended to have an increased miscarriage rate, 
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along with indications for slightly enhanced implantation. The observed incidence 
of ovarian hyperstimulation syndrome was comparable in both groups.  
Patient numbers involved in the current study are relatively limited, arguing 
for some caution regarding conclusions drawn. Despite this limitation, it was not 
possible to identify major differences comparing IVF outcome in WHO II 
anovulatory infertility compared with matched control subjects. Beforehand, it 
would be reasonable to expect a difference of 10 - 15% in cancellation rates 
(starting from a mean cancellation rate of 22%). A much larger difference in 
cancellation rates was found, which was statistically significant. Still, this study 
does not exclude that differences are in fact in the order of 10% or lower (e.g. 95% 
CI of cancellation rates (%) = 1.4 - 33.7). 
Dominant follicle selection is disturbed in polycystic ovaries, resulting in an 
increased number of follicles per ovary and presumably a variable number of 
healthy early antral follicles (Fauser and van Heusden, 1997). Women with PCOS 
seem to be at risk for multi-follicular development in response to gonadotropin 
stimulation (MacDougall et al., 1992a). Others reported an increased number of 
follicles produced in PCO patients compared with normal controls (MacDougall et 
al., 1993). The current study confirms that the number of small dominant follicles 
(10-13 mm) stimulated during ovarian stimulation in anovulatory patients is 
increased. Since the number and fertilization rates of retrieved oocytes were similar 
in patients and controls, the enhanced ovarian response may reflect stimulation of 
atretic follicles. This concept is in line with several previous observations reporting 
normal inhibin B concentrations in PCOS patients, suggesting a normal number of 
healthy early antral follicles despite increased overall follicle numbers in these 
women (Pigny et al., 2000; Laven et al., 2001a). 
According to most authors, patients with PCOS are particularly prone to 
develop OHSS because of the presumed enhanced ovarian response to 
gonadotropins (MacDougall et al., 1992b). Remarkably, the present data suggest 
that the incidence of OHSS may not be increased in women suffering from 
normogonadotropic anovulatory infertility. Cancellation was mostly due to 
insufficient response instead of hyperresponse. It cannot be excluded that the use 
of E2 concentrations next to ultrasound for monitoring of ovarian response would 
have resulted in lower cancellation rates. Moreover, the addition of exogenous LH 
(Lisi et al., 2001) next to FSH in GnRH antagonists cycles (Barri et al., 2002) may 
possibly improve ovarian response. In the current study, women with WHO II 
infertility undergoing IVF originate from a well-defined group of patients for whom 
ovulation induction is a treatment with good prospects of singleton live birth 
(Eijkemans et al., 2003). Therefore, differences in patient selection and preceding 
ovulation induction are the most likely explanation for this observed discrepancy. 
However, no discrepancy was observed in initial screening characteristics between 
the initial cohort and the women who finally underwent IVF. Nevertheless, 
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screening parameters indicative of ovulation induction outcome (Imani et al., 1998; 
Imani et al., 1999; Imani et al., 2000; Imani et al., 2002a; Imani et al., 2002b) 
showed a trend toward reduced treatment outcome for those women that finally 
underwent IVF. Given the low power of the study, this trend is not statistically 
significant. 
In the present analysis, a marked impact of obesity on the cycle cancellation 
rates was observed in women with anovulatory infertility. Since insufficient ovarian 
response following gonadotropin stimulation is related primarily to obesity, it might 
be speculated that in obese women exogenous FSH is diluted in a larger 
circulating volume. Indeed, after a fixed bolus injection of exogenous FSH, serum 
concentrations have been shown to be dependent on body weight (Mannaerts et 
al., 1993). However, varying the gonadotropin dose on the basis of body weight 
has never been shown to result in improved IVF outcome. In case oocyte retrieval 
is accomplished, obesity no longer compromises IVF outcome. This suggests that 
the importance of body weight is only related to the extent of ovarian response 
following FSH administration. Previous findings indicating that BMI is the most 
prominent predictor of the individual FSH response (threshold) dose in 
normogonadotropic, anovulatory infertile women undergoing gonadotropin 
induction of ovulation (Imani et al., 2002a) are in line with this observation.         
Remaining biologically plausible factors involved in ovarian dysfunction in 
normogonadotropic anovulation, such as serum LH (Fauser et al., 1991), inhibin B 
(Laven et al., 2001a), free IGF-I (van Dessel et al., 1999) and insulin/glucose ratios 
(Poretsky et al., 1999), all failed to predict cancellation or total amount of FSH 
administered during ovulation induction (Imani et al., 1998; Imani et al., 1999; Imani 
et al., 2000; Imani et al., 2002a; Imani et al., 2002b). Screening characteristics 
involved in the prediction of ovulation after CC are distinctly different from 
predictors of conception in ovulatory CC cycles (Imani et al., 1999; Imani et al., 
2002b). This disparity suggests that the FSH threshold (magnitude of FSH required 
for stimulation of ongoing follicle growth and ovulation) and oocyte quality (chances 
for conception in ovulatory cycles) may be differentially regulated. The present 
analysis again stresses this concept, since no differences in initial screening 
characteristics in WHO II women were found once oocyte retrieval had been 
achieved.  
Similar pregnancy rates have been reported following IVF in PCOS subjects 
and normo-ovulatory controls (Dor et al., 1990; Urman et al., 1992; Homburg et al., 
1993). According to these authors, these findings indicate no further impairment in 
treatment outcome once oocytes are fertilized. This is, however, in conflict with the 
present findings, where an increased number of clinical pregnancies in WHO II 
women resulted in a similar live birth rate because of an elevated number of 
miscarriages. Although the number of miscarriages was higher for women with 
anovulatory infertility, this finding was not statistically significant. It should be noted, 
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however, that the sample size of this group is limited. Hence, actual differences 
cannot be excluded.  
Hypersecretion of LH has initially been implicated as the cause of reduced 
fertilization and high miscarriage rate in women with PCOS (Homburg et al., 1988). 
However, more recently considerable disagreement has arisen with regard to the 
significance of elevated LH concentrations (Imani et al., 1999). Likewise, it has 
been reported that the incidence of spontaneous miscarriage increases with 
increasing BMI both in women with (Hamilton-Fairley et al., 1992) and without 
(Fedorcsak et al., 2000) PCOS. In previous studies (Imani et al., 1999; Imani et al., 
2002b), however, no influence of obesity on live birth rates was detected in patients 
who ovulated following CC therapy. Although the sample size was limited, the 
present analysis does not confirm a possible association of increased serum LH 
levels or BMI with pregnancy outcome.  
In summary, it has become evident that obesity is associated with an 
increased risk for cycle cancellations and requirements for increased amounts of 
exogenous FSH for IVF in women with WHO II infertility following previous 
unsuccessful ovulation induction. Although the total number of follicles recruited 
during ovarian stimulation is increased, the number of healthy follicles appears 
similar. Once oocyte retrieval is performed, pregnancy rates for these women are 
comparable to controls suffering from tubal infertility. This observation suggests 
that factors involved in chances for conception in WHO II infertility are similar 
compared with controls. However, there seems to be tendency for increased early 
pregnancy loss in WHO II women resulting in a comparable overall live birth rate 
following IVF treatment. 
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Chapter VI: General discussion and conclusions 
 
In every day clinical infertility practice all WHO II anovulatory patients will undergo 
the same treatment algorithm in case of a wish to conceive. Initial patient 
characteristics may help to discriminate patients with favourable from those with 
unfavourable chances to respond to fertility treatment strategies. By identifying high 
risk patients beforehand, these women could be monitored more closely or 
stimulation regimens could be individually adjusted, reducing chances for multiple 
gestations or other complications in a given patient. Hence, screening of 
anovulatory women should be recommended in order to counsel individual patients 
regarding treatment outcome.  
Hyperandrogenism expressed as either an elevated FAI or elevated level of 
testosterone (T) or androstenedione (AD) is observed in about 67% of all WHO II 
patients (Laven et al., 2002). Androgens have been identified as the most 
important endocrine feature predicting ovulation induction outcome. FAI has been 
recognized as the most significant parameter predicting patients remaining 
anovulatory following CC (Imani et al., 1998). In addition, androgens (i.e T, AD, and 
FAI) have been associated with the amount of exogenous FSH required for ovarian 
response during a low-dose step-up gonadotropin regimen for induction of 
ovulation (Imani et al., 2002a). Finally, it has been shown that women with 
increased serum levels of T and AD are at an increased risk of multiple follicle 
development during gonadotropin ovulation induction (Mulders et al., 2003a).  
Polycystic ovaries constitute yet another important feature of women 
presenting with WHO II anovulation. PCO morphology, as assesed by ultrasound, 
is also associated with ovulation induction treatment outcome (Imani et al., 1998; 
Mulders et al., 2003a). It has been shown that normogonadotropic anovulatory 
women who exhibit an augmented number of ovarian follicles, an important 
criterion for PCOS diagnosis, prior to ovarian stimulation are at an increased risk of 
multiple follicle development during gonadotropin ovulation induction (Mulders et 
al., 2003a). Consequently, these patients exhibit higher chances for cancellation of 
the FSH-induced cycle. Due to disturbed dominant follicle selection the number of 
early antral follicles is usually increased in these women (Fauser, 1994). As a 
consequence, serum levels of AMH, predominantly produced by small follicles, are 
increased in patients with polycystic ovaries (Cook et al., 2002; Pigny et al., 2003; 
Laven et al., 2004; Mulders et al., 2004a). The subgroup of WHO II women 
exhibiting polycystic ovaries presented with the highest AMH serum levels (Laven 
et al., 2004). Furthermore, it seems that AMH levels corrrelate with serum levels of 
LH and T, and follicle numbers and ovarian volume as established on ultrasound 
(Laven et al., 2004). In other words, serum AMH levels are probably predictive for 
the extent of the disease since they correlate well with other parameters of ovarian 
dysfunction (Laven et al., 2004).  
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Fertility treatment can be viewed as an extended ovarian challenge test. 
Patient characteristics being the most important predictors for ovarian response 
during ovulation induction treatment are perhaps the ones involved in the 
pathophysiology of ovarian dysfunction. Indeed, hyperandrogenism, together with 
polycystic ovary morphology, happen to be cardinal features of PCOS, a subgroup 
within the WHO II category, as recently determined by the 2003 Rotterdam 
consensus workshop (The Rotterdam ESHRE/ASRM sponsored PCOS consensus 
workshop group, 2004a; The Rotterdam ESHRE/ASRM sponsored PCOS 
consensus workshop group, 2004b). However, WHO II anovulatory women, as well 
as PCOS patients, known to suffer from ovarian dysfunction, present with variable 
clinical symptoms. Moreover, many WHO II patients also present with obesity 
and/or signs of insulin resistance. Hence, WHO II anovulatory infertility, including 
PCOS, does not seem to represent a clear-cut clinical disease but rather 
constitutes a syndrome. As a consequence, it is difficult to prove that clinical 
characteristics associated with fertility treatment outcome are indeed the causative 
factors involved in the etiology of this syndrome. Hence, women with WHO II 
anovulation (including PCOS) constitute an extremely heterogeneous patient group 
since various causative mechanisms might be responsible for the development of 
the same clinical entity.  
Many studies have shown an increased prevalence among first degree 
relatives and hence a genetic basis for the development of WHO II 
anovulation/PCOS seems to exist (Ferriman and Purdie, 1979; Lunde et al., 1989; 
Govind et al., 1999). The heterogeneity of the clinical phenotype suggests that a 
complex pattern of inheritance is most probably involved (Franks et al., 2001; 
Legro and Strauss, 2003). In complex disorders the relationship between genotype 
and phenotype is not straightforward, which may be explained by the interaction of 
a small number of key genes with environmental factors. Moreover, the observable 
phenotype is not a constant phenomenon for a given individual, but seems to be 
influenced by environmental features (i.e. BMI and OCP) (Norman et al., 2002; 
Mulders et al., 2004b).  
It has been recognized that obesity, usually of central origin (also referred to 
as the visceral, android or abdominal type), frequently coincides with anovulatory 
infertility and especially with PCOS. In addition, insulin resistance and 
compensatory hyperinsulinemia have been documented in women with PCOS. 
Both insulin resistance and hyperinsulinemia are magnified in the presence of 
obesity (Dunaif, 1997). In addition, hyperandrogenism (associated with 
anovulation) could result from hyperinsulinism leading to increased adrenal and 
ovarian production and decreasing serum sex hormone-binding globulin levels 
(Legro et al., 2004). When performing ovulation induction with CC in WHO II 
anovulatory women it has been shown that obesity is a strong independent 
predictor of patients remaining anovulatory (Imani et al., 1998). BMI also predicted 
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an individual patient’s exogenous FSH requirements for initation of ongoing follicle 
growth during gonadotropin induction of ovulation (Imani et al., 2002a). Indeed, 
obesity and insulin resistance are associated with adverse treatment outcome 
during gonadotropin induction of ovulation (Mulders et al., 2003c). Moreover, 
obesity seems to be associated with increased chances for cycle cancellation 
following IVF (Mulders et al., 2003b). These results once more demonstrate that 
obese WHO II anovulatory patients constitute a subgroup for whom fertility 
treatment outcome is less favourable. Obesity seems to be an important modulator 
of the clinical phenotype and life style modification might correct this. 
Switching from an anabolic to catabolic state of metabolism can improve 
insulin resistance and hyperandrogenism, and might eventually restore menstrual 
cyclicity and, in time, fertility. Moreover, it has been demonstrated that weight loss 
can improve the response to ovulation induction (Norman et al., 2002). There is, 
however, limited understanding of the details of how these weight changes affect 
human reproductive function (Norman et al., 2004). Dietary intervention and life 
style modification (through education and increased physical activity) remain the 
first line treatment strategies for overweight women suffering from PCOS (Norman 
et al., 2004). Hence, a well-developed weight loss program as a first line 
therapeutic option should be offered to all women with obesity and anovulatory 
infertility.  
Another environmental modulator of the clinical picture is the OCP which 
might change the clinical, endocrine and sonographic features characteristic for 
PCOS. When performing a study in a founder population (i.e. a genetically isolated 
population founded by < 200 ancestors), the genetic and environmental 
homogeneity of women provides a unique opportunity to asses the sole effect of 
OCP on the WHO II or PCOS phenotype. Indeed, it was confirmed that the PCOS 
phenotype is influenced by the use of OCP. However, despite taking OCP, women 
diagnosed as PCOS in the past currently still fulfilled PCOS criteria (Mulders et al., 
2004b). Hence, ovarian dysfunction in women with anovulatory infertility is 
modulated, but not completely corrected, by OCP use.  
Overlooking the present findings the following conclusions can be drawn. 
WHO II anovulation, including PCOS, is a heterogeneous syndrome of ovarian 
dysfunction. Furthermore, the observable phenotype is not a constant phenomenon 
for a given individual, but seems to be influenced by environmental factors (i.e. BMI 
and OCP). The present data again stress the concept that women with PCOS 
constitute a subgroup of women with WHO II anovulation with a more severe form 
of the disease. Hyperandrogenism and polcycystic ovary (PCO) morphology seem 
to be its cardinal fairly constant features. These cardinal features have proven to 
be important predictors in terms of fertility treatment outcome. Hence, these 
parameters are perhaps involved in its pathophysiology. Accordingly genetic 
General discussion and conclusions 
 
 
147
research should focus on genes involved in androgen synthesis (including insulin 
action) and follicle development.   
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Summary 
 
Chapter I:  
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
reproductive age women and a major cause of subfertility. Women with PCOS 
might present with a number of various features and hence PCOS does not seem 
to be a clear-cut clinical phenomenon. In order to elucidate the background and 
pathophysiology of all symptoms displayed in PCOS it might be helpful to focus on 
these specific characteristics and features. In this chapter pathophysiology of 
ovarian dysfunction is highlighted. Additionally, several characteristic PCOS 
features used for classification and involved in phenotypical heterogeneity, will be 
briefly described. Furthermore, the complexity of research regarding the genetic 
component involved in the disease is discussed. Finally, the clinical implications of 
differences in phenotype expression are mentioned. In addition, the objectives of 
the present thesis are described in brief.  
   
Chapter II:  
Section 2.1: The present study was conducted to compare anti-Müllerian hormone 
(AMH) serum levels in 128 World Health Organization (WHO) group II women to 
those of 41 normo-ovulatory premenopausal women of similar age. Serum AMH 
concentrations are significantly (P < 0.001) elevated in WHO II patients (median: 
7.6 µg/L (range: 0.1-40.0)) compared to controls (median: 2.1 µg/L (0.1-7.4)). In 
106 patients presenting with polycystic ovaries (PCO) (≥ 12 follicles/ovary 
measuring 2-9 mm and/or an ovarian volume > 10 mL) AMH levels are elevated 
(9.3 µg/L (1.8-40.0)) compared to 22 patients without PCO (6.4 µg/L (0.1-22.1)) (P 
< 0.0001). In WHO II patients AMH concentrations correlate with features 
characteristic for polycystic ovary syndrome (PCOS) such as luteinizing hormone 
(LH) concentrations (r = 0.331; P = 0.0001), testosterone (T) levels (r = 0.477; P = 
0.0001), mean ovarian volume (r = 0.421; P = 0.0001) and the number of ovarian 
follicles (r = 0.308; P = 0.0001). AMH levels correlated well with age in WHO II 
patients (r = -0.248; P = 0.002) as well as in controls (r = -0.465; P = 0.005). 
However, the relative decline in AMH with age is less pronounced in WHO II 
patients. In a subset of patients no significant correlation was found between AMH 
serum concentrations and the follicle-stimulating hormone (FSH) response dose, 
the duration of stimulation and the total number of ampoules of FSH used. In 
conclusion, serum AMH concentrations are elevated in WHO II women, especially 
in those patients exhibiting PCO. Since AMH concentrations correlated well with 
other clinical, endocrine and ultrasound markers associated with PCOS, AMH may 
be used as a marker for the extent of the disease. A less pronounced AMH 
decrease over time in these women may suggest retarded ovarian ageing.   
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Section 2.2: The current study was designed to investigate whether the decrease in 
AMH serum concentrations over time is different comparing women with 
normogonadotropic anovulation (WHO II) (including PCOS) and normo-ovulatory 
controls. AMH serum levels were assessed on 2 occasions in 98 patients suffering 
from WHO II anovulatory infertility as well as in 41 normo-ovulatory premenopausal 
women. Median time interval between both visits was 2.6 years (range: 0.3 - 9.0) 
for WHO II patients compared to 1.6 years (range: 1.0 - 7.3) in controls. Serum 
AMH concentrations were significantly (P < 0.0001) elevated at both occasions in 
WHO II patients (AMH1: median = 7.5 µg/L (range: 0.1 - 35.8) and AMH2: median = 
6.7 µg/L (range: 0.0 - 30.6)) compared to controls (AMH1: median = 2.1 µg/L 
(range: 0.1-7.4) and AMH2: median = 1.3 µg/L (range: 0.0-5.0)). Regression 
analysis, corrected for age, indicated a significant relative decrease in serum AMH 
concentrations over time for both groups (P < 0.001). However, the decline in 
serum AMH in WHO II patients was significantly less compared to controls (P = 
0.03). The present longitudinal study shows that serum AMH concentrations 
decrease over time both in women presenting with WHO II anovulatory infertility as 
well as in normo-ovulatory controls. The decrease in WHO II patients is less 
pronounced despite distinctly elevated concentrations. This observation may 
suggest retarded ovarian ageing and hence a sustained reproductive life-span in 
these patients. 
  
Chapter III:  
The present observational study was performed to assess the sole effect of the oral 
contraceptive pill (OCP) on phenotype expression of PCOS in women descendant 
from a founder population. All patients with normogonadotropic anovulatory 
infertility (WHO II), descendant from a restricted area as identified by ZIP codes, 
underwent a standardised clinical, sonographic and endocrine screening. The 
previous diagnosis WHO II anovulation could be reconfirmed for a total number of 
101 women. At present, a total of 81 (80%) women could be diagnosed as having 
PCOS (according to the revised 2003 criteria). From these women a total of 54 
(67%) did not use the OCP, whereas 27 (33%) did. Corrected for age, the latter 
group presented with significantly increased serum concentrations of cortisol (P < 
0.001) and sex-hormone binding globulin (SHBG) (P < 0.001). Serum 
concentrations of estradiol (E2) (P < 0.001), progesterone (P) (P = 0.02), 17-
hydroxyprogesterone (17-OH-P) (P < 0.001), T (P = 0.04) and androstenedione 
(AD) (P = 0.01) were significantly decreased in these women. These differences 
resulted in a significantly decreased free androgen index (FAI) (100 x T/ SHBG) for 
women presently on OCP (P < 0.001). Use of OCP influences phenotype 
expression (the observable trait) of individual women known to suffer from PCOS. 
Despite taking OCP, women diagnosed in the past as PCOS still fulfilled the 
revised 2003 criteria for the syndrome. Current data suggest that these women 
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may suffer from the most severe form of PCOS since ovarian dysfunction did not 
seem to be completely corrected. Moreover, the present study suggests that it is 
permitted to rely on historical data regarding diagnosis of PCOS for women 
presently on the OCP since its cardinal features appear to be relatively constant. In 
addition, OCP use does not appreciably affect the PCOS phenotype. 
 
Chapter IV:  
In the present cross-sectional study the incidence of different FSH receptor (FSHR) 
genotypes in normogonadotropic anovulatory infertile women (WHO II) and normo-
ovulatory controls was assessed. In addition, these genotypes were correlated with 
baseline characteristics and ovarian responsiveness during ovulation induction for 
the WHO II women. Thirty normo-ovulatory controls were compared to 148 WHO II 
women. In WHO II patients and controls a standardized evaluation including cycle 
history, body mass index (BMI) and transvaginal ultrasound scannning of ovaries 
was performed. Fasting blood samples were obtained for endocrine evaluation. 
Ovarian responsiveness to FSH in WHO II women was assessed during ovulation 
induction and DNA was analyzed to determine the FSHR genotype. The Thr/Thr 
307 genotype was significantly less (52% versus 23%; P < 0.05) and the Ser/Ser 
680 polymorphism was significantly more (40% versus 16%; P < 0.05) prevalent in 
WHO II patients compared to controls. WHO II patients with Ser/Ser 680 
polymorphism presented with higher median FSH serum levels (5.2 IU/L; range 2.4 
- 9.7) compared to the Asn/Asn 680 (4.6 IU/L; range 1.4 - 5.8) and Asn/Ser 680 
(4.5 IU/L; range 1.8 - 9.7) variants (P < 0.05). However, ovarian responsiveness to 
FSH was similar comparing different polymorphisms in anovulatory women. In 
conclusion, WHO II patients exhibit a different FSHR genotype compared to 
normo-ovulatory controls and although this is associated with increased baseline 
FSH serum levels, altered ovarian sensitivity to exogenous FSH during ovulation 
induction could not be established.  
 
Chapter V:  
Section 5.1: This follow-up study evaluated whether initial screening characteristics 
predict treatment outcome of gonadotropin induction of ovulation. One hundred and 
fifty four women with normogonadotropic anovulatory infertility for whom 
clomiphene citrate (CC) induction of ovulation was unsuccessful were included in 
the present study. Daily FSH injections were initiated on day 3-5 after a 
spontaneous or progestagen-induced withdrawal bleeding. In most patients a dose 
finding low-dose step-up regimen was applied during the first treatment cycle in 
order to identify the individual FSH reponse dose. In all subsequent cycles a step-
down protocol was applied. The total number of first step-up cycles is 103. The 
total number of step-down cycles is 441, with 47% of these cycles presenting with 
mono-follicular development (1 follicle > 15 mm on the day of human chorionic 
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gonadotropin (hCG)). Initial serum levels of LH, T and AD were significant 
predictors in univariate logistic regression analysis for the probability of multi-
follicular development. The area under the receiver operating characteristic (ROC) 
curve of the multivariate model (including AD and mean follicle number) to predict 
the chances of multiple dominant follicle development was 0.62. FSH treatment 
resulted in a total of 67 (44%) ongoing pregnancies. Comparing those women who 
did versus those who did not reach an ongoing pregnancy in a multi-variate Cox 
regression analysis, initial serum insulin-like growth factor-I (IGF-I), T and woman’s 
age entered into the final model (AUC = 0.67). In conclusion, individual treatment 
outcome - multi-follicular growth and ongoing pregnancy - following gonadotropin 
induction of ovulation may be predicted by initial screening characteristics.  
Section 5.2: A systematic review was conducted to determine if initial screening 
characteristics of women with normogonadotropic anovulatory infertility, predict 
clinically significant outcomes of ovulation induction with gonadotropins, and to 
obtain pooled estimates of their predictive value through meta-analysis. Relevant 
studies were identified by a search strategy which consisted of MESH headings 
and a check of bibliographies. Only those studies in which pre-treatment screening 
characteristics (such as BMI, serum LH and androgens, insulin sensitivity and 
ultrasound appearance of ovaries were related to outcome parameters (such as 
total amount of FSH administered, cancellation, ovulation, pregnancy and 
miscarriage), were included in this analysis. Studies reporting relationships 
between initial screening characteristics and outcome parameters of ovulation 
induction as measures of association (e.g. Odds ratios) were pooled if at least 2 
studies reported an association. The measures of association were pooled using 
inverse variance weighting. Thirteen studies fulfilled the inclusion criteria. A positive 
association was seen in all studies between the level of obesity (definition applied 
as assessed by individual studies) and total amount of FSH administered 
(Weighted Mean Difference (WMD) of 771 IU (95% CI: 700 - 842)). Pooled Odds 
ratios of 1.86 (95% CI: 1.13 - 3.06) and 0.44 (95% CI: 0.31 - 0.61) were found 
between obesity with cancellation and ovulation, respectively. Pooled analysis did 
not show a significant association between obesity and pregnancy rate. The pooled 
Odds ratio for obese versus non-obese women and miscarriage was significant 
(3.05 (95% CI: 1.45 - 6.44)). Association measures between insulin resistance 
(definition applied as assessed by individual studies) and total amount of FSH 
administered produced a Weighted Mean Difference (WMD) of 351 (95% CI: 73 - 
630) IU. A pooled Odds ratio of 0.29 (95% CI: 0.10 - 0.80) was found for insulin 
resistance with pregnancy rate. The pooled Odds ratio for insulin resistance 
(hyperinsulinemia versus normoinsulinemia) and miscarriage rate was not 
significant. A pooled Odds ratio of 1.04 (95% CI: 1.01 - 1.07) was found for LH 
(IU/L) with pregnancy rate. The pooled odds ratio for LH and miscarriage rate was 
not significant. Finally, pooled analysis did not find a significant association 
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between T and pregnancy rate. The included studies did not address possible links 
between initial sonographic parameters and treatment outcome. This analysis 
suggests that the most clinically useful predictors of gonadotropin ovulation 
induction outcome in normogonadotropic women are obesity and insulin 
resistance. These findings might be of clinical relevance since they discriminate 
between women with low or high chances for success. However, the best available 
evidence testing measures of association between screening characteristics and 
outcome is limited.  
Section 5.3: This follow-up study represents in-vitro fertilization (IVF) treatment 
characteristics and outcomes in women with WHO group II anovulatory infertility 
after previous unsuccessful ovulation induction compared to controls. Furthermore, 
the possibility of initial screening parameters of these anovulatory women to predict 
IVF outcome was examined. Twenty six patients with WHO II anovulatory infertility 
who failed to establish a live birth following previous induction of ovulation (using 
clomiphene citrate as first line and FSH as second line) were compared with 26 IVF 
patients with tubal infertility matched for age, treatment period and treatment 
regimen. The WHO II patients underwent 49 IVF cycles, whereas the normo-
ovulatory controls underwent 46 cycles. In WHO II patients 15 cycles were 
cancelled compared to 6 cycles in controls (P = 0.04). Cycles were predominantly 
cancelled due to insufficient response (P = 0.04). In case the cycle was cancelled, 
BMI was significantly higher (P < 0.001) in WHO II women compared to controls. 
Overall live birth rates were comparable (P = 0.9). Obese women suffering from 
WHO II anovulatory infertility are at an increased risk to have their IVF cycle 
cancelled due to insufficient response. Once oocyte retrieval is achieved live birth 
rates are comparable to controls.   
 
Chapter VI:  
This chapter summarises the conclusions which could be drawn from the work 
presented in the current thesis. 
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Samenvatting 
 
Hoofdstuk I:  
Het polycysteus ovarium syndroom (PCOS) is de meest voorkomende endocriene 
aandoening bij vrouwen in de reproductieve leeftijd en een belangrijke oorzaak van 
subfertiliteit. Vrouwen met PCOS presenteren zich mogelijk met een diversiteit aan 
klinische kenmerken met als gevolg dat PCOS niet lijkt samen te gaan met een 
eenduidig klinisch beeld. Ten einde de achtergrond en de pathofysiologie van alle 
symptomen die voorkomen bij PCOS duidelijk te begrijpen en te verhelderen kan 
het nuttig zijn om het onderzoek op deze specifieke patiëntkarakteristieken en 
kenmerken te richten. In dit hoofdstuk wordt de pathofysiologie van 
ovariumdysfunctie beschreven. Aanvullend volgt een korte beschrijving van een 
aantal karakteristieken gebruikt voor de classificatie van PCOS en tevens 
betrokken bij de heterogeniteit van het phenotype. Vervolgens wordt de 
complexiteit van onderzoek naar de genetische component betrokken bij de ziekte 
besproken. Tot slot, worden de klinische implicaties van verschillen in phenotype 
genoemd. Daarnaast worden de doelen van het huidige proefschrift kort 
beschreven.  
 
Hoofdstuk II: 
Paragraaf 2.1: Deze studie werd uitgevoerd om de serum waardes van anti-
Müllerian hormoon (AMH) van 128 World Health Organization (WHO) groep II 
vrouwen te vergelijken met die van 41 normo-ovulatoire premenopauzale vrouwen 
van vergelijkbare leeftijd. De AMH serum concentraties waren significant (P < 
0,001) verhoogd bij WHO II patiënten (mediaan: 7,6 µg/L (bereik: 0,1-40,0)) in 
vergelijking met de controles (mediaan: 2,1 µg/L (bereik: 0,1-7,4)). Bij 106 
patiënten met polycysteuse ovaria (PCO) (≥ 12 follikels 2-9 mm/ovarium  en/of een 
ovarieel volume > 10 mL) waren de AMH spiegels verhoogd (9,3 µg/L (1,8-40,0)) in 
vergelijking met 22 patiënten zonder PCO (6,4 µg/L (0,1-22,1)) (P < 0,0001). Bij 
WHO II patiënten correleerden de AMH spiegels met parameters karakteristiek 
voor PCOS zoals luteïniserend hormoon (LH) concentraties (r = 0,331; P = 
0,0001), testosteron (T) spiegels (r = 0,477; P = 0,0001), gemiddeld ovarieel 
volume (r = 0,421; P = 0,0001) en het aantal ovariële follikels (r = 0,308; P = 
0,0001). AMH spiegels correleerden met leeftijd zowel voor de WHO II patiënten (r 
= -0,248; P = 0,002) als voor de controles (r = -0,465; P = 0,005). Echter de 
relatieve afname van AMH met de leeftijd was minder uitgesproken voor de WHO II 
patiënten. Bij een deel van de patiënten werd er geen significante correlatie 
gevonden tussen AMH serum spiegels an de FSH respons dosis, de duur van 
stimulatie en het totale aantal gebruikte ampullen FSH. Concluderend, AMH serum 
concentraties zijn verhoogd bij WHO II vrouwen, in het bijzonder bij die patiënten 
met PCO. Omdat de AMH concentraties goed correleren met andere klinische, 
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endocriene en echografische markers geassocieerd met PCOS kan AMH gebruikt 
worden als een maat die de ernst van de ziekte weergeeft. Een minder 
uitgesproken afname van AMH over de tijd bij deze vrouwen is suggestief voor 
vertraagde ovariële veroudering.  
Paragraaf 2.2: De huidige studie werd uitgevoerd om te onderzoeken of er een 
verschil bestaat in de afname van de AMH serum concentratie in de tijd tussen 
vrouwen met normogonadotrope anovulatie (WHO groep II) (inclusief PCOS) en 
normo-ovulatoire controles. De AMH serum spiegels werden bepaald zowel bij 98 
patiënten met WHO II anovulatoire infertiliteit als bij 41 normo-ovulatoire 
premenopauzale controles. Het mediane tijdsinterval tussen beide bezoeken was 
2,6 jaar (bereik: 0,3 - 9,0) voor de WHO II patiënten vergeleken met 1,6 jaar 
(bereik: 1,0 - 7,3) voor de controles. De serum AMH concentraties waren 
significant (P < 0,0001) verhoogd op beide momenten bij de WHO II patiënten 
(AMH1: mediaan = 7,5 µg/L (bereik: 0,1 - 35,8) en AMH2: mediaan = 6,7 µg/L 
(bereik: 0,0 - 30,6)) vergeleken met de controles (AMH1: mediaan = 2,1 µg/L 
(bereik: 0,1 - 7,4) en AMH2: mediaan = 1,3 µg/L (bereik: 0,0 - 5,0). Regressie 
analyse, gecorrigeerd voor leeftijd duidde op een significante afname in serum 
AMH concentraties over de tijd voor beide groepen (P < 0,001). Echter de afname 
in serum AMH spiegels bij de WHO II patiënten was significant kleiner in 
vergelijking met de controles (P = 0,03). De huidige longitudinale analyse toont aan 
dat serum AMH concentraties afnemen over de tijd zowel voor vrouwen met WHO 
II anovulatoire infertiliteit als voor normo-ovulatoire controles. De relatieve afname 
bij de WHO II patiënten is minder uitgesproken ondanks onmiskenbaar verhoogde 
concentraties. Deze observatie is suggestief voor vertraagde ovariële veroudering 
en gaat dus mogelijk gepaard met een verlengde reproductieve levensduur bij 
deze patiënten.   
 
Hoofdstuk III:  
De huidige observationele studie werd uitgevoerd om te onderzoeken wat het 
effect is van het gebruik van de orale anticonceptiepil op het PCOS fenotype bij 
vrouwen afkomstig uit een genetisch geïsoleerde populatie. Alle patiënten met 
anovulatoire infertiliteit (WHO groep II), afkomstig uit een beperkt gebied 
gedefinieerd met behulp van postcodes, ondergingen een random uitgevoerde 
klinische, endocriene en echografische screening. Voor een totaal van 101 
vrouwen (118 vrouwen hebben uiteindelijk toegestemd in deelname) kon de 
diagnose WHO II anovulatie worden bevestigd. De diagnose PCOS (volgens de 
herziene 2003 criteria) gesteld in het verleden kon voor een totaal van 41 vrouwen 
bevestigd worden. Een totaal van 27 (73%) vrouwen van deze groep gebruikten 
ten tijde van de studie geen anticonceptiepil terwijl 10 (27%) van hen dit wel deden. 
De laatste groep had significant verhoogde serum concentraties van cortisol (P = 
0,003) en sex-hormoon bindend globuline (SHBG) (P < 0,001). De serum 
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concentraties van LH (P = 0,030), estradiol (E2) (P < 0,001), 17-
hydroxyprogesteron (17-OH-P) (P = 0,012), de vrije androgenen index (FAI)(100 x 
T/SHBG) (P < 0,001) en de glucose:insuline (G:I) ratio (P = 0,035) waren 
significant verlaagd voor hen die de anticonceptiepil gebruikten. Bij een totaal van 
81 (80%) vrouwen werd de diagnose PCOS gesteld. Van deze vrouwen gebruikte 
een totaal van 54 (67%) geen anticonceptiepil terwijl 27 (33%) vrouwen deze wel 
gebruikten. Gecorrigeerd voor leeftijd had de laatste groep significant verhoogde 
serum concentraties van cortisol (P< 0,001) en SHBG (P < 0,001) en verlaagde 
serum concentraties van E2 (P < 0,001), P (P = 0,02), 17-OH-P (P < 0,001), T (P = 
0,04) en androsteendion (AD) (P = 0,01). Deze verschillen resulteerden in een 
significant verlaagde FAI voor vrouwen die de anticonceptiepil gebruikten (P < 
0,001). Samenvattend, het gebruik van de anticonceptiepil beïnvloedt expressie 
van het phenotype (de waarneembare kenmerken) van individuele vrouwen 
bekend met PCOS. Ondanks het gebruik van de anticonceptiepil voldoet een 
aantal vrouwen vanuit het verleden bekend met PCOS nog steeds aan de criteria 
voor de ziekte. Deze data suggereren dat deze groep mogelijk leidt aan de meest 
ernstige vorm van de ziekte aangezien de ovariumdysfunctie niet volledig is 
gecorrigeerd. Daarnaast staan de resultaten van deze studie toe om te vertrouwen 
op historische data aangaande de diagnose van PCOS voor vrouwen die nu de 
anticonceptiepil gebruiken. Aanvullend kan worden gezegd dat het gebruik van de 
anticonceptiepil het PCOS phenotype niet aanzienlijk lijkt te beïnvloeden.  
  
Hoofdstuk IV:  
In de huidige cross-sectionele studie werd de incidentie van verschillende FSH 
receptor (FSHR) genotypes bij vrouwen met normogonadotrope anovulatoire 
onvruchtbaarheid (WHO groep II) vergeleken met normo-ovulatoire controles. Voor 
de WHO II vrouwen werden de genotypes tevens gecorreleerd aan 
basiskarakteristieken en ovariumrespons tijdens ovulatie inductie. Dertig normo-
ovulatoire controles werden vergeleken met 148 WHO II vrouwen. Bij WHO II 
patiënten en de controles werd een gestandaardiseerde evaluatie betreffende de 
cyclusanamnese, body mass index (BMI) en transvaginale echografie van de 
ovaria verricht. Nuchtere bloedafnames werden verkregen voor de endocriene 
evaluatie. De ovarium respons op FSH bij de WHO II vrouwen werd vastgesteld 
tijdens ovulatie inductie. Tevens werd DNA geanalyseerd om het FSHR genotype 
vast te stellen. Het Thr/Thr 307 genotype kwam significant minder (52% versus 
23%; P < 0,05) en het Ser/Ser 680 genotype kwam significant vaker (40% versus 
16%; P < 0,05) voor bij WHO II patiënten in vergelijking met de controlegroep. 
WHO II patiënten met het Ser/Ser 680 polymorfisme toonden hogere mediane FSH 
serum spiegels (5,2 IU/L; bereik 2,4 - 9,7) vergeleken met de Asn/Asn 680 (4,6 
IU/L; bereik 1,4 - 5,8) en Asn/Ser 680 (4,5 IU/L; bereik: 1,8 - 9,7) variant (P < 0,05). 
Echter, de respons van het ovarium voor FSH was hetzelfde wanneer de 
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verschillende polymorfismen van anovulatoire vrouwen met elkaar werden 
vergeleken. Concluderend, WHO II patiënten tonen een verschillend FSHR 
genotype in vergelijking met normo-ovulatoire controles. Alhoewel, het FSHR 
genotype geassocieerd is met verhoogde basale FSH serum spiegels kan een 
veranderde ovariële gevoeligheid voor exogeen FSH tijdens ovulatie inductie niet 
worden vastgesteld.  
 
Hoofdstuk V: 
Paragraaf 5.1: In deze vervolgstudie werd onderzocht of het mogelijk was om met 
behulp van initiële screeningskarakteristieken de behandelingsuitkomst van 
gonadotrofinen ovulatie inductie te voorspellen. Honderdvierenvijftig vrouwen met 
normogonadotrope anovulatoire onvruchtbaarheid voor wie ovulatie inductie met 
clomifeen citraat (CC) niet succesvol was werden geïncludeerd. Dagelijkse 
injecties met FSH werden gestart op dag 3-5 na een spontane of progestageen 
geïnduceerde onttrekkingsbloeding. Bij de meeste patiënten werd tijdens de eerste 
behandelcyclus een low-dose step-up schema toegepast ten einde de individuele 
FSH respons dosis vast te stellen. In alle volgende cycli werd een step-down 
protocol toegepast. Het totale aantal eerste step-up cycli bedroeg 103. Het totale 
aantal step-down cycli bedroeg 441 waarbij er in 47% van deze cycli sprake was 
van mono-folliculaire ontwikkeling (1 follikel > 15 mm op de dag van humaan 
chorion gonadotrofine (hCG)). De initiële serum spiegels van LH, T en AD waren 
significante voorspellers in univariate logistische regressie analyse voor de 
waarschijnlijkheid van multi-folliculaire ontwikkeling. Het oppervlak onder de 
“receiver operating characteristic (ROC) curve” van het multivariate model (waarin 
opgenomen de serum spiegel AD en het gemiddelde aantal follikels) om de kans 
op multipele dominante follikelgroei te voorspellen was 0,62. De behandeling met 
FSH resulteerde in een totaal van 67 (44%) doorgaande zwangerschappen. Indien 
de vrouwen die wel en die geen doorgaande zwangerschap bereikten werden 
vergeleken in een multi-variate Cox regressie analyse kwamen de initiële serum 
spiegel van insuline-gelijkende groeifactor-I (IGF-I), T en de leeftijd van de vrouw in 
het uiteindelijke model (AUC = 0,67). Geconcludeerd kan worden dat de 
individuele behandeluitkomst - multi-folliculaire groei en doorgaande zwangerschap 
- volgend op gonadotrofinen ovulatie inductie kan worden voorspeld aan de hand 
van initiële screeningskarakteristieken.  
Paragraaf V.2: Een systematische literatuurstudie werd verricht om vast te stellen 
of initiële screeningskenmerken van vrouwen met normogonadotrope anovulatoire 
infertiliteit klinisch significante uitkomsten van ovulatie inductie met gonadotrofinen 
voorspellen. Tevens werd gezocht naar samengevoegde schattingen van de 
voorspellende waarde van screeningsparameters met behulp van meta-analyse. 
De relevante studies werden geïdentificeerd met behulp van een zoekstrategie die 
bestond uit MESH termen en een controle van de referentielijsten. Alleen die 
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studies waarin vooraf bekende screeningskarakteristieken (zoals BMI, serum LH 
en androgenen, insulinegevoeligheid en het echoscopisch beeld van de ovaria) 
werden gerelateerd aan uitkomstparameters (zoals totale hoeveelheid toegediend 
FSH, het staken van de behandelcyclus, ovulatie, zwangerschap en miskraam), 
werden geïncludeerd in deze analyse. Studies die rapporteerden over relaties 
tussen initiële screeningskenmerken en uitkomstparameters als maten van 
associatie (bv. Odds ratio’s) werden samengevoegd als tenminste 2 studies over 
deze associatie rapporteerden. De maten van associatie werden samengevoegd 
door gebruik te maken van het omgekeerde gewicht. Dertien studies voldeden aan 
de inclusiecriteria. Een positieve associatie werd gezien in alle studies tussen het 
niveau van overgewicht (de toegepaste definitie werd door de individuele studies 
vastgesteld) en de totale hoeveelheid toegediend FSH (gewogen gemiddelde 
verschil (WMD) van 771 IU (95% betrouwbaarheidsinterval: 700 - 842)). De 
samengevoegde Odds ratio’s van 1,86 (95% betrouwbaarheidsinterval: 1,13 - 3,06) 
en 0,44 (95% betrouwbaarheidsinterval: 0,31 - 0,61) werden gevonden tussen 
overgewicht met staken van de behandelcyclus en ovulatie, respectievelijk. De 
samengevoegde analyse liet geen significante associatie zien tussen overgewicht 
en het zwangerschapscijfer. De samengevoegde Odds ratio voor vrouwen met 
versus vrouwen zonder overgewicht en miskraam was significant (3,05 (95% 
betrouwbaarheidsinterval: 1,45 - 6,44)). De associatiematen tussen 
insulineresistentie (de toegepaste definitie is vastgesteld door de individuele 
studies) en de totale hoeveelheid toegediend FSH leverde een gewogen 
gemiddelde verschil (WMD) van 351 IU (95% betrouwbaarheidsinterval: 73 - 630) 
op. Een samengevoegde Odds ratio van 0,29 (95% betrouwbaarheidsinterval: 0,10 
- 0,80) werd gevonden voor insulineresistentie met zwangerschapscijfer. De 
samengevoegde Odds ratio voor insulineresistentie (hyperinsulinaemie versus 
normoinsulinaemie) en het aantal miskramen was niet significant. Een 
samengevoegde Odds ratio van 1,04 (95% betrouwbaarheidsinterval: 1,01 - 1,07) 
werd gevonden voor LH (IU/L) met het zwangerschapscijfer. De samengevoegde 
Odds ratio voor LH met miskramen was niet significant. Tot slot, vond de 
samengevoegde analyse geen significante associatie tussen T en het 
zwangerschapscijfer. De geïncludeerde studies hebben de mogelijke verbanden 
tussen initiële echografische parameters en behandeluitkomst niet onderzocht. 
Deze analyse suggereert dat overgewicht en insulineresistentie bij 
normogonadotrope vrouwen de klinisch bruikbare voorspellers van gonadotrofinen 
ovulatie inductie zijn. Deze bevindingen kunnen van klinische relevantie zijn omdat 
zij een onderscheid maken tussen vrouwen met een hoge en een lage kans op 
succes. Echter, de hoeveelheid bewijs beschikbaar voor het onderzoek naar maten 
van associatie tussen screeningskarakteristieken en uitkomst is beperkt.  
Paragraaf 5.3: In-vitro fertilisatie (IVF) behandelingskarakteristieken en uitkomsten 
van vrouwen met WHO groep II anovulatoire infertiliteit werden in deze 
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vervolgstudie vergeleken met controles. Daarnaast werd onderzocht of initiële 
screeningsparameters de uitkomst van de IVF behandeling voor anovulatoire 
vrouwen konden voorspellen. Zesentwintig patiënten met WHO II anovulatoire 
infertiliteit bij wie geen kind is geboren na voorafgaande ovulatie inductie 
(gebruikmakend van CC als 1e lijns en FSH als 2e lijns therapie) werden 
vergeleken met 26 IVF patiënten met tubaire infertiliteit met gelijke leeftijd, 
behandelperiode en behandelregiem. De WHO II patiënten ondergingen 49 IVF 
cycli, terwijl de normo-ovulatoire controlegroep 46 cycli ondergingen. Bij de WHO II 
patiënten werden 15 cycli gestaakt in vergelijking met 6 cycli bij de controles (P = 
0,04). De cycli werden voornamelijk gestaakt wegens onvoldoende ovariële 
respons (P = 0,04). In het geval dat de behandelcyclus werd gestaakt was de BMI 
significant (P < 0,001) verhoogd voor de WHO II vrouwen in vergelijking met de 
controles. Het totale aantal levendgeboren kinderen was vergelijkbaar (P = 0,9). 
Vrouwen met overgewicht die lijden aan WHO II anovulatoire onvruchtbaarheid 
lopen een grotere kans op het staken van de gestarte IVF cyclus als gevolg van 
onvoldoende ovariële respons. Na het verrichten van de punctie zijn de aantallen 
levend geborenen vergelijkbaar met de controlegroep.  
 
Hoofdstuk VI:  
Dit hoofdstuk bevat de conclusies die kunnen worden gehaald uit de hoofdstukken 
opgenomen in dit proefschrift. 
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Dankwoord 
 
Het ligt in mijn aard (velen zullen dit onmiddellijk herkennen) om zorgvuldig en 
uitgebreid te werk te gaan. Echter, de afgelopen jaren is mij middels het gebruik 
van krachtige termen (“Focus! To the point!”) duidelijk geworden dat je de 
boodschap (zonder daarbij tekort te schieten) ook met een beperkt aantal woorden 
kunt weergeven. In het kader van het dankwoord volstaat dan: iedereen 
waanzinnig bedankt! Toch wil ik op deze plaats een aantal personen in het 
bijzonder noemen en bedanken voor de bijdrage die ze hebben geleverd aan het 
tot stand komen van dit proefschrift.  
 
Allereerst, het verrichten van klinisch wetenschappelijk onderzoek is niet mogelijk 
zonder de deelname van patiënten en vrijwilligsters. Graag wil ik alle vrouwen die 
hun enthousiaste medewerking hebben verleend aan de studies van harte danken.  
 
Geachte Prof. Dr. B.C.J.M. Fauser (staat er in mijn eerste brief aan je uit 2000), 
Beste Bart, ik voel me bevoorrecht om een van je promovendi te zijn. Je hebt me 
laten kennis maken met een wereld die voor mij totaal nieuw was. Je heldere kijk 
op het verrichten van wetenschappelijk onderzoek en je ideeën heb ik zeer 
stimulerend gevonden. Jouw enthousiasme en je energieke onderzoeksgeest 
hebben een onuitwisbare indruk op mij gemaakt. De afgelopen jaren heb ik dan 
ook veel geleerd en ben ik persoonlijk gegroeid. Tot slot, eveneens mijn dank voor 
jouw bijzondere aandacht voor het groepsgevoel (de jaarlijkse festiviteiten bij je 
thuis zijn voor mij bijzondere herinneringen). 
 
Geachte Dr. J.S.E. Laven, Lieve Joop! Waar moet ik beginnen? Allereerst bedankt 
voor al die ontelbare keren dat je me hebt verteld dat het wel goed zou komen 
(ondanks mijn gemopper wist je me steeds op het positieve te wijzen). Dank voor 
al je steun, want gedurende het hele traject was je beschikbaar (overal en altijd) 
voor advies, motiverende en relativerende gesprekken. Bovendien had je naast 
wetenschappelijke onderwerpen gelukkig ook aandacht voor de gewone zaken des 
levens tijdens de vele besprekingen (in het ziekenhuis, maar ook bij jouw gastvrije 
thuis) en uitstapjes (het is zo waar bij slechts één aanrijding gebleven). Dank voor 
al jouw inbreng en je enthousiasme. Joop, je was voor mij een fantastische 
begeleider tijdens mijn onderzoeksperiode, hopelijk mag ik ook tijdens mijn 
klinische opleiding nog veel van je leren.  
 
Geachte Prof. Dr. F.H. de Jong, Beste Frank, ik ben u zeer dankbaar voor uw 
gevoel van betrokkenheid bij het onderzoek en uw kritische opmerkingen ten 
aanzien van de interpretatie van de resultaten. Uw suggesties ter verbetering van 
het manuscript waren zeer waardevol. Aanvullend: het lijden (leiden?) aan het 
complex der Nederlandse taal (voor zover een erkend fenomeen) is hopelijk 
verleden tijd. Bedankt voor uw bereidheid om plaats te nemen in de kleine 
commissie.  
 
Geachte Prof. Dr. B.A. Oostra, Beste Ben, ik ben u zeer dankbaar voor de vele 
keren dat u bereid was met mij te spreken over de bouwstenen (DNA moleculen) 
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van het bestaan. Het blijft bijzonder dat eenvoud zo complex kan zijn. Bedankt voor 
uw waardevolle beoordeling van het manuscript en uw bereidheid deel te nemen 
aan de kleine commissie.  
 
Dear professor D. Dewailly, I very much appreciate the hard and excellent work of 
your group in Lille. I am very honoured that you have decided to participate in the 
small committee and I would like to thank you for that.  
 
Geachte Prof. Dr. J.D. Habbema en Prof. Dr. E.G. te Velde, al vanaf het begin bent 
u beiden verbonden geweest aan de onderzoekslijn: predictie van uitkomst van 
vruchtbaarheidsbehandeling bij vrouwen met anovulatie. Ik ben vereerd dat ik met 
u mag discussiëren (onder andere) ten aanzien van de laatste resultaten van de 
onderzoekslijn. Ik wil u dan ook hartelijk danken voor het uw deelname aan de 
promotiecommissie. 
 
Geachte Dr. Ir. A. Themmen, Beste Axel, ik heb veel van je geleerd op het gebied 
van AMH en polymorfismen. Zeer veel dank ook voor je belangstelling voor mijn 
onderzoek de afgelopen jaren. Ik vind het een eer dat je in de promotiecommissie 
hebt willen plaatsnemen. 
 
Geachte Dr. M.J.C. Eijkemans, Lieve René (met streepje), wat heerlijk was het om 
in een project te duiken waar jij je (als vreemde eend in de bijt) al als een vis in het 
water voelde. Tevens bedankt voor je geduld (je liet me telkens weer uitrazen), 
voor je creativiteit (je weet overal wel een aanname voor te bedenken!) en voor je 
bereikbaarheid te alle tijde. Bovenal bedankt voor het behandelen van mijn angst 
voor getallen! Tot slot, onze manier van samenwerken was uniek en zeer plezierig; 
ik hoop je niet uit het oog te verliezen!  
 
De Rotterdamse WHO II database vormde de basis voor diversie studies. Ik dank 
allen, maar Babak Imani in het bijzonder, die een belangrijke rol speelde bij het 
ontwerpen van deze database. Babak, wat een eer om jouw werk over te nemen. 
Ik hoop dat je je kunt vinden in de afronding van het project. Ik wens je veel geluk 
(waar ook ter wereld).  
 
Furthermore, I would like to thank professor M. Simoni for the collaboration 
regarding the FSH receptor polymorphism study (I really appreciated your warm 
welcome in Munster). In addition, I would like to thank professor E. Hughes for his 
collaboration and critical appraisal when writing the meta-analysis (I really 
appreciated our communication by email; however, I still hope to meet you in 
person somewhere). Tot slot, wil ik dr. Jenny Visser (goed geregeld die lekkernijen 
tijdens de vergaderingen van het WHO II beraad) en dr. André Uitterlinden 
bedanken voor hun bijdrage aan diverse wetenschappelijke artikelen.  
 
Het behalen van de finish van de Rotterdamse skatemarathon in 2001 (hoezo door 
weer en wind?) samen met Nicole (Beckers) en Manon (van Seters) maakte mij 
duidelijk dat ik met hun steun ook mijn promotietraject goed zou kunnen afronden. 
Dat jullie dus mijn paranimfen zijn spreekt voor zich. 
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Lieve Nicole, zeer naaste onderzoekscollega en inmiddels ook dierbare vriendin, al 
vanaf de eerste ontmoeting tijdens mijn keuze co-schap IVF, klikte het tussen ons. 
Wat een toeval dat we enige tijd later collega’s werden. Ik heb de afgelopen jaren 
ontzettend veel van je geleerd en met je genoten. Jouw inzet, kritische bijdrage, 
hulp (vooral bij het voorbereiden van voordrachten) en adviezen (hoe om te gaan 
met bijzondere (!!) personen) zijn onmisbaar geweest voor het tot stand komen van 
dit proefschrift.  
Lieve Manon, dierbare vriendin en zeer naaste onderzoekscollega, al vanaf de 
eerste colleges bewandelen we een soort van gelijk traject (en dan heb ik het nog 
niet eens over onze gezamenlijke liefde(s) (hint: onder andere Peugeot 504)). Je 
kent me als geen ander en weet mijn reacties (gelukkig) altijd in het juiste 
perspectief te plaatsen. Daarnaast help je me met het corrigeren en sturen van 
mijn fanatisme waarvoor mijn dank. Tot slot hoop ik dat het starten van de 
opleiding voor jou niet lang meer op zich laat wachten! Succes!  
Ter afsluiting….zullen we de komende zomer weer eens flink veel gaan skaten?  
 
Ja, en dan inmiddels traditiegetrouw een woord van dank voor het follikelteam: 
allereerst de girls (gezeteld op de kopkamer onder het toeziende oog van de baas):  
Lieve Fem(ke Hohmann!!), zelden iemand ontmoet zoals jij die naast haar eigen 
drukke bezigheden zoveel tijd vrij maakt om mij èn vele anderen te helpen. 
Daarnaast heb je me (onder andere) geleerd om te anticiperen en te zorgen daar 
waar het kan “in control” te zijn. Tot slot, mijn partner in het delen van veel 
(bazen!)leed! Nu, op naar de afronding van jouw onderzoekstraject. Het einde 
hiervan is gelukkig al in zicht!  
Lieve (H)Esther (Heijnen!!), wat een gezelligheid met jou als kamergenoot; lekker 
doorwerken op onze design computers (RSI proof!!) en op zijn tijd (ahum) wat 
koetjes en kalfjes (is: vette roddels uitwisselen vooral als je weer terug kwam uit 
Utrecht) tussendoor. Bovenal, je was altijd een luisterend oor als ik weer (het viel 
hopelijk mee?) in de stress zat! Bedankt voor je geduld! Enne, viva Madrid! 
Lieve (B)Esther (Baart!!), jij hebt het embryo voor mij tot leven gebracht (echt 
werelds). Bovenal wisten jouw pittige reacties op een ongenuanceerde opmerking 
van deze en genen vaak een glimlach op mijn gezicht te toveren. Rest mij je nog te 
bedanken voor je input bij het maken van (afscheids)liedjes (doctorandus P. in het 
bijzonder; breng het met Christien nog eens ten gehore!).  
Lieve Christien (Weenen!!), New York City en Rotterdam: een wereld van verschil 
(hoezo verwarrend?). Ik hoop dat je je draai nu hebt gevonden. Je was de 
drijvende kracht achter de gezamenlijke lunch (om 11:30!!). Bedankt! Nog steeds 
geen chocolade? Bizar! 
Lieve Anne (von Bergh) en Annemarie ((Wassing-) De Vet): kort en krachtig met 
veel ups en downs! Bedankt voor jullie gezelligheid.  
 
Nu, de boys:  
Lieve Mark (van der Gaast!!), jij bent het pre-ovulatoire type van het stel. Heel wat 
uren (van s’morgens vroeg tot s’avonds laat) hebben we samen de kopkamer 
onveilig gemaakt (jij al dan niet snurkend); inclusief de ontelbare ruzies over het 
aan/uit zetten van de ventilatie en het openen/sluiten van de deur (rechts/links). 
O’ja: dokter Van de Staag (!!); nog even knuffelen!! De overige follikelboys (Thierry 
Pache, Evert van Santbrink, Jits Schipper, Arne van Heusden, Diederick de Jong, 
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Bernd Berning en Babak Imani) (inmiddels de luteale fase al bereikt): dank ik voor 
hun fantastische voorbeeld, hulp en adviezen bij het worden van een ovulatoire 
follikel.   
 
Verder dank ik Nick Macklon voor zijn geduld en discretie: geen onvertogen woord 
(ja toch?) kwam er over zijn lippen ondanks het feit dat hij getuige is geweest van 
(vele (in een enkel geval slechts) verhitte) discussies tussen copromotor en 
promovenda. In addition, I would like to thank you for correcting my English 
grammar. 
 
En dan de meiden met wie ik vele kilometers in het Brabantse land heb 
rondgereden: super die buitengewone inzet bij het opsporen en werven van 
deelneemsters aan het erfelijkheidsonderzoek.  
Lieve Liz(ka Nekrui), een paar keer in de week het gevoel hebben op vakantie te 
gaan doet een mens erg goed (vooral als je ook nog mag gaan tolken, want dan ga 
je namelijk echt ver weg!). Daarnaast aandacht voor de gewone dingen: mannen 
(jouw onderscheid tussen het natte en het droge type ga ik nooit vergeten) en 
roddels op lokaal (Erasmus MC) en landelijk (Beau Monde) niveau. Wat is het 
heerlijk relaxed om met jou te werken. Dank je! 
Lieve M’lijn (Marjolijn de Kruif), ik wil je bedanken voor de enorme berg werk die je 
verricht hebt als student. Daarnaast bedankt voor je gezelligheid. Veel succes met 
het behalen van je artsexamen.  
 
Zonder organisatorische ondersteuning zou hier nooit een proefschrift hebben 
gelegen. Ik mag mij gelukkig prijzen met de hulp van de staf, verpleegkundigen en 
medewerkers van de polikliniek Verloskunde en Vrouwenziekten van het Erasmus 
MC voor de faciliteiten en het vele prikwerk (COLA-screening). In het bijzonder wil 
ik de artsen, verpleegkundigen en secretaresses (Annemarie Slingerland, Beate 
Pawliszak en Marita Meeuwes) van de IVF afdeling bedanken voor hun hulp. 
Daarnaast gaat mijn dank uit naar de medewerkers van het IVF laboratorium (in 
het bijzonder Elena Martini (je hebt nog steeds strippen van me tegoed; deze 
volgen tzt) en Diana Bulkmans) voor hun hulp bij het scoren van embryo’s. Tot slot, 
dank voor de medewerkers van de Clinical Research Unit voor hun hulp bij de 
uitvoering van de studies.  
 
Zonder de nodige ontspanning geen wetenschappelijke productiviteit: Aagje Bais, 
Sabina de Weerd, Nanette Roelfsema, Hilmar Bijma, Nicolette Ursem, Sandra 
Stekelenburg - De Vos, Heidy van Wijk en Suzanne Gielen: bedankt voor jullie hulp 
bij het nuttigen van de juiste hoeveelheden borrelhappen en wijn!  
 
Zonder hormoonuitslagen geen data: mijn dank gaat uit naar Ronald Van der Wal, 
Jolanda Bot - Blijd, Sandra Bruggemans en Brigitte Van de Lang van het 
voormalige laboratorium Inwendige Geneeskunde 3 (thans: Endocrinologisch 
Diagnostisch en Researchlaboratorium): mede dankzij jullie inzet en bereidheid 
verliep het op rolletjes. 
 
Tijdens mijn onderzoeksperiode is een PCOS erfelijkheidsonderzoek gestart (‘Een 
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(PCOS) in een Nederlandse genetisch geïsoleerde gemeenschap’). Dit project is 
een samenwerkingsverband tussen de divisie Voortplantingsgeneeskunde van de 
afdeling Verloskunde & Vrouwenziekten en de afdeling Klinische Genetica van het 
Erasmus MC. Daarnaast wordt samengewerkt met de afdeling Obstetrie en 
Gynaecologie van het Amphia Ziekenhuis (Breda) en het Franciscus Ziekenhuis 
(Roosendaal). In dit kader hiervan wil ik Dr. R. Pal en Dr. M. Ten Kate-Booij 
bedanken voor hun inzet bij het opstarten van de studie en het werven van 
deelnemers. Mijn bijzondere dank gaat uit naar de onafgebroken en fantastische 
inzet van Edith Froger van het Amphia Ziekenhuis. Met een onvoorstelbare 
hoeveelheid energie wist zij honderden statussen te voorschijn te toveren.  
 Voor de uitvoering van het onderzoek konden we terecht in de Oude 
Pastorie te Sprundel. Ik dank Leon Testers voor zijn hulp bij de organisatorische 
zaken, Petra Veraart voor haar hulp bij het uitzoeken van de familieverbanden en 
Elly de Hoon voor haar hulp bij de bloedafnames. Mijn dank gaat tevens uit naar 
Jeanette Lokker, Erik Simons en Onno Schaap; zonder jullie hulp bij de logistiek, 
opslag en het analyseren van samples in het lab van zijn er straks geen resultaten.  
 
Beste dokter Ten Kate-Booij, vanaf 1 januari 2004 mag ik u ook mijn opleider 
noemen! Het frustreerde me het afgelopen jaar steeds te moeten kiezen tussen het 
afronden van mijn proefschrift en het oppakken van de opleiding. Wat een 
opluchting: die tweestrijd is nu van de baan. Eveneens heel veel dank voor het 
geduld van alle andere gynaecologen: dokter Berger, dokter Gietelink, dokter 
Heydanus, dokter Papatsonis, dokter Knol, dokter Feijen, dokter Smalbraak, dokter 
Shekary, dokter Vonsée, dokter Van Weering, dokter Wijffels, dokter Bongers, 
dokter Kok, dokter Vermeer en dokter Van Bommel. Mede dankzij jullie open 
manier van werken en opleiden voelde ik mij direct thuis in het Amphia Ziekenhuis. 
Natuurlijk dank ik hiervoor ook alle verloskundigen, verpleegkundigen, poli-
assistenten, echoscopisten en al het andere personeel van de afdeling 
Gynaecologie en Verloskunde van het Amphia Ziekenhuis.  
 
Mijn directe collega arts-assistenten van het Amphia Ziekenhuis: Marjolein de 
Vries, Kees Avezaat, Klaartje van Antwerpen, Anet Klaassens, Rudi de Mulder, 
Anouk van der Honing, Sandra Kotey en Jojanneke Van de Swaluw, wil ik 
bedanken voor hun interesse en begrip voor een drukke promovendus. Geja van 
Goor, jouw begrip en hulp voor het combineren van de opleiding en de afrondingen 
van dit proefschrift hebben mij gered. Geja, ik mis onze gezamenlijke ritjes met de 
vele discussies onder het genot van een vitaminebommetje! Ik wens je in het 
bijzonder als gynaecoloog (het is 1 november 2004 geweest; dus het mag nu!) heel 
veel geluk! Je kunt je geen beter maatje wensen!  
 
En dan het thuisfront; onmisbaar voor dit resultaat!!  
 
Dank aan alle familie en vrienden die door hun medeleven, interesse en de 
broodnodige ontspanning in de (meestal) avonduren een belangrijke bijdrage 
hebben geleverd aan het tot stand komen van dit boek.  
 
Lieve Daan, Marlou, Angela, Yessy, Simone, Marieke, Vera, Martine en alle 
SCHATJES; jullie vriendschap (respectievelijk vanaf de start van de middelbare 
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school in Waalwijk, de eerste minuten in Utrecht, de aanvang van colleges in 
Rotterdam en de vorming van de superclub) is van onschatbare waarde geweest 
bij de tot standkoming van dit boek. Dank jullie wel voor al jullie begrip, interesse 
en bezorgdheid. Dank voor al jullie lieve kaartjes, emails en ondersteunende 
woorden. Ik ga het allemaal goed maken (daar ga ik weer!).  
Liefste Mariek, ik weet zeker dat je erbij bent! Ik mis je!  
 
Lieve Daniël, hartelijk bedankt voor je fantastische hulp bij de vormgeving van dit 
proefschrift. Het resultaat mag er zijn! Annemiek, Pacal en Rozan, bedankt voor 
het lenen van jullie lief en jullie pap!  
 
Lieve Richard en Maud (inclusief hetgeen (hij/zij) er geboren gaat worden; ik heb 
namelijk echt niet gekeken!!), jullie zijn voor mij in ondersteunde zin onmisbaar. 
Dank voor jullie begrip, bezorgdheid en jullie relativerende kijk op mijn werk; wat 
dat betreft kan ik nog veel leren.  
 
Lieve papa en mama, al van jongs af aan hebben jullie mij gestimuleerd en 
gezorgd dat ik alle kansen kreeg om te studeren. Mede dankzij mijn enorme 
enthousiasme en de grote hoeveelheid doorzettingsvermogen (eigenschappen die 
ik zo overduidelijk van jullie heb gekregen) is dit proefschrift tot stand gekomen. 
Daarnaast waren jullie belangstelling en hulp (het hele totaalpakket aan facilitaire 
diensten) onmisbaar voor de afronding van dit project. Bedankt dat jullie er altijd 
voor me zijn; ik had mij geen betere ouders kunnen wensen. Ik hou van jullie! 
 
Liefste, onwijs bedankt voor het zijn van Guy! Guy, vooral bedankt voor het hebben 
van zoveel (engelen)geduld! Eindelijk, weer samen (Hero) zingen: er was een 
donder, een bliksem! Ann(i)e luves joe! 
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